

# Uncovering Molecular Biomarkers That Correlate Cognitive Decline with the Changes of Hippocampus' Gene Expression Profiles in Alzheimer's Disease

Martín Gómez Ravetti<sup>1,2,3</sup>, Osvaldo A. Rosso<sup>1,2,4</sup>, Regina Berretta<sup>1,2</sup>, Pablo Moscato<sup>1,2,3\*</sup>

**1** Centre for Bioinformatics, Biomarker Discovery and Information-Based Medicine, The University of Newcastle, Callaghan, New South Wales, Australia, **2** Hunter Medical Research Institute, Information Based Medicine Program, John Hunter Hospital, New Lambton Heights, New South Wales, Australia, **3** Australian Research Council Centre of Excellence in Bioinformatics, Callaghan, New South Wales, Australia, **4** Instituto de Cálculo, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Buenos Aires, Argentina

## Abstract

**Background:** Alzheimer's disease (AD) is characterized by a neurodegenerative progression that alters cognition. On a phenotypical level, cognition is evaluated by means of the *MiniMental State Examination* (MMSE) and the post-mortem examination of *Neurofibrillary Tangle* count (NFT) helps to confirm an AD diagnostic. The MMSE evaluates different aspects of cognition including orientation, short-term memory (retention and recall), attention and language. As there is a normal cognitive decline with aging, and death is the final state on which NFT can be counted, the identification of brain gene expression biomarkers from these phenotypical measures has been elusive.

**Methodology/Principal Findings:** We have reanalysed a microarray dataset contributed in 2004 by Blalock *et al.* of 31 samples corresponding to hippocampus gene expression from 22 AD subjects of varying degree of severity and 9 controls. Instead of only relying on correlations of gene expression with the associated MMSE and NFT measures, and by using modern bioinformatics methods based on information theory and combinatorial optimization, we uncovered a 1,372-probe gene expression signature that presents a high-consensus with established markers of progression in AD. The signature reveals alterations in calcium, insulin, phosphatidylinositol and wnt-signalling. Among the most correlated gene probes with AD severity we found those linked to synaptic function, neurofilament bundle assembly and neuronal plasticity.

**Conclusions/Significance:** A transcription factors analysis of 1,372-probe signature reveals significant associations with the EGR/KROX family of proteins, MAZ, and E2F1. The gene homologous of EGR1, zif268, Egr-1 or Zenk, together with other members of the EGR family, are consolidating a key role in the neuronal plasticity in the brain. These results indicate a degree of commonality between putative genes involved in AD and prion-induced neurodegenerative processes that warrants further investigation.

**Citation:** Gómez Ravetti M, Rosso OA, Berretta R, Moscato P (2010) Uncovering Molecular Biomarkers That Correlate Cognitive Decline with the Changes of Hippocampus' Gene Expression Profiles in Alzheimer's Disease. PLoS ONE 5(4): e10153. doi:10.1371/journal.pone.0010153

**Editor:** Stefan Wölfl, Universität Heidelberg, Germany

**Received:** December 14, 2009; **Accepted:** March 22, 2010; **Published:** April 13, 2010

**Copyright:** © 2010 Gómez Ravetti et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** The authors acknowledge partial support from the Australian Research Council (ARC) Centre for Bioinformatics, Australia. OAR acknowledges partial support from the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

\* E-mail: pablo.moscato@newcastle.edu.au

## Introduction

Gomez Ravetti and Moscato have recently shown that the abundance of five proteins, within a panel that also measured the other 115 cytokines and growth factors, can be used to predict the development of clinical Alzheimer's Disease (AD) [1]. The biomarker molecular signature is composed of IL-1a, TNF-a, IL-3, EGF and G-CSF and has the same level of specificity and sensitivity as the original 18-protein signature proposed by Ray *et al.* [2] in late 2007, who introduced this important dataset in the literature. In the original work, Ray *et al.* had employed the abundance of 120 signalling proteins in plasma to obtain their 18-protein signature set. They used a training set of 83 samples to identify patients that progressed to AD in two to six years. The proposed 5-protein signature has an average of 96% accuracy in

predicting clinical AD but it is still linked to the joint measurement of 120 protein abundances.


In this paper, we are revisiting the quest of finding biomarkers of AD. However, this time we aim at finding biomarkers in hippocampus tissue samples which would complement the results of the previous studies on plasma biomarkers. This study will now give a different perspective on the progression of the disease, keeping a systems biology and functional genomics approach. Towards this end, we have chosen to rely on an informative experimental design and dataset contributed by Blalock *et al.* [3]. We believe that their dataset may help us to locate, either directly or indirectly, other biomarkers of interest that could eventually be detectable in plasma.

Blalock *et al.* analysed samples from 35 patients with four different levels of AD severity: control, incipient, moderate and

severe; for this paper we used only 31 samples for which information is available online. The label assigned to each sample (its “level of severity”) was decided after considering two important scores, those provided by the *MiniMental State Examination* (MMSE) and the *Neurofibrillary Tangle* count (NFT). The MMSE score is based on a questionnaire that aims at measuring the level of cognitive impairment of a patient. The questions are aimed at evaluating different aspects of cognition, such as orientation, short-term memory (retention and recall), attention and language. A normal score can range from 24 to 30, mild cognitive impairment on the interval 20 to 23, moderate AD between 10 to 19, and the rest (from 0 to 9) are all considered severe AD cases.


As previously mentioned, Blalock *et al.* [3] also used the NFT score to assign a severity label to each sample. The NFT score is a well established method for the neuropathological diagnosis of AD [4]. The score is usually based on the average counts of neurofibrillary tangles considering different regions of the brain. A NFT score is a recognised indicator of AD, nevertheless, it is not completely effective as there is evidence that NFTs were also identified in healthy aging brains [5,6,7,8].

The analysis by Blalock *et al.* [3] focused on the identification of AD-related genes (ADG) and incipient ADG (IADG) using a methodology based on the correlation of the genes with NFT and MMSE scores. In turn, they identified putative biological processes and signalling pathways that are significantly present in those gene lists. Our analysis takes a different direction. While still based on the same dataset, we are attempting to map the progression of the disease, finding biomarkers linked to disease severity, by *identifying the genes associated with the divergence of the gene expression profile of a sample with the gene expression average profile of the*




**Figure 1.** This plot illustrates that the third step of our methodology, the use of the *Jensen-Shannon divergence*, does not appear to give an interesting separation of the samples in the absence of a previous feature selection step. For this graph, all 22,215 genes were considered in the average profile of the samples in the “Control” and “Severe AD” classes. The square root of the *Jensen-Shannon divergences* to the “Control” and “Severe AD” average profile are computed, respectively giving, for each sample, its x and y coordinates in this plot. Observe that most of the “Control” samples have values lower than 0.12, with two exceptions. This result is expected, as the probability distribution function of the “Control” class was used. However, most of the samples from AD patients (having either “Incipient AD”, “Moderate” or “Severe” labels), show a divergence with the Control average gene expression profile. Figure 2 shows the important contribution provided by the feature selection step.

doi:10.1371/journal.pone.0010153.g001



**Figure 2.** This plot illustrates that after application of the feature selection steps, followed by the computation of the gene expression profile’s average profile of the samples in the “Control” and “Severe AD” classes (now on a set of 1,372 probes), the samples are now more clearly separated. Here, all “Control” samples have the square root of the *Jensen-Shannon divergences* to the average gene expression of the “Control” samples (x-coordinate) smaller than 0.12 (almost all severe AD have x-coordinates greater than 0.15). In addition to that, most samples labelled “Severe AD” are located on the same region. Both results are expected. However, it is interesting that in this (x,y)-plot most samples that are labelled “Incipient AD” or “Moderate AD” seem to “bridge” between the regions that have most of the “Control” samples and the region that have most of the “Severe AD” group. This result is interesting as no samples from “Incipient AD” nor “Moderate AD” have been used in the first three steps of our methodology. In essence, the work is a “test set” indicating that it is reasonable to expect that some genes in the genetic signature of 1,372 probes have information about a putative “progression” trend of the disease, from the “Control” to the “Severe AD” profile. In what follows, correlations across all the samples with these divergences are used as a method to try to identify those gene profiles that are most correlated with the progression from “Control” to “Severe AD”.

doi:10.1371/journal.pone.0010153.g002



**Figure 3.** This plot shows the MMSE scores as a function of the square root of the *Jensen-Shannon divergences* to the average gene expression of the “Control” samples. ‘Incipient AD’ samples, although having a lower value for their MMSE score, still do not show a dramatic change in their x-coordinates compared to the ‘Control’ samples. ‘Moderate AD’ samples appear to be more scattered, with some of them already having a significant divergence from the ‘Control’ average profile.

doi:10.1371/journal.pone.0010153.g003

“Control” group. Analogously, we are interested in identifying the genes that seem to best correlate with the “convergence” to the average profile of the “AD Severe” group of samples. The difference between Blalock *et al.*'s [3] methodological approach to data analysis and ours is very important. We aim to uncover genes that correlate with the divergence of the gene expression profiles, instead of relying only on correlations with the NFT and MMSE values.


Our objective is to uncover genes which are highly correlated to the progression of the disease. With this objective in mind, we will concentrate the first part of our analysis on the two most extremely separated classes, the sets of samples that have been labelled as “Control” and those labelled “AD Severe”. This important initial decision was made based on the fact that the four classes are, in some sense, arbitrarily defined as specific thresholds for the MMSE and NFT scores that were decided *ad hoc*. Therefore, we decided to first focus on the transitional patterns that can be identified from a “normally aging” to an “AD-severe” gene expression profile in hippocampus. With this approach, we also avoid selecting genes that diverge from the normal-aged profile by causes other than AD, as we expect that the severity scale in AD has a higher probability of being correct in the “Severe AD” cases (since they have high values of NFT and low MMSE scores, clearly a joint combination highly appreciated as a disease hallmark). This

approach has an additional advantage. Using this particular dataset and with focus on the effects of incorrect diagnoses, two publications identify four possible misdiagnoses between control and incipient AD [9,10]. In our case, the samples that have been labelled either “Incipient AD” or “Moderate AD” play the role of a “Test set”, as they are not used to select probes for establishing a molecular signature, thus avoiding misdiagnoses problems.

## Results

The results have been obtained using four steps in tandem: 1) abundance quantization of gene expression values and filtering of probes (this step is supervised by using the samples labelled either “Control” or “Severe AD”); 2) a feature selection algorithm to refine the probe selection based on numerical solution of a combinatorial optimization problem (the  $(\alpha, \beta)$ -k-Feature Set methodology); 3) a correlation analysis (that requires the computation of Jensen-Shannon divergences). Finally, a fourth step involves the pathway and Gene Ontology analysis of the results.

The first two steps only used the samples labelled either “Control” or “Severe AD”. The third step requires several procedures and uses all of the samples. We first compute an



**Figure 4. Correlation of the expression profiles of 1,372 probes (across samples) with the  $\sqrt{\text{JSD}}$  of the samples of two reference groups (“Control” and “Severe AD”, represented by the average expression profile in the group). The 50 probes in red are those most distant from the origin of this system of coordinates. Those probes have expression-value variations that are correlated with the divergences of the average “Control” profile and at the same time with the “Severe AD”.**  
doi:10.1371/journal.pone.0010153.g004

**Table 1.** For each sample, we have calculated the sample's Jensen-Shannon divergence with the average Control gene expression profile.

	Gene symbol	Probe	Spearman rank correlation
1	<b>CSF1</b>	<b>211839_s_at</b>	<b>0.79388</b>
2	<b>MCL1</b>	<b>214057_at</b>	<b>0.75484</b>
3	PSMC3IP	205956_x_at	0.74816
4	ZHX3	217367_s_at	0.74416
5	C10orf76	55662_at	0.74093
6	FCAR	211307_s_at	0.72002
7	TUBD1	210389_x_at	0.71835
8	AW974666	222365_at	0.71835
9	LRP10	201412_at	0.71079
10	<b>SERTAD2</b>	<b>202656_s_at</b>	<b>0.70679</b>
11	ITGB5	201125_s_at	0.7059
12	CDC2L6	212899_at	0.70412
13	RNF19A	220483_s_at	0.70367
14	<b>TTN</b>	<b>208195_at</b>	<b>0.70278</b>
15	<b>DHFR</b>	<b>202534_x_at</b>	<b>0.69844</b>
16	FYCO1	218204_s_at	0.69655
17	<b>HBEGF</b>	<b>38037_at</b>	<b>0.69388</b>
18	<b>ZBTB20</b>	<b>205383_s_at</b>	<b>0.69121</b>
19	KCNK5	219615_s_at	0.69121
20	KLHL20	204177_s_at	0.68988
21	DLG5	201681_s_at	0.68899
22	CHD2	203461_at	0.68821
23	TUG1	222244_s_at	0.68721
24	ZNF500	213641_at	0.68454
25	N58524	222332_at	0.68276
26	KIR2DL5A	211410_x_at	0.68165
27	CYBRD1	217889_s_at	0.67964
28	<b>DLG1</b>	<b>217208_s_at</b>	<b>0.67831</b>
29	<b>IL15</b>	<b>205992_s_at</b>	<b>0.67731</b>
30	RND2	214393_at	0.67508
31	TNS1	221748_s_at	0.67253
32	CTBP2	210835_s_at	0.6703
33	AL050204	213929_at	0.66852
34	YES1	202933_s_at	0.66763
35	MYBL1	213906_at	0.66719
36	No gene associated	213256_at	0.66363
37	C5orf4	48031_r_at	0.66363
38	<b>FOXO1</b>	<b>202724_s_at</b>	<b>0.66318</b>
39	<b>UPF1</b>	<b>211168_s_at</b>	<b>0.66096</b>
40	STAG3L1	221191_at	0.66007
41	SLC12A7	218066_at	0.65784
42	<b>CYP3A4</b>	<b>205999_x_at</b>	<b>0.65695</b>
43	KRCC1	218303_x_at	0.65562
44	P53AIP1	220402_at	0.65462
45	TLE3	212769_at	0.6535
46	ZNF669	220215_at	0.65206
47	<b>CFLAR</b>	<b>214486_x_at</b>	<b>0.65206</b>
48	<b>PAK4</b>	<b>203154_s_at</b>	<b>0.65028</b>

**Table 1.** Cont.

	Gene symbol	Probe	Spearman rank correlation
49	M78162	217536_x_at	0.6485
50	MMP11	203876_s_at	0.6485
51	RGS7	206290_s_at	-0.67475
52	ASTN1	213197_at	-0.67653
53	TMSB10	217733_s_at	-0.67653
54	SUPT4H1	201484_at	-0.67731
55	COX6B1	201441_at	-0.67742
56	WASF1	204165_at	-0.67742
57	RALYL	213967_at	-0.67786
58	BBS7	219688_at	-0.67875
59	SEC31A	200945_s_at	-0.68009
60	DDX1	201241_at	-0.68009
61	RP11-336K24.9	218291_at	-0.68098
62	GABBR2	209990_s_at	-0.68231
63	<b>SLC25A12</b>	<b>203340_s_at</b>	<b>-0.68454</b>
64	ATP5C1	205711_x_at	-0.68587
65	<b>NEFL</b>	<b>221805_at</b>	<b>-0.68632</b>
66	NDUFB8	201226_at	-0.68854
67	<b>OPA1</b>	<b>212214_at</b>	<b>-0.69255</b>
68	KPNA2	201088_at	-0.69522
69	<b>PPIA</b>	<b>211765_x_at</b>	<b>-0.69566</b>
70	CYP26B1	219825_at	-0.69566
71	COX7AP2	217249_x_at	-0.69878
72	<b>VSNL1</b>	<b>203798_s_at</b>	<b>-0.69878</b>
73	ATP6V1D	208898_at	-0.70145
74	ATP5C1	213366_x_at	-0.70234
75	NRXN1	209915_s_at	-0.7059
76	<b>PCSK2</b>	<b>204870_s_at</b>	<b>-0.70901</b>
77	<b>AI108767</b>	<b>211978_x_at</b>	<b>-0.71034</b>
78	UGCGL2	218801_at	-0.71257
79	KIAA0528	212943_at	-0.7139
80	<b>SERPINI1</b>	<b>205352_at</b>	<b>-0.71657</b>
81	LZTS1	219042_at	-0.71835
82	<b>NEFM</b>	<b>205113_at</b>	<b>-0.71835</b>
83	FRY	204072_s_at	-0.71924
84	CSPG5	205344_at	-0.72291
85	COX6A1	200925_at	-0.7277
86	COX4I1	202698_x_at	-0.73037
87	KIAA0368	212428_at	-0.73126
88	MYT1L	210016_at	-0.73304
89	PPP3CA	202457_s_at	-0.74194
90	<b>LOC100131599</b>	<b>213222_at</b>	<b>-0.74549</b>
91	CACNG3	206384_at	-0.75484
92	<b>PPP3R1</b>	<b>204506_at</b>	<b>-0.75573</b>
93	MAN1A1	221760_at	-0.75929
94	NETO2	218888_s_at	-0.76819
95	<b>LPHN1</b>	<b>219145_at</b>	<b>-0.76852</b>
96	CAPRIN2	218456_at	-0.76997
97	CAMK1G	215161_at	-0.77041
98	LDB2	206481_s_at	-0.7802

**Table 1.** Cont.

	Gene symbol	Probe	Spearman rank correlation
99	TRIM36	219736_at	-0.79622
100	LDHA	200650_s_at	-0.80245

These values are then correlated with the individual expression profiles of each probe across the set of samples. We list here the 100 probes that have the highest Spearman correlation (absolute value, computed over all samples) between the expression of the probe and the square root of the Jensen-Shannon divergence of the sample with the average Control gene expression profile. Rows in boldface indicate the cases for which a putative relationship exist in the published literature between the gene and AD. A probe that has a positive correlation with the square root of the Jensen-Shannon divergence with the average Control gene expression profile roughly indicates, in this case, a probe that, over all samples in the set, tends to increase its expression from their values in the "Control" group to the "Severe AD".  
doi:10.1371/journal.pone.0010153.t001

average gene expression profile for the classes "Control" and "Severe AD". This step is followed by the computation of the square root of the Jensen-Shannon divergence [11] of the gene expression profile of each sample with the average profiles of the classes "Control" and "Severe AD". Finally, we perform a correlation analysis of each gene expression profile (now across all samples) with the results of the square root of the Jensen-Shannon divergence (we do it twice, one for the "Control" and the other for the "Severe AD" case). With this information, and using state-of-the-art pathway analysis and text mining tools, as a result of our final analysis step, we provide a comprehensive list of results of the differentially regulated genes, patterns of up (down)-regulation and the pathways that seem to be implicated in the progression of AD. We refer to the Methods section for a completely reproducible and in-depth explanation of our methodology.

### Probe selection and Jensen-Shannon divergence computations based on class information

We start our analysis with a baseline comparison, which we have chosen to include for illustrative purposes. Figure 1 provides an example of the importance of performing an initial probe/gene selection step. The example serves as an argument for the necessity of the first two steps of our method. We have normalized each individual gene expression profile, and we have computed the average gene expression profile for classes "Control" and "Severe AD" (following the same procedure we will use in the third step of our method, but in this case using all probes in the array).

We have used the square root of the Jensen-Shannon divergence of a pair of samples (a pair of gene expression profiles) as our measure of "dissimilarity" between them. The square root of the Jensen-Shannon divergence quantifies the difference between two probability distribution functions (PDFs) and it is a metric (we refer the reader to the Methods section for a mathematical definition and a discussion of its properties). Figure 1 plots the divergence of each sample with the average expression profile of the classes 'Control' and 'Severe AD';  $\sqrt{JSD}(P, \bar{P}_C)$  denotes the square root of the Jensen-Shannon divergence between sample  $P$  and the average profile on the 'Control' class ( $\bar{P}_C$ ). Analogously,  $\sqrt{JSD}(P, \bar{P}_S)$  denotes the square root of the Jensen-Shannon divergence between sample  $P$  and the average profile on the 'Severe AD' class ( $\bar{P}_S$ ). The advantage of using the probe/gene selection steps, which reduces the number of genes to the most informative ones, will be evident when we later compare Figure 1 with Figure 2. However, Figure 1 already shows some interesting patterns. For instance, we can

observe that a high percentage of the samples from AD patients (having either 'Incipient AD', 'Moderate' or 'Severe' labels) show  $\sqrt{JSD}(P, \bar{P}_C)$  values greater than 0.115, which indicates measurable divergence with the Control average gene expression profile.

Figure 2 presents the same procedure, but only after the feature selection step has significantly reduced the number of probes from 22,215 to 1,372. We refer to the Methods section for details. In Figure 2, an arguably more coherent arrangement can be observed. As expected, the group of control samples (in green) have lower values of  $\sqrt{JSD}(P, \bar{P}_C)$  and higher values of  $\sqrt{JSD}(P, \bar{P}_S)$ . Obviously, the opposite behaviour is observed for the samples belonging to the severe cases. What cannot be expected, however, is a layout of the samples that could provide evidence of a continuous "progression" of the disease. The Figure shows that the samples of 'Incipient AD' are close to the control group and the 'Moderate AD' samples are closer to them and also link to severe AD. A priori, since those samples had not been used for probe selection, they could have been in any position in the  $(\sqrt{JSD}(P, \bar{P}_C), \sqrt{JSD}(P, \bar{P}_S))$  plane.

Finally, Figure 3 presents the results of the MMSE score as a function of the  $\sqrt{JSD}(P, \bar{P}_C)$ , showing an inverse correlation between them. A similar situation happens between MMSE and  $\sqrt{JSD}(P, \bar{P}_S)$ , but in this case low MMSE scores correspond to low values of  $\sqrt{JSD}(P, \bar{P}_S)$ , giving a positive correlation. It is this interplay between positive and negative correlations that has enabled us to find interesting biomarkers. In the next subsection, we explain how these correlations were used to identify probes that "diverge from" their values in the "Control" group and "converge to" the values in the "Severe AD" group.

### Gene correlation analysis

The third step employs a correlation analysis to select the group of probes that are the most strongly correlated. Intuitively, the idea is fairly straightforward as illustrated in the following "Gedankenexperiment" (a thought experiment). Assume, for argument's sake, that the MMSE of each patient  $P$  is not actually phenotypical information assigned to each sample. Instead, assume that the MMSE values are the microarray probe expression of some gene. In this "thought experiment", let  $MMSE(P)$  be the expression of this hypothetical gene probe on sample  $P$ , and  $f_{Dataset}$  be the set of values it has for each sample. The correlation of the sample-ordered set of values  $\{MMSE(P)\}$  with the set of sample-ordered values  $\{\sqrt{JSD}(P, \bar{P}_C)\}$  is negative, indicating that, in general, this hypothetical MMSE probe reduces its values as the whole gene expression profile of sample  $P$  diverges from the average "Control" profile (Figure 3). Analogously, there exists a positive correlation of the set of values  $\{MMSE(P)\}$  with the values of the set  $\{\sqrt{JSD}(P, \bar{P}_S)\}$ . This indicates that the values of MMSE tend to be reduced as the profile of sample  $P$  "converges to" the average profile of samples in the "Severe AD" group. We have computed these correlations for all probes in the signature, which are given in the supplementary material (File S2 sheet 'correlation Analysis') and are the basis for our analysis.

We also refer the reader to Figure 4, which presents the computed correlations. Tables 1 and 2 present the one hundred most correlated probes (in absolute values). In the supplementary material (File S2 sheet 'correlation Analysis'), the correlation of each of the 1,372 probes that were selected by our method is given (and annotated, including Affymetrix and Stanford's Source outputs) to facilitate further analyses.

As the objective is to detect the probes correlated with the progression of AD, we will select those probes with high absolute correlations values with both groups, an indication of a

**Table 2.** List of the 100 probes with the highest Spearman correlation (absolute value, computed over all samples) between the expression of the probe and the square root of the *Jensen-Shannon* divergence of all samples with the average Severe AD gene expression profile.

	Gene symbol	Probe	Spearman rank correlation
1	NEFM	205113_at	0.84472
2	NRG1	206343_s_at	0.83003
3	VSNL1	203798_s_at	0.80156
4	NEFL	221805_at	0.79889
5	SLC25A12	203340_s_at	0.79666
6	BCL11A	219497_s_at	0.79266
7	RALYL	213967_at	0.78776
8	SERPINI1	205352_at	0.78242
9	ATP2B2	204685_s_at	0.78154
10	LDB2	206481_s_at	0.7802
11	ENSA	202596_at	0.77931
12	NDUFV2	202941_at	0.77753
13	KIAA0319	206017_at	0.76418
14	ATP5C1	213366_x_at	0.7584
15	TAGLN3	204743_at	0.75617
16	SV2B	205551_at	0.75484
17	DOPEY1	213271_s_at	0.75439
18	FAR2	220615_s_at	0.75395
19	SNRK	209481_at	0.7535
20	TRIM36	219736_at	0.74994
21	NRXN1	209915_s_at	0.74772
22	PKP4	214874_at	0.74461
23	CALM3	200622_x_at	0.74149
24	PIP4K2C	218942_at	0.73971
25	CRYM	205489_at	0.73437
26	SCFD1	215548_s_at	0.73037
27	COX6A1	200925_at	0.72992
28	OPA1	212214_at	0.7277
29	ATP5C1	205711_x_at	0.72414
30	LETMD1	207170_s_at	0.71969
31	PPP2R2B	213849_s_at	0.71657
32	UQCRQ	201568_at	0.71301
33	FKBP3	218003_s_at	0.71268
34	PBX1	212148_at	0.71123
35	CACNG3	206384_at	0.71079
36	TMSB10	217733_s_at	0.70812
37	KIAA1467	213234_at	0.70812
38	INA	204465_s_at	0.7059
39	ARF5	201526_at	0.70545
40	CD200	209582_s_at	0.70456
41	CAMK1G	215161_at	0.70367
42	TUBG2	203894_at	0.70234
43	LDHA	200650_s_at	0.70189
44	LOC100131599	213222_at	0.70056
45	DIMT1L	210802_s_at	0.697
46	RGS4	204339_s_at	0.69655

**Table 2.** Cont.

	Gene symbol	Probe	Spearman rank correlation
47	CAMKK2	212252_at	0.69611
48	BE731738	212661_x_at	0.69477
49	PPP2CA	208652_at	0.69388
50	SRD5A1	211056_s_at	0.69388
51	DMN	212730_at	-0.68409
52	AW974666	222365_at	-0.68721
53	SLC33A1	203164_at	-0.68899
54	SYNC1	221276_s_at	-0.68954
55	ITGB5	201125_s_at	-0.69299
56	CNOT6	217970_s_at	-0.69655
57	DYNLT1	201999_s_at	-0.697
58	ZMYND8	214795_at	-0.697
59	TBL1X	213400_s_at	-0.69967
60	RND2	214393_a	-0.70378
61	LRP10	201412_at	-0.70545
62	GMPR	204187_at	-0.70768
63	LTF	202018_s_at	-0.70812
64	CSNK1A1	208865_at	-0.70812
65	NBPF12	213612_x_at	-0.70901
66	ZFP36L2	201368_at	-0.70945
67	AV712577	201305_x_at	-0.71212
68	FDFT1	208647_at	-0.71257
69	ADARB2	220648_at	-0.71301
70	CPT2	204264_at	-0.7139
71	ADD3	201753_s_at	-0.71524
72	37681	213256_at	-0.71613
73	ITGB8	205816_at	-0.71924
74	RBM19	205115_s_at	-0.71969
75	HIST1H1C	209398_at	-0.72058
76	NM_018612	220882_at	-0.73037
77	CD68	203507_at	-0.73259
78	GTF2A1L	213413_at	-0.73348
79	FAM114A1	213455_at	-0.73571
80	FOXO1	202724_s_at	-0.73749
81	C6orf145	212923_s_at	-0.73882
82	KRCC1	218303_x_at	-0.74149
83	TGFBR3	204731_at	-0.74372
84	ZHX3	217367_s_at	-0.74594
85	TSPO	202096_s_at	-0.74816
86	STAT5A	203010_at	-0.74994
87	AFF1	201924_at	-0.75039
88	RASL12	219167_at	-0.75217
89	AL359052	214927_at	-0.75528
90	ALDH3A2	202054_s_at	-0.75706
91	C1S	208747_s_at	-0.76062
92	AV700298	217523_at	-0.76062
93	HBEGF	38037_at	-0.76819
94	BG251521	213156_at	-0.77086
95	ZBTB20	205383_s_at	-0.77353
96	AL049443	215306_at	-0.78109

**Table 2.** Cont.

	Gene symbol	Probe	Spearman rank correlation
97	PTTG1IP	200677_at	-0.78154
98	FYCO1	218204_s_at	-0.78598
99	ATP6V0E1	214150_x_at	-0.802
<b>100</b>	<b>SERTAD2</b>	<b>202656_s_at</b>	<b>-0.84338</b>

We listed the top fifty probes with positive and negative correlation. Rows in boldface indicate the cases for which a putative relationship exist in the published literature between the gene and AD. A probe that has a positive correlation with the *square root of the Jensen-Shannon divergence* with the average Control gene expression profile roughly indicates a probe that, over all samples in the set, tends to increase its expression from their values in the "Control" group to the "Severe AD".


doi:10.1371/journal.pone.0010153.t002

divergence of the average control profile together with a convergence to the severe AD profile; these correlations computed over all sample types. We need to check both groups according to their correlations to the average profile. The first group of probes we are interested in are those that have a positive correlation with the  $\delta(\text{sqrtJSD}(P, P_C))$  and a negative correlation with  $\delta(\text{sqrtJSD}(P, P_S))$ . The probes in this group are those probes with under-expression in the non-disease sample but are over-expressed in the severe AD cases. The second group has the opposite behaviour, the probes' expression values have a negative correlation with  $\delta(\text{sqrtJSD}(P, P_C))$  and a positive correlation with

$\delta(\text{sqrtJSD}(P, P_S))$ . This pattern can be visualised in Figure 4, where the elliptical shape of the dispersion of the probes in this scatter plot indicates that our methodology has preserved all the significant probes for both classes and that there are no probes (after the filter) presenting a high correlation simultaneously with the control and severe AD profiles.


On these values a new selection criterion is applied, as we wanted to identify the group of probes that have strong correlations to both groups in absolute value. This symmetry of our argument stems from the interest in understanding the biology of the progression of the disease. For identifying disease biomarkers we may just concentrate in finding the probes that present an upregulation trend when progressing from "Control" to "Disease". However, here we would also like to identify those probes that become increasingly downregulated, which, in turn, would help us to identify significantly dysregulated biological pathways (as members of the pathway will be either up or downregulated). Towards this end, we rank the probes in the order given by their Euclidean distance from the origin of coordinates in Figure 4. We selected an arbitrary cut-off value of fifty probes (the selected probes are marked in red). These fifty probes are also identified by their Gene Symbols in Figures 5 and 6.

Calculating the distance of each probe to the origin, on the  $\text{sqrtJSD}$  system of coordinates, we further selected the 50 most distant probes and analysed their behaviour. Table 3 presents the 50 probes (corresponding to 48 genes), their correlation to each group and their distance to the origin of coordinates. File S2 sheet 'correlation Analysis' column 'E - Distance' of the supplementary



**Figure 5. Zoom of Figure 4, identifying the most distant probes from the origin with negative correlation with the control profile,  $\delta(\text{sqrtJSD}(P, P_C))$  and positive correlation with the severe profile,  $\delta(\text{sqrtJSD}(P, P_S))$ .**

doi:10.1371/journal.pone.0010153.g005



**Figure 6. Zoom of Figure 4, identifying the most distant probes from the origin with positive correlation with the control profile,  $\delta(\sqrt{\text{JSD}}(P, P_c))$  and negative correlation with the severe profile,  $\delta(\sqrt{\text{JSD}}(P, P_s))$ .**  
doi:10.1371/journal.pone.0010153.g006

material presents the distance to the origin of the 1,372 probes analysed. In Table 3, it can be seen which genes have some putative annotation that links them to AD (17 genes out of 48).

Figure 7 shows the heat map of the 50-probe signature, where the probes and patient samples are ordered by considering the similarity of their gene-expression values only. It can be observed that the Memetic Algorithm (MA), a high performance combinatorial optimization ordering method [12] for microarray datasets introduced in 2007, ordered most of the patients with or without an incipient level of AD on the left and the more severe cases on the right. When ordering the probes' gene expression, the MA perfectly sorted the groups previously described. We refer to [12,13] for details of the MA. The supplementary material (File S2 '1372 norm. +heat map+GO') presents the heat map of the 1,372 gene-probes, with samples and probes sorted by the MA.

### Transcription factors analysis of most correlated probes

The signature of 50 probes we present in Figure 7 has 48 different genes (some probes are related to the same gene). The two repeated genes in this 50-probe list are ATP5C1 (ATP synthase, H<sup>+</sup> transporting, mitochondrial F1 complex, gamma polypeptide 1) and PPIA (peptidylprolyl isomerase A (cyclophilin A)) [14,15,16,17], a calcineurin regulatory protein. A recent study that used RT-PCR to examine tissue from 90 AD and 81 control human brains reports that cyclophilin is reduced in AD (both for females and males as compared with their gender-matched groups) [18]. We note here that the cutoff of 50 probes circumscribes the initial description a little, but most of the later discussion uses information from the whole signature to identify dysregulated

pathways. Figure 8 presents the heat map of the 1,372-probe signature. The probes were sorted with the MA but the samples remain in the same position as obtained previously with the 50-probe signature.

We analysed this list of genes using GATHER [19], an online tool for annotating signatures. Forty-one genes out of fifty have a motif for EVI1 (ecotropic viral integration site 1) and thirty-nine of them have a binding motif with V\$TCF1P\_Q6 (TCF1: transcription factor 1, hepatic; LF-B1, hepatic nuclear factor (HNF1), albumin proximal factor). The same analysis can be done if we divide the set of genes in two groups. The first group has positive correlation with the control profile and are overexpressed in AD; the second group has a positive correlation with the severe profile, and tend towards being underexpressed in AD (see Table 3). Table 4 presents the overrepresented motifs. We note, however, that we believe that the best results to identify putative overrepresented regulatory motifs can be obtained using the whole signature of 1,372 probes, and we will present the results of this investigation after presenting the case of the most correlated probes.

Another interesting pattern emerged when analysing the KEGG Pathways of the 50-probe signature using GATHER and PATHWAY Studio [20]. Using GATHER, three KEGG Pathways appear significantly represented, Amyotrophic lateral sclerosis (ALS), Oxidative phosphorylation and ATP synthesis. Using PATHWAY Studio, we automatically built the "common-regulators" diagram by selecting a filter that only considers protein interactions and binding. The resulting diagram is presented in Figure 9. As can be seen from the figure, we have chosen a circular



**Table 3.** The 50 genes most distant to the origin of the coordinates space  $\delta(\text{sqrtJSD}(P,P_C)) \times \delta(\text{sqrtJSD}(P,P_S))$ .

Probe Set ID	Gene Symbol	Gene Title	$\delta(\text{sqrtJSD}(P,P_C))$	$\delta(\text{sqrtJSD}(P,P_S))$	Dist O	Ref (ADG)
206481_s_at	LDB2	LIM domain binding 2	-0.7988	0.7427	1.0907	
219736_at	TRIM36	tripartite motif-containing 36	-0.8077	0.7242	1.0848	
200650_s_at	LDHA	lactate dehydrogenase A	-0.8210	0.6984	1.0778	
205113_at	NEFM	neurofilament, medium polypeptide 150kDa	-0.7448	0.7742	1.0743	[379,649,672,673,674,675,676,677,678,679,680,681,682,683,684,685,686,687,688,689,690,691,692,693,694,695,696,697,698,699,700,701,702]
202656_s_at	SERTAD2	SERTA domain containing 2	0.7343	-0.7827	1.0732	
203798_s_at	VSNL1	visinin-like 1	-0.7093	0.7923	1.0634	[565,566,638,641,642,703,704,705]
205352_at	SERPINI1	serpin peptidase inhibitor, clade I (neuroserpin), member 1	-0.7432	0.7496	1.0555	[706,707,708,709,710,711,712,713,714]
217367_s_at	ZHX3	zinc fingers and homeoboxes 3	0.7677	-0.7129	1.0477	
209915_s_at	NRXN1	neurexin 1	-0.7282	0.7496	1.0451	
221805_at	NEFL	neurofilament, light polypeptide 68kDa	-0.7153	0.7552	1.0402	[715,716,717]
213366_x_at	ATP5C1	ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1	-0.7302	0.7327	1.0344	
203340_s_at	SLC25A12	solute carrier family 25 (mitochondrial carrier, Aralar), member 12	-0.7141	0.7444	1.0315	[718]
213967_at	RALYL	RALY RNA binding protein-like	-0.6786	0.7758	1.0307	
215161_at	CAMK1G	calcium/calmodulin-dependent protein kinase IG	-0.7819	0.6682	1.0285	
218204_s_at	FYCO1	FYVE and coiled-coil domain containing 1	0.7250	-0.7222	1.0233	
213222_at	PLCB1	phospholipase C, beta 1 (phosphoinositide-specific)	-0.7694	0.6738	1.0227	[719,720,721,722,723,724]
200925_at	COX6A1	cytochrome c oxidase subunit VIa polypeptide 1	-0.7532	0.6883	1.0204	
38037_at	HBEGF	heparin-binding EGF-like growth factor	0.7222	-0.7194	1.0193	[725]
209481_at	SNRK	SNF related kinase	-0.7048	0.7331	1.0169	
201412_at	LRP10	low density lipoprotein receptor-related protein 10	0.6964	-0.7399	1.0161	
202941_at	NDUFV2	NADH dehydrogenase (ubiquinone) flavoprotein 2, 24kDa	-0.6984	0.7379	1.0160	
205383_s_at	ZBTB20	zinc finger and BTB domain containing 20	0.6774	-0.7569	1.0157	[726,727]
206384_at	CACNG3	calcium channel, voltage-dependent, gamma subunit 3	-0.7778	0.6516	1.0147	
218888_s_at	NETO2	neuropilin (NRP) and tolloid (TLL)-like 2	-0.7899	0.6246	1.0070	
212214_at	OPA1	optic atrophy 1 (autosomal dominant)	-0.7194	0.7024	1.0054	[728,729,730,731,732,733,734,735,736,737,738,739,740,741,742]
218456_at	CAPRIN2	caprin family member 2	-0.7915	0.6186	1.0046	
211307_s_at	FCAR	Fc fragment of IgA, receptor for	0.7297	-0.6886	1.0033	
202724_s_at	FOXO1	forkhead box O1	0.6875	-0.7270	1.0006	[743,744,745]
219145_at	LPHN1	latrophilin 1	-0.7293	0.6826	0.9989	[746]
205711_x_at	ATP5C1	ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1	-0.7153	0.6968	0.9986	
55662_at	C10orf76	chromosome 10 open reading frame 76	0.7632	-0.6420	0.9973	
211978_x_at	PPIA	peptidylprolyl isomerase A (cyclophilin A)	-0.7363	0.6726	0.9972	[747,748,749,750]
210016_at	MYT1L	myelin transcription factor 1-like /// hypothetical protein LOC100134306	-0.7577	0.6395	0.9915	
204072_s_at	FRY	furry homolog (Drosophila)	-0.7456	0.6512	0.9899	
219497_s_at	BCL11A	B-cell CLL/lymphoma 11A (zinc finger protein)	-0.6843	0.7117	0.9873	
201125_s_at	ITGB5	integrin, beta 5	0.7323	-0.6613	0.9867	

**Table 3.** Cont.

Probe Set ID	Gene Symbol	Gene Title	$\delta(\text{sqrtJSD } (P,P_c))$	$\delta(\text{sqrtJSD } (P,P_s))$	Dist O	Ref (ADG)
211765_x_at	PPIA	peptidylprolyl isomerase A (cyclophilin A)	-0.7230	0.6714	0.9866	[747,748,749,750]
214057_at	MCL1	Myeloid cell leukemia sequence 1 (BCL2-related)	0.7722	-0.6137	0.9864	[751]
211839_s_at	CSF1	colony stimulating factor 1 (macrophage)	0.8120	-0.5590	0.9858	[752,753,754,755,756,757,758,759,760,761,762,763,764,765,766,767,768,769,770,771,772,773,774,775,776,777,778,779,780,781,782]
205551_at	SV2B	synaptic vesicle glycoprotein 2B	-0.6915	0.7008	0.9846	[66]
219167_at	RASL12	RAS-like, family 12	0.6226	-0.7605	0.9828	
214393_at	RND2	Rho family GTPase 2	0.7051	-0.6799	0.9796	
212899_at	CDC2L6	cell division cycle 2-like 6 (CDK8-like)	0.7319	-0.6504	0.9791	
220615_s_at	MLSTD1	male sterility domain containing 1	-0.6665	0.7149	0.9774	
201681_s_at	DLG5	discs, large homolog 5 (Drosophila)	0.7093	-0.6706	0.9761	
208195_at	TTN	titin	0.7173	-0.6617	0.9759	[783]
202457_s_at	PPP3CA	protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform	-0.7661	0.6016	0.9741	
214150_x_at	ATP6V0E1	ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e1	0.6230	-0.7488	0.9741	
204743_at	TAGLN3	transgelin 3	-0.6952	0.6802	0.9726	
213197_at	ASTN1	astrotactin 1	-0.7069	0.6673	0.9721	

The column "Dist O" shows the Euclidean distance from the origin for each gene. If the gene has a known relation with AD (ADG), the reference's codes are display in column "Ref ADG".

doi:10.1371/journal.pone.0010153.t003

membrane layout and our previously uncovered 5-protein signature [1] (IL1-a, TNF-a, IL-3, EGF and G-CSF) in plasma (plus IL-6) appears to have a strong relationship with CSF1 (colony stimulating factor 1 (macrophage)), the most positive correlated gene with the control profile (see Table 1). It is also worth mentioning, that CSF1 was found differentially expressed in blood of AD and Control subjects and belongs to the 18-protein signature uncovered by Ray *et al.* [2] in 2007.

#### Five of the 50 most correlated probes correspond to genes already mapped to KEGGs Alzheimer's disease Pathway KEGG:05010 and together with LDHA they link to impaired metabolism and the "novel glucocorticoid hypothesis"


We have observed that five genes, which are the most correlated probes with our putative signature for disease severity, can be mapped to the AD pathway of the Kyoto Encyclopaedia of Genes KEGG:05010. They are ATP5C1, COX6A1 [21,22], NDUFV2 [23,24,25,26,27,28,29,30], PLCB1 [31,32,33,34], and PPP3CA (protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform), the last one also known as Calmodulin-dependent calcineurin A subunit alpha isoform. In all cases, the probes showed a reduction of expression with AD severity, which may indicate a sign of impaired mitochondrial functions and energy uptake [35,36].

In addition to these five, we observed the reduced expression of the glycolytic enzyme LDHA, which may also indicate another challenge for energy metabolism in these neurons. Although glucose is generally considered to be the only substrate for brain energy metabolism, monocarboxylates have also been hypothesised as alternative substrates [37]. Laughton *et al.* report segregation in

the hippocampus, with LDHA present in astrocytes and not in neurons. Instead, it is pyruvate dehydrogenase that is present in neurons but not in astrocytes and as a consequence of this study they support the argument that a metabolic compartmentalization exists in the human cortex and hippocampus where lactate produced by astrocytes could be oxidized by neurons [37]. We have also observed a reduction in expression of a probe that corresponds to PDHA1 (Pyruvate dehydrogenase (lipoamide) alpha 1, 200980\_s\_at) with increasing AD severity. The reduction of PDH expression, and the concurrent increase in pyruvate carboxylase gene expression, was discussed by Landfield *et al.* [38], who argue that: "These changes suggest that reduced pyruvate flux through PDH and decreased oxidative metabolism of glucose may develop early in AD. Interestingly, the inactivation of PDH is also a major pathway through which glucocorticoid activity acts to conserve glucose, and apparently, to induce insulin resistance [65,66]. Thus, our data are consistent with the possibility that GC effects on this and other important target pathways in brain are enhanced in both aging and AD. If so, such alterations in glucocorticoid efficacy may have implications for AD pathogenesis as well as for the increased risk of AD associated with normal aging." Our results seem to indicate that LDHA might also be discussed within the extended metabolic pathways that serve as the basic framework of this novel, more complex hypothesis [38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55].

#### Four of the 50 most correlated gene probes are linked to synaptic function and neurofilament bundle assembly and also have reduced expressions with AD severity

NEFM, NRXN1, SV2B, and NEFL all have a similar pattern of reduced gene expression with AD severity. Experiments with mice depleted of the NEFL have been previously reported in the



**Figure 7. Heat map of the 50-probe signature and the transcription factors with best  $p$ -values, for the whole set of 50 probes and for the two groups considered.** The samples and probes were sorted using the memetic algorithm given in [12], using the Euclidean distance. The transcription factors were obtained using Chang and Nevins' GATHER system to interpret genomic signatures [634]. The coloured cell and the number 1 indicate that the transcription factor has a binding motif with the gene for that row. The levels of severity as defined by Blalock *et al.* [635] are indicated in the first line: (0) Control, (1) Incipient AD, (2) Moderate AD and (3) Severe AD.  
doi:10.1371/journal.pone.0010153.g007


literature. Dubois *et al* state that this procedure: “mimics the reduced *NFL* mRNA levels seen in amyotrophic lateral sclerosis and causes perikaryal accumulation of neurofilament proteins and axonal hypotrophy in motoneurons. *NFL*−/− mice was evaluated for regional brain metabolism by means of quantitative histochemical estimation of cytochrome oxidase activity.” [56]. Mutations in the *NEFL* gene [56,57,58,59,60,61,62] and in the *NEFM* [63] have been linked to Charcot-Marie-Tooth disease. We will discuss the loss of expression of *NRXN1* (Neurexin 1) later, when we comment on its presence in a panel of putative genes linked to prion-induced neurodegeneration [64]. However, we note here that both *NRXN1* and *NEFL* appeared to be downregulated on a transcriptional profiling study of prion infection in mice [65].

The loss of expression of *SV2B* is also interesting. In 2001, Heese *et al.* [66] reported “a new transcript of *SV2B* (*SV2Bb*) mRNA that is up-regulated at mRNA level in neurons by amyloid beta peptide (*Abeta*) fragment (1–42). In comparison to *SV2B* this new mRNA encodes for the same protein but it has an elongated 3′-untranslated region (3′ UTR) that contains several AU-rich (*AUR*) cis-acting elements which are probably involved in posttranscriptional regulating of *SV2Bb* translation. In conclusion, alteration of *SV2B(b)* expression appears to be involved in processes of neuronal degeneration” (see also [67]). We note that *SV2B* is only expressed in vesicles that undergo calcium-regulated exocytosis [68] and is a regulator of synaptotagmin 1 [69], which is a synaptic calcium sensor with a role in neurotransmitter release previously studied in

AD [70,71,72,73,74,75]. We present a number of genes related to synaptic function and neuronal plasticity which are increasingly down/up regulated later on the manuscript and on the supplementary material (File S3 Sheet ‘Synapse’).

### Analysis of the 1,372-probe signature reveals alterations in calcium and insulin signalling

Using GATHER, we have identified 32 genes in the Calcium signalling pathway [http://www.genome.jp/dbget-bin/show\\_pathway?hsa04020](http://www.genome.jp/dbget-bin/show_pathway?hsa04020) ( $p$ -value<0.009). They are *ADCY2*, ***ADORA2B***, ***AGTR1***, *ATP2A3*, *ATP2B1*, *ATP2B2*, *ATP2B4*, ***AVPR1A***, *CALM1*, *CALM3*, *CREBBP*, *GNA14*, *GNAS*, ***GRM5***, ***HTR2A***, *ITPR1*, *ITPR2*, ***LHCGR***, *NFATC1*, *PHKA2*, *PLCB1*, *PLCE1*, *PPP3CA*, *PPP3R1*, *PRKCB1*, ***PTAFR***, *SLC25A6*, *SLC8A2*, *SYK*, ***TBXA2R***, *TNNC2*, and *TTN*. We cannot do enough justice in this manuscript to the several different hypotheses that point at imbalances/deregulation in calcium signalling and AD pathology. Instead, we contribute to these interesting discussions with our findings of genes related to this pathway within this group of 32 genes. The gene symbols in boldface can be mapped to the KEGG Pathway *hsa04080*, *Neuroactive ligand-receptor interaction*; those in italics can be mapped to KEGG Pathway *hsa04310*, *Wnt Signalling*. Being aware of the existing interest on Wnt Signalling and AD, we went back to the list of genes present in our (*alpha,beta*)-*k*-feature set signature and we identified others that can also be linked to Wnt signalling, like *CSNK1G3*, *CSNK2A2*, *FRAT1*[76,77,78,79,



**Figure 8. Heat map of 1,372-probe signature.** The probes were sorted using the memetic algorithm but the samples remain in the same order than the 50-probe signature.  
doi:10.1371/journal.pone.0010153.g008

80,81,82,83,84,85,86,87,88,89], FZD5[89,90,91], MDFIC, PIAS4, SOX2 [92,93,94,95,96], TCF7L1/TCF3[89,97,98], TCF7L2/TCF4 [99,100,101,102,103,104,105,106], and TLE3[106,107,108,109].

**Table 4. Binding factors related to two groups of genes.**

Transcription Factors	Description	P value
<i>First group</i>		
V\$EVI1_04	Ectopic viral integration site 1 encoded factor	0.00069
V\$SMAD4_Q6	SMAD family member 4	0.0033
<i>Second Group</i>		
V\$HNF1_C	Hepatic nuclear factor 1	0.0022
V\$ACAAT_B	Avian C-type CCAAT box	0.0015

The second group has the opposite behaviour, that is, positive correlation with the severe profile.

The first group has positive correlation with the control profile.

doi:10.1371/journal.pone.0010153.t004

In addition, most of the remaining 32 genes in the *Calcium signalling pathway* can be mapped to KEGG Pathway hsa04070, *Phosphatidylinositol signalling system* (CALM1, CALM3, ITPR1, ITPR2, PLCB1, PLCE1, PRKCB1), and *Gap Junction* (ADCY2, GNA14, GNAS, GRM5, HTR2A, ITPR1, ITPR2, PLCB1, PRKCB1).

This fact suggested that we should check how many genes were mapped to these pathways. We found that *Phosphatidylinositol signalling system* was indeed the third pathway with most “hits” in our signature, and also with other 12 genes (CDIPT, CSNK1G3, PIK3C3, PIK3R1, PIK3R4, PI4KB, PIP5K1A, PIP5K1C, PIP4K2C, PTEN, SKIP and TTK) which brings the total number to 19. We have also found (CCND3, CSNK1A1, CSNK2A2, CTBP1, CTBP2, FRAT1, FZD5, PPAR, PPP2CA, PPP2R2B, RBX1, SMAD3, TBL1X, TCF7L1, TCF7L2, VANGL1) bringing the total to 22 genes. We refer the reader to the supplementary material (File S3 Sheet ‘Phosphatidylinositol signalling’) for inspection of the individual pattern of expression of all these genes.


Together with the 20 genes mapped to the Insulin signalling pathway KEGG hsa04910 (ACACA, CALM1, CALM3, EIF4E2, FOXO1A, INSR [110,111,112,113,114,115,116,117], MAPK1, PDE3A, PHKA2, PIK3R1, PIK3R4, PPP1CC, PRKAR2A, PRKAR2B, PRKCI, RHEB, RHOQ, RPS6KB2, SKIP, and TSC2), our results seem to give some support to the hypothesis of altered calcium dynamics [35,118,119,120,121,122,123,124, 125,126,127], deregulation of insulin signalling [36,41,113,114, 115,116,128,129,130,131,132,133,134,135,136,137,138,139,140, 141,142,143,144,145,146,147,148,149,150,151,152,153,154,155, 156,157,158,159,160,161,162,163,164,165] and the implication of the Wnt pathway [166,167,168,169,170,171,172,173,174, 175,176,177,178,179,180,181,182,183,184,185,186,187,188,189, 190,191,192,193,194,195,196,197,198,199] in AD pathogenesis.

Figures 10, 11, 12, 13, and 14 illustrate down(up)-regulation of genes in these signalling pathways (Calcium signalling, Neuroactive ligand receptor pathway, WNT, Phosphatidylinositol and Insulin signalling, respectively). Figure 15 shows the expression of probes corresponding to genes for which there are known associations to synaptic function and neuronal plasticity. We refer the reader to the supplementary material (File S3) for more searchable information.

#### Transcription factors analysis of 1,372-probe signature reveals significant associations with the EGR/KROX family of proteins, MAZ, and E2F1

The analysis of the 1,372-probe signature indicates that they can be linked to putative transcription factors that have been previously implicated in AD and other neurodegenerative diseases. Using GATHER, we have observed that there is a strong association with motif V\$KROX\_Q6 ( $p$ -value<0.0004) with 719 out of 1294 genes in our signature; V\$MAZ\_Q6 ( $p$ -value<0.001, with 1003 genes); and V\$E2F1\_Q6\_01 and V\$E2F1\_Q3\_01 (with  $p$ -values which are smaller than 0.002 and 0.009 respectively). Of the 1294 genes associated with the 1,372 probes (by GATHER), more than half of them (656) have a motif for V\$E2F1\_Q6\_01 and 603 have a motif for V\$E2F1\_Q3\_01.

MAZ (MYC-associated zinc finger protein (purine-binding transcription factor)), also known as ZF87 and Cys2His2-type zinc finger transcription factor serum amyloid A activating factor 1 [200], has been previously implicated in Alzheimer’s disease [201] and as a blood biomarker in schizophrenia [202]. MAZ interacts with DCC, the receptor for netrin-1, a neuronal survival factor [203]. Deregulation of cyclin-dependent kinases and abnormal patterns of E2F1 regulation have also been linked with Alzheimer’s




**Figure 9. 'Common-regulators' 50-probes' signature.** The figure was obtained using Pathway Studio [569]. The program received as input the 50-probes displayed in Fig. 7 and automatically searched all the known putative common regulators relationships. The highlighted proteins are the 5-protein signature (IL1- $\alpha$ , TNF- $\alpha$ , IL-3, EGF and GCSF) of [1]. We have also highlighted IL-6 (discussed in [1] in the context of results of classifiers that also use it) and CSF1, Colony-stimulating factor 1, (macrophage). doi:10.1371/journal.pone.0010153.g009


disease [204,205,206,207,208], neurodegeneration [205,207,209,210, 211,212,213,214,215], and neuronal apoptosis [216,217,218,219,220].

The involvement of the EGR/KROX (immediate early genes) family of proteins in the pathogenesis of Alzheimer's disease was first suggested in [221]. Studies of the behavioural consequences of stress have shown a link between the activation of the glucocorticoid receptor mediated response and EGR1, one of the members of this family [222]. It has been recently proposed that different members of the EGR/KROX family have dif-

ferent roles in learning and memory and cognitive functions [223,224,225,226,227,228]. Mutant mice experiments showed that EGR1/KROX24 is required for the consolidation of long-term memory, while it is EGR3 the one linked to short-term memory [229], with EGR2 having perhaps other type of phenotypic characteristics not yet mapped [230]. In rat hippocampus, EGR1 decreases with aging [231]. In a recent study, it has been shown that initial playbacks of novel songs transiently increase EGR1 but that the observed response selectively




**Figure 10. Calcium signaling pathway.** The upper graph presents the stacked normalized expression values of all the probes involved in the Calcium signaling with an upregulation trend. The lower graph analyses the genes involved in the pathway with a downregulation tendency. In the supplementary material (File S3 sheet 'Calcium signalling pathway'), the reader will find all the individual gene expression values, normalised and not normalised. doi:10.1371/journal.pone.0010153.g010




**Figure 11. Neuroactive ligand-receptor interaction pathway.** The upper graph presents the stacked normalized expression values of all the probes involved in the pathway with an upregulation trend. The lower graph analyses the genes involved in the pathway with a downregulation tendency. In the supplementary material (File S3 sheet 'Neuroactive ligand-receptor'), the reader will find all the individual gene expression values, normalised and not normalised.

doi:10.1371/journal.pone.0010153.g011





**Figure 12. WNT signaling pathway.** The upper graph presents the stacked normalized expression values of all the probes involved in the pathway with an upregulation trend. The lower graph analyses the genes involved in the pathway with a downregulation tendency. In the supplementary material (File S3 sheet 'Wnt Signalling'), the reader will find all the individual gene expression values, normalised and not normalised. doi:10.1371/journal.pone.0010153.g012





**Figure 13. Phosphatidylinositol signaling pathway.** The upper graph presents the stacked normalized expression values of all the probes involved in the pathway with an upregulation trend. The lower graph analyses the genes involved in the pathway with a downregulation tendency. In the supplementary material (File S3 sheet 'Phosphatidylinositol signalling'), the reader will find all the individual gene expression values, normalised and not normalised.  
doi:10.1371/journal.pone.0010153.g013



**Figure 14. Insulin signaling pathway.** The upper graph presents the stacked normalized expression values of all the probes involved in the pathway with an upregulation trend. The lower graph analyses the genes involved in the pathway with a downregulation tendency. In the supplementary material (File S3 sheet 'Insulin signalling'), the reader will find all the individual gene expression values, normalised and not normalised.  
doi:10.1371/journal.pone.0010153.g014

habituates after repetition of the stimulus, with a different expression profile after one day [232] (see [233] and also [234] in which the homolog of NEFM, one of our biomarkers of reduced expression with increasing 'AD severity' called NF-M, is showed to be involved in the development and/or maturation of the oscine song control system).

We found the following connection between EGR/KROX, E2F1 and MAZ transcription factors that makes their concurrent finding notable. A recent study of microRNA signature of prion-induced neurodegeneration [64] has shown that EGR1, E2F1 and MAZ might be also implicated in the putative deregulation of immune response related genes by miRNAs via modulation of transcriptional regulators in scrapie-infected mice. We leave these findings for the next section of the manuscript where we will discuss them and present a list of common differentially expressed genes in these two neurodegenerative processes.

### The 1,372-probe signature contains a significant number of genes differentially expressed that are linked to synaptic function and neuronal plasticity



The existence of several genes among the most correlated ones (NRXN1, SV2B, NEFM, etc.) motivated us to try to identify which genes were present in the 1,372-probe signature that are also related to synaptic function and neuronal plasticity. We have identified 42 probes that can be divided into two groups, those that seem to be increasingly downregulated with AD severity (CABP1 [235,236,237,238,239,240,241,242,243], CADPS2 [244,245,246,247,248,249], COLQ [250], DMD [251,252,253,254,255,256], ELOVL2 [257], FAIM2/LFG [258,259,260,261], GABBR2 [262,263,264,265], GRIA2/GLUR2 [266,267,268,269,270,271,272,273,274,275,276,277], ITPR1 [278,279,280,281,282,283], KIAA0528, LZTS1/FEZ1 [284,285], NEFM, NRG1, NRXN1, NUFIP1 [286,287,288], PPT1 [289,290,291,292,293,294,295,296,297,298,299,300,301], PSD3, RAB3B [302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317], RIMS2 [318,319,320,321], SHANK2 [322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340], SV2B [68,69,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359]) and those that present an upregulation pattern (CASK [360,361,362], CDK5R1 [363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379], CHRNA1, CHRNA9, CHRN3, CTBP2, DLG1/SAP97 [380,381,382,383,384,385,386,387,388], DLGAP2, GABRA5 [389,390,391,392,393,394], GABRQ [395], GLRA3 [396,397,398], GRIK3/GLUR7 [399], HOMER3 [400], ICA1 [401], ITGB1 [402,403], MCTP1 [404,405], PPP1CC [406], SNPH [407,408,409,410,411,412,413,414], SSPN [415], SYNC1, and USH1C [416,417,418]). The reader can consult the supplementary material (File S2) for the individual expression patterns of these genes. If, in agreement with Klemmer *et al.* [362], consider synapses as the most complex cellular organelle, with approximately 1500 proteins interacting in an activity dependent manner, we can argue that we must be inclusive with our list of references to help other researchers map the literature of their functions. Our aim is that experts can use this information to find ways of building novel testable hypotheses of AD neuronal plasticity impairment in the hippocampus. Our approach here has been to map what is currently known, and link it with the current biomedical literature, to facilitate experts that understand processes in detail.

We have already discussed some of the increasingly downregulated genes, another important candidate for further study is NRG1 (Neuregulin 1), a gene that has already been linked to several neuronal diseases. It is a candidate for susceptibility to schizophrenia and bipolar disorder (see [419,420,421,422,423,424,425,426,427,428,429,430,431,432,433,434] and references therein). There have been reported links of NRG1 with AD. BACE1 (beta-Site APP-cleaving enzyme) is necessary for the cleavage of the amyloid-beta precursor protein, and BACE1 participates in the proteolytic processing of NRG1 [435,436], and there exists some concerns about BACE1 inhibition as a potential therapeutic intervention due to its interaction with NRG1 and potential effects on remyelination [437]. In particular, NRG1 has been reported as a possible biomarker in cerebral spinal fluid, since its levels have been reported to be significantly increased in AD. Pankonin *et al.* suggest that: "While (NRG1) is not detected in human serum, a novel neuregulin antagonist activity was identified in human serum that could have prevented its detection. These results suggest that human neuregulin is selectively targeted from cortical neurons to white matter extracellular matrix where it exists in steady-state equilibrium with cerebral spinal fluid where it has the potential to serve as a biological marker in human neuronal disorders" [438]. NRG1 seems to collaborate with the ERBB4 receptor, and Li *et al.* propose that together they control glutamatergic synapse maturation and plasticity [439]. A single nucleotide polymorphism in NRG1 has also been associated as a risk factor to positive symptoms of psychosis in a proportion of late-onset AD [440]. With this evidence it is clear that NRG1 [439,441,442,443,444,445,446,447] as well as the whole panel presented here are excellent candidates for further studies due to their well supported role in synaptic function in health and disease states.

### Other biomarkers of interest

We should also mention some other biomarkers that could be interesting for further studies, including imaging purposes, like TSPO/PBR (translocator protein (18kDa)) also known as Mitochondrial Benzodiazepine Receptor (peripheral), thus supporting its current role as a putative imaging biomarker for AD [448,449,450,451,452,453,454,455], C1S (complement component 1, s subcomponent) [456,457,458,459,460,461], FDFT1 (the squalene synthase gene), which is critical for cholesterol synthesis [462,463], BMP4 [92,96,464,465], CD68 (as marker of enhanced lysosomal activity) [450,466,467,468,469,470,471,472], SERTAD2/TRIP-Br2 [473,474,475], LTF (Lactotransferrin) [476,477,478], FTL (ferritin, light polypeptide; Ferritin light chain) [479,480,481,482], MTF1 (Metal-regulatory transcription factor 1) [483,484,485], GSTA3 (Glutathione S-transferase A3), GSTM4 (Glutathione S-transferase M4), MT1L (Metallothionein 1L (gene/pseudogene) [486] (a human-specific truncated protein which may have changed its function or suppressed it [487]), MT1H (Metallothionein 1H) [488], MT1F (Metallothionein 1F) [488,489] (Figure 16). These last three upregulated genes need to be put in concert with other reports on methallothioneins in AD brains [490,491,492]. Figure 16 shows the upregulation of Lactotransferrin, FTL (ferritin, light polypeptide; Ferritin light chain), and the Metallothionein family with increasing AD severity.

Other probes which present an upregulation trend that we would like to highlight are BCL2 [493,494], FYCO1 [495,496], PAX6 [111,497,498,499] (Figure 17), and QKI [500] (Figure 18).




**Figure 15. Genes related to synapse and neuronal plasticity.** The upper graph presents the stacked normalized expression values of all the related probes with an upregulation trend. The lower graph analyses the genes involved with a downregulation inclination. In the supplementary material (File S3, Sheet 'Synapse'), the reader will find all the individual gene expression values, normalised and not normalised. doi:10.1371/journal.pone.0010153.g015


The increase of expression of these probes, together with SOX2, is intriguing as they are related to differentiation from stem cells and are considered critical in neurogenesis [501,502,503,504,505,506, 507,508,509,510]. Our results support the combined use of them in tracking AD progression in this tissue. In addition, we have previously mentioned the relevance of EGR1 in coordinating a large number of genes that seem to be differentially expressed in this study. EGR1 also appears with a marked upregulation in severe AD patients (we refer to the supplementary material File S2 Sheet '1372 norm. +heat map+GO' for its gene expression profile). We found that this link is very important, as the homologues of EGR1, zif268, Egr-1 or ZENK, together with other members of the EGR family, are consolidating a key role in the neuronal plasticity in the brain [226,230,511,512,513,514,515,516,517, 518,519,520,521,522,523,524,525,526,527,528,529,530,531,532, 533,534,535,536,537,538,539,540,541,542,543,544,545,546,547, 548,549] and links with AD and cognitive decline progression are starting to be reported [514,515,550,551,552,553,554].

At the same time, prospective studies should encompass some other genes which appear downregulated with increasing AD

severity. Top of the list is perhaps LDB2/CLIM1 (LIM domain binding 2), recently pointed as a marker (with LMO4 [555,556]) of the control program of the development of neuronal subtype diversity of the cerebral cortex [557]. TRIM36 is another interesting candidate for further studies [558]. A gene that shares the same trend of downregulation is CAMK1G (calcium/calmodulin-dependent protein kinase IG) [559,560,561,562, 563,564]. When analysing prefrontal cortical tissue from mice with inducible deletions of BDNF (Brain-derived neurotrophic factor), Glorioso *et al.* employed microarray gene expression profiling to show that there were alterations to early-immediate genes (including EGR1) and CAMK1G [563]. They conclude their manuscript stating that: "while altered BDNF expression may not represent the primary disturbance in AD, changed expression of, or altered responsiveness to BDNF (and subsequently decreased SST levels) may represent a critical feature of Alzheimer's disease progression." VSNL1 (Visinin-like protein 1) [565], a CA<sup>++</sup> sensor protein is also down-regulated (see Figure 19), a finding which is paralleled in the work of Youn *et al.* [566], who found similar changes in hippocampus.



**Figure 16. Metallothionein family.** Stacked line graph of the probes related to the Metallothionein family in the 1372-probe signature. doi:10.1371/journal.pone.0010153.g016



**Figure 17. Stacked line graph of the probe expression of Ferritin Light Chain, Lactotransferrin, and the Methallothionein family, in the 1,372-probe signature, that shows an increasing upregulation with AD severity. The expression of a PAX6 probe shows increasing upregulation with AD severity.**

doi:10.1371/journal.pone.0010153.g017

## Discussion


### Putative common genes involved in Alzheimer's disease and prion-induced neurodegenerative processes

In late 2008, a paper was published in PLoS ONE, shortly after the publication of our signature for prediction of clinical symptoms of AD [1] appeared online [64]. In this other contribution, Saba *et al.* present a microRNA signature of prion induced neurodegeneration [64]. By examination of the promoter regions of putative microRNA targets, they found that some transcription factor motifs were significantly enriched, E2F-1 ( $p$ -value =  $6.01 \times 10^{-14}$ ), KROX ( $p$ -value =  $9.34 \times 10^{-14}$ ), MAZ ( $p$ -value =  $2.23 \times 10^{-11}$ ) and PAX6 ( $p$ -value =  $1.76 \times 10^{-9}$ ). Our identification of EGR1/KROX-24 and PAX-6 as upregulated with AD progression, and the identification of motif V\$KROX\_Q6, V\$MAZ\_Q6, V\$E2F1\_Q6\_01, V\$E2F1\_Q3\_01 as enriched in our signature were two contributing factors that motivated us to explore any further similarities that we could find.

In [64], an analysis of the predicted target genes of their microRNA signature, linked with differentially expressed genes in scrapie-infected mice [65] as well as two other publications [567,568], led Saba *et al.* [64] to identify a network of de-regulated immune response-related genes. Additionally, they identified the putative transcription regulator genes that are targets of

miRNAs similarly de-regulated. In essence, a possible hierarchy of deregulations of microRNAs, which, deregulated transcription factors that then, modify 1282 target genes. A Gene Ontology analysis also indicated that the “data sets were found to be in the significant enrichment for genes involved in cell death, regulation of the cell cycle, nervous system development and function and cell signalling pathways.”

As a consequence, we have investigated if some of the 1,282 putative target genes of the miRNA signature of prion induced neurodegeneration also appear in our lists. Of those 1,282 genes we immediately noticed that there were 9 genes listed in our list of the 50 most correlated genes (Table 3). These genes are BCL11A, CSF1, DLG5, FOXO1, HBEGF, NRXN1, SERTAD2, SNRK and ZBTB20. Two of these genes, CSF1 (colony stimulating factor 1 (macrophage)) and HBEGF (heparin-binding EGF-like growth factor) appear to be conspicuous mediators of cytokine and growth factor signalling as Figure 9 illustrates (we obtained this network using *Pathway Studio* [569] as described in the previous section), and CSF1 and HBEGF seems to be increasing with AD severity. In opposition, the probe corresponding to NRXN1 (Neurexin 1, 209915\_s\_at) has decreasing expression (Figure 20). Although no connection has been found between NRXN1 and AD yet, this gene has been implicated in autism [570,571,572,573,574, 575,576], schizophrenia [577,578,579,580,581], nicotine and




**Figure 18. The expression of a QKI probe, like PAX6, also shows increasing upregulation with AD severity.**  
doi:10.1371/journal.pone.0010153.g018

alcoholism dependence [582,583,584], and mental retardation [585]. SERTAD2 (SERTA domain containing 2), mentioned in the previous section, is also known as Transcriptional regulator interacting with the PHD-bromodomain 2, TRIP-Br2, a member of the TRIP-Br family of transcriptional regulators, required for the transduction of mitogenic signals and the execution of serum-inducible E2F-mediated cell cycle progression [473]. In our data, the probe for SERTAD2 is increasing with AD severity. It has also been reported that overexpression of SERTAD2 is sufficient to transform murine fibroblasts and promotes tumorigenesis in athymic nude mice due to the deregulation of the E2F/DP-transcriptional pathway thanks to the upregulation of the key E2F-responsive genes [474]. FOXO1 (Forkhead box O1) also appears upregulated with increasing AD severity, and has been reported as a negative regulator of EGR1 expression via the activation of the PI3K/Akt/Forkhead pathway [586]. The expression of FOXO1 is also induced by E2F1 [587]. The product of this gene has also been reported as a survival factor in deprivation-induced neuronal cell death [588,589] (see also the review in [590]). Although FOXO1 has not been previously implicated in AD, an exception may exist. van Der Heide *et al.* describe in [591] how the Forkhead transcription factors are involved in insulin signalling. The “PI3K route” is a name given to common signal transduction cascade that links neuronal survival, synaptic plasticity (and, as a consequence, learning and memory) [592]. This “PI3K-Akt-FOXO1 mechanism” and its role in neurons warrant the current

intensive investigation [593,594,595,596,597,598,599,600]. From this group of 9 genes, seven of them (NRX1, SERTAD2, SNRK, HBGEF, FOXO1, CSF1, BCL11A) and QKI have been predicted to be targeted by mmu-mir128 by two or more microRNA prediction tools. We found this to be a connection that is worth exploring. Lukiw and Pogue have reported that following metal-induced reactive oxygen species production (by iron and aluminium-sulfate at nanomolar concentrations) upregulates miR-128 in human neural cells in primary culture [601]. They also report that, together with miR-9, miR-125a, miR-128 is upregulated in AD brain. In the previously cited reference Lukiw reported that: “miR-9, miR-124a, miR-125b, miR-128, miR-132 and miR-219 are abundantly represented in fetal hippocampus, are differentially regulated in aged brain, and an alteration in specific micro-RNA complexity occurs in Alzheimer hippocampus.”

The expression of probes corresponding to PP2A and PP2B catalytic subunits (i.e. PPP2CA, Protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform, and PPP3CA, Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform, Calcineurin A1) shows increasing downregulation with the progression of AD., see Figure 21. This finding supports a role for downregulation of PPP2CA, PPP3CA in AD pathology [619–647].

Finally, in addition to the presence of hyperphosphorylated tau, the accumulation of Amyloid-beta (Aβ) peptide in brain tissue is a hallmark of AD [602]. The identification of the genes involved in



**Figure 19. The expression of a probe for VSNL1 (Visinin-like protein-1) shows increasing downregulation with AD severity.** VSNL1, a neuronal calcium sensor that has received recent attention in AD [636,637,638,639] has also been linked to model systems of schizophrenia, where it has been found upregulated in hippocampus [640]. A previous result by Schnurra *et al.* raised the possibility that the reduction of VSNL1 expressing neurons indicate a selective vulnerability of these cells, since they observed that VSNL1 expression enhanced hyperphosphorylation of tau protein (in contrast with nontransfected or calbindin-D28K-transfected cells) [641]. In 2001, Braunewell *et al.* had already reported the reduction of VSNL1-immunoreactive neurons in the temporal cortex of AD patients as compared with controls [642].  
doi:10.1371/journal.pone.0010153.g019


the proteolytic processing of APP (beta-amyloid precursor protein), which in turn produces Abeta, is a subject of intense research. Researchers are currently looking at the alterations of APP cellular localization and endocytic trafficking as one mechanism that can modify the processing of APP to Abeta. LRP10 are known to regulate APP's endocytic trafficking [603,604,605,606], and seem to be a hub of a number of mounting evidences on processes that link to cholesterol metabolism and atherosclerosis [607]. In our selected panel of 50 proteins we have one member of this family, LRP10 (low density lipoprotein receptor-related protein 10), as one of the most correlated gene expression profiles. In our list of 1372 gene probe signature we also have another member of this family, LRP1B (low density lipoprotein-related protein 1B (deleted in tumors))[608]. While LRP10 appears to be positively upregulated with cognitive decline an inverse relationship is observed for LRP1B.

LRPs are also known to be linked to APP via a mechanism that involves the alternative splicing of APBB3/Fe65L2 [609,610,611]. Tanahashi and Tabira have proposed that the splicing of APBB3/Fe65L2 alters the ability to bind with APP and low-density-lipoprotein-receptor-related protein. They propose that the secretion of beta-amyloid peptide Abeta40 and Abeta42 is increased following the overexpression of APBB3, but there are

no visible changes of half-life and maturation of APP, or the secretion of secreted APP [612]. In our dataset, we observe APBB3 expression being upregulated with the increasing cognitive decline, following the same pattern of LRP10.

Polymorphisms on these genes have previously been linked to AD. Tanahashi, Asada and Tabira have reported an association between a polymorphism in APBB3/Fe65L2 and early-onset AD [612] (the link between APBB3 and AD is being increasingly explored, we refer to [613,614,615,616] for further references). Using 500K SNP microarray technology, Poduslo, Huang and Spiro have identified haplotypes in LRP1B as significant for successful aging without cognitive decline in a study involving individuals that were 85 years old or older, had MMSE scores greater than 26, no history of dementia in their families, and no major illnesses (i.e. no cardiovascular problems, diabetes, obesity, or major cancer diseases) and most of them had normal cholesterol levels. Their genome-wide association screening compared these individuals with those that have late-onset AD [617]. Poduslo *et al.* have suggested that if the decreased production of Abeta42 in successful aging is due to the haplotypes they describe, then LRP1B may be a new target for treatment of AD [608,617]. Taken together these results indicate that integrative bioinformatics analytic





**Figure 20. It is possible to observe that one of the probes for NRXN1 (Neurexin 1, 209915\_s\_at) has decreasing expression with increasing AD severity.** We have found no previous evidence of a connection of NRXN1 and AD, but this gene has been previously implicated in autism [570,571,572,573,574,575,576], schizophrenia [577,578,579,580,581], nicotine and alcoholism dependence [582,583,584], and mental retardation [585].

doi:10.1371/journal.pone.0010153.g020

approaches will be needed to elicit the interactome of LRPs and their role in AD.

## Conclusions

This re-analysis of the microarray dataset hippocampal gene expression contributed by Blalock *et al.* has shown that there exist a relatively large number of probes (1,372) that present a clear pattern of either up or down regulation with increasing AD severity. The signature reveals alterations in calcium, insulin, phosphatidylinositol and Wnt-signalling. Among the group of most correlated gene probes with AD severity we found some linked to synaptic function, neurofilament bundle assembly, neuronal plasticity and inflammation.

A transcription factors analysis of 1,372-probe gene expression signature reveals significant associations with the EGR/KROX family of proteins, MAZ, and E2F1. The gene homologous of EGR1, zif268, Egr-1 or ZENK, together with other members of the EGR family, are consolidating as key players in short and long-term memory and neuronal plasticity in the brain. We have also uncovered a large consensus of this gene expression signature with current genes putatively involved in AD progression. Our results also indicate a degree of commonality between putative genes involved in AD and prion-induced neurodegenerative processes that warrants further investigation.



## Materials and Methods

### Dataset

In this contribution, we have used a MIAME compliant, Affymetrix gene expression dataset that is public available and was contributed by Blalock *et al.* [3] in 2004. We thank the authors of that publication for making this useful dataset available to the research community at large allowing further exploration and reanalysis.

The dataset is available from GEO Dataset Browser, accession number GDS1297 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1297>). The Affymetrix human GeneChip, HG-U133A, containing 22,283 targets was used. The dataset is de-identified and the methods for disease classification, based on MMSE and NFT scores, are described in full detail by Blalock *et al.* in Ref. [3].

The hippocampal samples used by Blalock *et al.* were obtained from the autopsy of 31 subjects through the Brain Bank of the University of Kentucky Alzheimer's Disease Research Center (ADRC), Sanders-Brown Center on Aging, University of Kentucky. The ADRC was established in 1985 and in operation since 1989 a pool of research volunteers that have agreed in principle to be research participants. Participants were asked questions based on NINCDS/ADRDA criteria [618] to establish their physical



**Figure 21. The expression of two probes for PPP2CA (Protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform,) and PPP3CA (Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform, Calcineurin A1) show increasing downregulation with AD severity.** A similar plot exists for PPP3R1 (protein phosphatase 3 (formerly 2B), regulatory subunit B, alpha isoform, Calcineurin subunit B type 1). This result supports a role for downregulation of PPP2CA, PPP3CA in AD pathology [643,644,645,646,647,648,649,650,651,652,653,654,655,656,657,658,659,660,661,662,663,664,665,666,667,668,669,670,671]. doi:10.1371/journal.pone.0010153.g021

and mental condition to determine if they were eligible for the study. When a mutual agreement existed, the individuals were visited in their homes to review and sign the informed-consent document (which was approved by the University of Kentucky Institutional Review Board). Participants also signed a donor card, and the visit also aimed to establish their baseline mental-status testing. Eligibility for the purpose of the study included having a Mini-Mental State Exam score above 24 [619], passing a series of cognitive tests, and a previous history of absence of neurological disease [620], as well as neither substance abuse nor major psychiatric illnesses. All eligible volunteers were 60 years of age or older and satisfactorily performed normal activities of daily living. The Wechsler Adult Intelligence Scale (Vocabulary) was also applied to exclude significant other medical diseases that could affect cognition and eligible participants must had no previous history of head injury with loss of consciousness.

The research participants that were deemed eligible also signed a form (in addition to the consent document) indicating their agreement to donate their brain to the Sanders-Brown Center on Aging. A full description of the methods used can be found in Brain Donation in Normal Aging Procedures, Motivations, and Donor Characteristics from the Biologically Resilient Adults in Neurological Studies (BRAiNS) Project [621].

Blalock et al. [3] categorized the samples in four groups, with a labelling that indicates different “levels of severity”. These labels were decided based on the *MiniMental State Examination* (MMSE) and the *Neurofibrillary Tangle* count (NFT) of each sample [622]. Samples are then separated in the types ‘Control’, ‘Incipient AD’, ‘Moderate AD’ and ‘Severe AD’. Table 1 of Blalock et al. shows the mean values of MMSE and NFT for each one of these groups. In addition, they give the mean Braak stage [623,624,625] for each one of the groups (2.1 for ‘Control’, 5 for ‘Incipient’, 5.6 for ‘Moderate’ and 5.9 for ‘Severe’). We are grateful to Dr. Blalock who has kindly given us these values of the Braak stage for each sample in the dataset. Together with the individual values of MMSE, NFT, the Braak stage of each sample is included in the Supplementary Material (File S2 sheet ‘Braak’) section of this publication.

## Methodology

Our analysis method consisted of four steps: abundance quantization and filtering of probes; a feature selection algorithm to refine the probe selection; a Jensen-Shannon divergence computation; and finally, a correlation analysis. Each of these steps is described below.

As mentioned in the Results section, we only used the samples labelled as “Control” or “Severe AD” for feature selection, thus we have a two-class probe/gene selection task. We did not use the samples labelled as “Incipient AD” or “Moderate AD” for the probe selection steps. Those samples were only used in the final step, at the time of computing the correlation of the gene profile, across all samples, with the Jensen-Shannon divergences computed for the “Control” and “Severe” classes as explained later in this section.

For the first step, the quantization of the expression values, as well as for the initial data pruning, we used Fayyad and Irani’s algorithm [626]. The heuristic algorithm minimises the feature-

class entropy and discards genes according to the Minimum Description Length principle. The application of Fayyad and Irani’s algorithm not only filters several thousand genes, it also provides thresholds for each probe remaining in the dataset. These quantized values of gene expression leave us with an instance of a combinatorial optimization problem, the  $(\alpha, \beta)$ -*k-Feature Set problem* [13,627,628].

The  $(\alpha, \beta)$ -*k-Feature Set problem* is a combinatorial optimisation problem introduced by Cotta, Sloper and Moscato[628] in 2004 to address the problem of feature selection in high-dimensional datasets. We solve an instance of this problem numerically using an integer programming formulation. This approach has been previously employed to obtain molecular biomarker signatures in Alzheimer’s Disease [1,629], models of Parkinson disease [630], prostate cancer [631], electrode selection in EEGs [632], and elsewhere. To obtain mathematically proven optimal solutions of the integer programming formulation, the CPLEX commercial optimization solver was used. As in previous contributions of our group, we found gene expression signatures corresponding to values of  $\alpha$  maximum and  $\beta$  maximal [1,13,627,628,633]. We refer the reader to these previous contributions for a detailed explanation of the methodology.

At this point, we have a selection of 1,372 probes, a set which we denote as  $\Omega$ . For each sample  $m$  and probe  $i \in \Omega$ , let  $f_{im}$  be its expression value. We now define a probability distribution function (PDF) for each sample. For sample,  $m$  its PDF  $P^{(m)} = \{p_i^{(m)}, \forall i \in \Omega\}$ , is given by

$$p_i^{(m)} = \frac{f_{im}}{\sum_{i \in \Omega} f_{im}}$$

We can now compute an average PDF profile for samples in the “Control” and “Severe AD” groups, denoted by  $\bar{P}_C$  and  $\bar{P}_S$  respectively. Let  $C$  and  $S$  be the set of samples with the labels “Control” and “Severe AD” respectively. The average profile  $\bar{P}_C = \{\bar{p}_i^{(C)}, \forall i \in \Omega\}$ , is then:

$$\bar{p}_i^{(C)} = \frac{\bar{f}_i^{(C)}}{\sum_{j \in \Omega} \bar{f}_j^{(C)}}, \forall i \in \Omega,$$

where

$$\bar{f}_i^{(C)} = \frac{1}{N_C} \sum_{m \in C} f_{im}, \forall i \in \Omega,$$

where  $N_C$  represents the number of samples in class  $C$ .  $\bar{P}_S$  is analogously defined.

The *Jensen-Shannon divergence* between two sample PDFs, i.e. samples  $l$  and  $k$  ( $P^{(l)}$  and  $P^{(k)}$ ) is defined as

$$JSD[P^{(l)}, P^{(k)}] = S\left[\frac{P^{(l)} + P^{(k)}}{2}\right] - \frac{S[P^{(l)}]}{2} - \frac{S[P^{(k)}]}{2}$$

where

$$S[P] = - \sum_{i=1}^N P_i \cdot \ln(P_i)$$

$S[P]$  is the *Shannon Entropy* for a specific PDF sample with  $N$  states. It is well known that the square root of the JSD ( $\sqrt{\text{JSD}}$ ) is a metric, which means that for a given set of PDFs the following four properties are satisfied:

- i.  $\sqrt{\text{JSD}}(P^{(l)}, P^{(k)}) \geq 0$ ,
- ii.  $\sqrt{\text{JSD}}(P^{(l)}, P^{(k)}) = \sqrt{\text{JSD}}(P^{(k)}, P^{(l)})$ ,
- iii.  $\sqrt{\text{JSD}}(P^{(l)}, P^{(k)}) = 0 \Leftrightarrow P^{(l)} = P^{(k)}$ ,
- iv.  $\sqrt{\text{JSD}}(P^{(l)}, P^{(k)}) + \sqrt{\text{JSD}}(P^{(k)}, P^{(m)}) \geq \sqrt{\text{JSD}}(P^{(l)}, P^{(m)})$ .

Once the  $\sqrt{\text{JSD}}$  between each patient and the two average profiles ( $\bar{P}_C$  and  $\bar{P}_S$ ) has been computed, the genes most correlated with these metrics can be uncovered. We used the Spearman rank correlation, which is a well-known non-parametric method, and can thus be used even when the data does not satisfy assumptions about normality, homoscedasticity and linearity.

### Supplementary Material

Supplementary ‘File S1’ provides a glossary of each gene referenced in this paper including synonyms and references to iHOP (<http://www.ihop-net.org/>).

The results referenced in this manuscript are provided in supplementary ‘File S2’ and ‘File S3’ in Microsoft Excel format.

### References

1. Gomez Ravetti M, Moscato P (2008) Identification of a 5-Protein Biomarker Molecular Signature for Predicting Alzheimer’s Disease. *PLoS One* 3: e3111.
2. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, et al. (2007) Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. *Nat Med* 13: 1359–1362.
3. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, et al. (2004) Incipient Alzheimer’s disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses. *Proceedings of the National Academy of Sciences of the United States of America* 101: 2173–2178.
4. Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, et al. (2000) “Preclinical” AD revisited: Neuropathology of cognitively normal older adults. *Neurology* 55: 370–376.
5. Haroutunian V, Purohit DP, Perl DP, Marin D, Khan K, et al. (1999) Neurofibrillary Tangles in Nondemented Elderly Subjects and Mild Alzheimer Disease. *Arch Neurol* 56: 713–718.
6. Price DL, Sisodia SS (1998) Mutant genes in familial Alzheimer’s disease and transgenic models. *Annual Review of Neuroscience* 21: 479–505.
7. Price JL (1993) The relationship between tangle and plaque formation during healthy aging and mild dementia. *Neurobiology of Aging* 14: 661–663.
8. Price JL, Davis PB, Morris JC, White DL (1991) The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer’s disease. *Neurobiology of Aging* 12: 295–312.
9. Robbins K, Sandeep J, Zhang W, Rekaya R (2006) Classification of incipient Alzheimer patients using gene expression data: Dealing with potential misdiagnosis. *Online Journal of Bioinformatics* 7: 9.
10. Sandeep J, Robbins K, Zhang W, Rekaya R (2008) Effects of Misdiagnosis in Input Data on the Identification of Differential Expression Genes in Incipient Alzheimer Patients. *In Silico Biology* 8: 9.
11. Grosse I, Bernaola-Galvan P, Carpena P, Roman-Roldan R, Oliver J, et al. (2002) Analysis of symbolic sequences using the Jensen-Shannon divergence. *Phys Rev E Stat Nonlin Soft Matter Phys* 65: 041905.
12. Moscato P, Mendes A, Berretta R (2007) Benchmarking a memetic algorithm for ordering microarray data. *Biosystems* 88: 56–75.
13. Berretta R, Costa W, Moscato P (2008) Combinatorial Optimization Models for Finding Genetic Signatures from Gene Expression Datasets. In: Keith JM, ed. *Bioinformatics Humana Press*. pp 363–377.
14. Gubern C, Hurtado O, Rodriguez R, Morales JR, Romera VG, et al. (2009) Validation of housekeeping genes for quantitative real-time PCR in in-vivo and in-vitro models of cerebral ischaemia. *BMC Mol Biol* 10: 57.
15. Santos AR, Duarte CB (2008) Validation of internal control genes for expression studies: effects of the neurotrophin BDNF on hippocampal neurons. *J Neurosci Res* 86: 3684–3692.
16. Johansson S, Fuchs A, Okvist A, Karimi M, Harper C, et al. (2007) Validation of endogenous controls for quantitative gene expression analysis: application on brain cortices of human chronic alcoholics. *Brain Res* 1132: 20–28.
17. Hughes V, Smith S, Garcia-Sanchez A, Sales J, Stevenson K (2007) Proteomic comparison of *Mycobacterium avium* subspecies paratuberculosis grown in vitro and isolated from clinical cases of ovine paratuberculosis. *Microbiology* 153: 196–205.
18. Prece P, Cairns NJ (2003) Quantifying mRNA in postmortem human brain: influence of gender, age at death, postmortem interval, brain pH, agonal state and inter-lobe mRNA variance. *Brain Res Mol Brain Res* 118: 60–71.
19. Chang JT, Nevins JR (2006) GATHER: a systems approach to interpreting genomic signatures. *Bioinformatics* 22: 2926–2933.
20. Ariadne Genomics I (2007) Pathway Studio™. 5.0 ed.
21. Ongwijitwat S, Wong-Riley MT (2004) Functional analysis of the rat cytochrome c oxidase subunit 6A1 promoter in primary neurons. *Gene* 337: 163–171.
22. Wong-Riley M, Guo A, Bachman NJ, Lomax MI (2000) Human COX6A1 gene: promoter analysis, cDNA isolation and expression in the monkey brain. *Gene* 247: 63–75.
23. Ben-Shachar D, Karry R (2008) Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. *PLoS One* 3: e3676.
24. Ji B, La Y, Gao L, Zhu H, Tian N, et al. (2009) A Comparative Proteomics Analysis of Rat Mitochondria from the Cerebral Cortex and Hippocampus in Response to Antipsychotic Medications. *J Proteome Res* 8: 3633–3641.
25. Zhang J, Li X, Wang Y, Ji J, Yang F, et al. (2009) Association study on the mitochondrial gene NDUFV2 and bipolar disorder in the Chinese Han population. *J Neural Transm* 116: 357–361.
26. Washizuka S, Iwamoto K, Kakiuchi C, Bundo M, Kato T (2009) Expression of mitochondrial complex I subunit gene NDUFV2 in the lymphoblastoid cells derived from patients with bipolar disorder and schizophrenia. *Neurosci Res* 63: 199–204.
27. Xu C, Li PP, Kennedy JL, Green M, Hughes B, et al. (2008) Further support for association of the mitochondrial complex I subunit gene NDUFV2 with bipolar disorder. *Bipolar Disord* 10: 105–110.
28. Ben-Shachar D, Karry R (2007) Sp1 expression is disrupted in schizophrenia; a possible mechanism for the abnormal expression of mitochondrial complex I genes, NDUFV1 and NDUFV2. *PLoS One* 2: e817.
29. Lazarou M, McKenzie M, Ohtake A, Thorburn DR, Ryan MT (2007) Analysis of the assembly profiles for mitochondrial- and nuclear-DNA-encoded subunits into complex I. *Mol Cell Biol* 27: 4228–4237.
30. Nakatani N, Hattori E, Ohnishi T, Dean B, Iwayama Y, et al. (2006) Genome-wide expression analysis detects eight genes with robust alterations specific to bipolar I disorder: relevance to neuronal network perturbation. *Hum Mol Genet* 15: 1949–1962.
31. Spires TL, Molnar Z, Kind PC, Cordery PM, Upton AL, et al. (2005) Activity-dependent regulation of synapse and dendritic spine morphology in developing barrel cortex requires phospholipase C-beta1 signalling. *Cereb Cortex* 15: 385–393.

### Supporting Information

**File S1** iHop Glossary of Genes.

Found at: doi:10.1371/journal.pone.0010153.s001 (0.15 MB DOC)

**File S2** Supplementary Data 1.

Found at: doi:10.1371/journal.pone.0010153.s002 (4.10 MB XLS)

**File S3** Supplementary Data 2.

Found at: doi:10.1371/journal.pone.0010153.s003 (1.26 MB XLS)

### Acknowledgments

The authors wish to thank the late Dr. William Markesbery, Dr. Erik Blalock and through them the whole team of the University of Kentucky’s Sanders-Brown Center on Aging who have contributed a very valuable dataset.

### Author Contributions

Conceived and designed the experiments: MGR OAR RB PM. Performed the experiments: MGR OAR RB PM. Analyzed the data: MGR OAR RB. Wrote the paper: MGR OAR RB PM.

32. Litosch I (2002) Novel mechanisms for feedback regulation of phospholipase C-beta activity. *IUBMB Life* 54: 253–260.
33. Bohm D, Schwegler H, Kotthaus L, Nayernia K, Rickmann M, et al. (2002) Disruption of PLC-beta 1-mediated signal transduction in mutant mice causes age-dependent hippocampal mossy fiber sprouting and neurodegeneration. *Mol Cell Neurosci* 21: 584–601.
34. Hannan AJ, Blakemore C, Katsnelson A, Vitalis T, Huber KM, et al. (2001) PLC-beta1, activated via mGluRs, mediates activity-dependent differentiation in cerebral cortex. *Nat Neurosci* 4: 282–288.
35. Tiveci S, Akin A, Kadir T, Saybasili H, Ulgen K (2005) Modelling of calcium dynamics in brain energy metabolism and Alzheimer's disease. *Comput Biol Chem* 29: 151–162.
36. Moreira PI, Santos MS, Seica R, Oliveira CR (2007) Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. *J Neurol Sci* 257: 206–214.
37. Loughton JD, Bittar P, Charnay Y, Pellerin L, Kovari E, et al. (2007) Metabolic compartmentalization in the human cortex and hippocampus: evidence for a cell- and region-specific localization of lactate dehydrogenase 5 and pyruvate dehydrogenase. *BMC Neurosci* 8: 35.
38. Landfield PW, Blalock EM, Chen KC, Porter NM (2007) A new glucocorticoid hypothesis of brain aging: implications for Alzheimer's disease. *Curr Alzheimer Res* 4: 205–212.
39. Elgh E, Lindqvist Astot A, Fagerlund M, Eriksson S, Olsson T, et al. (2006) Cognitive dysfunction, hippocampal atrophy and glucocorticoid feedback in Alzheimer's disease. *Biol Psychiatry* 59: 155–161.
40. Bao AM, Meynen G, Swaab DF (2008) The stress system in depression and neurodegeneration: focus on the human hypothalamus. *Brain Res Rev* 57: 531–553.
41. Lee HK, Kumar P, Fu Q, Rosen KM, Querfurth HW (2009) The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid. *Mol Biol Cell* 20: 1533–1544.
42. Escribano L, Simon AM, Perez-Mediavilla A, Salazar-Colocho P, Del Rio J, et al. (2009) Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. *Biochem Biophys Res Commun* 379: 406–410.
43. Bonomo SM, Rigamonti AE, Giunta M, Galimberti D, Guaita A, et al. (2009) Menopausal transition: a possible risk factor for brain pathologic events. *Neurobiol Aging* 30: 71–80.
44. Aisa B, Gil-Bea FJ, Marcos B, Tordera R, Lasheras B, et al. (2009) Neonatal stress affects vulnerability of cholinergic neurons and cognition in the rat: Involvement of the HPA axis. *Psychoneuroendocrinology*.
45. Sotiropoulos I, Cerqueira JJ, Catania C, Takashima A, Sousa N, et al. (2008) Stress and glucocorticoid footprints in the brain—the path from depression to Alzheimer's disease. *Neurosci Biobehav Rev* 32: 1161–1173.
46. Jing H, Iwasaki Y, Nishiyama M, Taguchi T, Tsugita M, et al. (2008) Multisignal regulation of the rat NMDA1 receptor subunit gene—a pivotal role of glucocorticoid-dependent transcription. *Life Sci* 82: 1137–1141.
47. White LD, Cory-Slechta DA, Gilbert ME, Tiffany-Castiglioni E, Zawia NH, et al. (2007) New and evolving concepts in the neurotoxicology of lead. *Toxicol Appl Pharmacol* 225: 1–27.
48. Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM (2006) Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. *J Neurosci* 26: 9047–9056.
49. de Quervain DJ, Poirier R, Wollmer MA, Grimaldi LM, Tzolaki M, et al. (2004) Glucocorticoid-related genetic susceptibility for Alzheimer's disease. *Hum Mol Genet* 13: 47–52.
50. Dai J, Buijs R, Swaab D (2004) Glucocorticoid hormone (cortisol) affects axonal transport in human cortex neurons but shows resistance in Alzheimer's disease. *Br J Pharmacol* 143: 606–610.
51. Polleri A, Gianelli MV, Murialdo G (2002) Dementia: a neuroendocrine perspective. *J Endocrinol Invest* 25: 73–83.
52. Chen H, Sun S, Mei Y, Liu C, Liu A, et al. (2002) The effect of beta-amyloid on neurons and the influence of glucocorticoid and age on such effect. *J Huazhong Univ Sci Technolog Med Sci* 22: 250–252.
53. Aisen PS (2002) The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. *Lancet Neurol* 1: 279–284.
54. Rasmuson S, Andrew R, Nasman B, Seckl JR, Walker BR, et al. (2001) Increased glucocorticoid production and altered cortisol metabolism in women with mild to moderate Alzheimer's disease. *Biol Psychiatry* 49: 547–552.
55. Pedersen WA, McCullers D, Culmsee C, Haughey NJ, Herman JP, et al. (2001) Corticotropin-releasing hormone protects neurons against insults relevant to the pathogenesis of Alzheimer's disease. *Neurobiol Dis* 8: 492–503.
56. Dubois M, Lalonde R, Julien JP, Strazielle C (2005) Mice with the deleted neurofilament of low-molecular-weight (Nefl) gene: 1. Effects on regional brain metabolism. *J Neurosci Res* 80: 741–750.
57. Jordanova A, De Jonghe P, Boerkoel CF, Takashima H, De Vriendt E, et al. (2003) Mutations in the neurofilament light chain gene (NEFL) cause early onset severe Charcot-Marie-Tooth disease. *Brain* 126: 590–597.
58. Abe A, Numakura C, Saito K, Koide H, Oka N, et al. (2009) Neurofilament light chain polypeptide gene mutations in Charcot-Marie-Tooth disease: nonsense mutation probably causes a recessive phenotype. *J Hum Genet* 54: 94–97.
59. Tradewell ML, Durham HD, Mushynski WE, Gentil BJ (2009) Mitochondrial and axonal abnormalities precede disruption of the neurofilament network in a model of charcot-marie-tooth disease type 2E and are prevented by heat shock proteins in a mutant-specific fashion. *J Neuropathol Exp Neurol* 68: 642–652.
60. Evgrafov OV, Mersyanova I, Irobi J, Van Den Bosch L, Dierick I, et al. (2004) Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. *Nat Genet* 36: 602–606.
61. Nakagawa M, Takashima H (2004) [Update on hereditary neuropathy]. *Rinsho Shinkeigaku* 44: 991–994.
62. Takashima H (2006) [Molecular genetics of inherited neuropathies]. *Rinsho Shinkeigaku* 46: 1–18.
63. Lus G, Nelis E, Jordanova A, Lofgren A, Cavallaro T, et al. (2003) Charcot-Marie-Tooth disease with giant axons: a clinicopathological and genetic entity. *Neurology* 61: 988–990.
64. Saba R, Goodman CD, Huzarewicz RL, Robertson C, Booth SA (2008) A miRNA signature of prion induced neurodegeneration. *PLoS One* 3: e3652.
65. Sorensen G, Medina S, Parchaliuk D, Phillipson C, Robertson C, et al. (2008) Comprehensive transcriptional profiling of prion infection in mouse models reveals networks of responsive genes. *BMC Genomics* 9: 114.
66. Heese K, Nagai Y, Sawada T (2001) Identification of a new synaptic vesicle protein 2B mRNA transcript which is up-regulated in neurons by amyloid beta peptide fragment (1–42). *Biochem Biophys Res Commun* 289: 924–928.
67. Heese K, Nagai Y, Sawada T (2002) The 3' untranslated region of the new rat synaptic vesicle protein 2B mRNA transcript inhibits translational efficiency. *Brain Res Mol Brain Res* 104: 127–131.
68. Morgans CW, Kinsel-Hammes P, Hurley JB, Burton K, Idzerda R, et al. (2009) Loss of the Synaptic Vesicle Protein SV2B results in reduced neurotransmission and altered synaptic vesicle protein expression in the retina. *PLoS One* 4: e5230.
69. Lazzell DR, Belizaire R, Thakur P, Sherry DM, Janz R (2004) SV2B regulates synaptotagmin 1 by direct interaction. *J Biol Chem* 279: 52124–52131.
70. Veinbergs I, Mante M, Jung MW, Van Uden E, Masliah E (1999) Synaptotagmin and synaptic transmission alterations in apolipoprotein E-deficient mice. *Prog Neuropsychopharmacol Biol Psychiatry* 23: 519–531.
71. Davidsson P, Blennow K (1998) Neurochemical dissection of synaptic pathology in Alzheimer's disease. *Int Psychogeriatr* 10: 11–23.
72. Ferrer I, Marti E, Tortosa A, Blasi J (1998) Dystrophic neurites of senile plaques are defective in proteins involved in exocytosis and neurotransmission. *J Neuropathol Exp Neurol* 57: 218–225.
73. Shimohama S, Kamiya S, Taniguchi T, Akagawa K, Kimura J (1997) Differential involvement of synaptic vesicle and presynaptic plasma membrane proteins in Alzheimer's disease. *Biochem Biophys Res Commun* 236: 239–242.
74. Davidsson P, Jahn R, Bergquist J, Ekman R, Blennow K (1996) Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid: a new biochemical marker for synaptic pathology in Alzheimer disease? *Mol Chem Neurobiol* 27: 195–210.
75. Reddy PH, Mani G, Park BS, Jacques J, Murdoch G, et al. (2005) Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. *J Alzheimers Dis* 7: 103–117. discussion 173–180.
76. Kirikoshi H, Katoh M (2002) Expression of WNT7A in human normal tissues and cancer, and regulation of WNT7A and WNT7B in human cancer. *Int J Oncol* 21: 895–900.
77. Wang Y, Liu S, Zhu H, Zhang W, Zhang G, et al. (2008) FRAT1 overexpression leads to aberrant activation of beta-catenin/TCF pathway in esophageal squamous cell carcinoma. *Int J Cancer* 123: 561–568.
78. Hongisto V, Vainio JC, Thompson R, Courtney MJ, Coffey ET (2008) The Wnt pool of glycogen synthase kinase 3beta is critical for trophic-deprivation-induced neuronal death. *Mol Cell Biol* 28: 1515–1527.
79. Hagen T, Cross DA, Culbert AA, West A, Frame S, et al. (2006) FRAT1, a substrate-specific regulator of glycogen synthase kinase-3 activity, is a cellular substrate of protein kinase A. *J Biol Chem* 281: 35021–35029.
80. Hongisto V, Smeds N, Brecht S, Herdegen T, Courtney MJ, et al. (2003) Lithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3. *Mol Cell Biol* 23: 6027–6036.
81. Hino S, Michiue T, Asashima M, Kikuchi A (2003) Casein kinase I epsilon enhances the binding of Dvl-1 to Frat-1 and is essential for Wnt-3a-induced accumulation of beta-catenin. *J Biol Chem* 278: 14066–14073.
82. Hay E, Faucheu C, Suc-Royer I, Touitou R, Stiot V, et al. (2005) Interaction between LRP5 and Frat1 mediates the activation of the Wnt canonical pathway. *J Biol Chem* 280: 13616–13623.
83. Fraser E, Young N, Dajani R, Franca-Koh J, Ryves J, et al. (2002) Identification of the Axin and Frat binding region of glycogen synthase kinase-3. *J Biol Chem* 277: 2176–2185.
84. Franca-Koh J, Yeo M, Fraser E, Young N, Dale TC (2002) The regulation of glycogen synthase kinase-3 nuclear export by Frat/GBP. *J Biol Chem* 277: 43844–43848.
85. Saitoh T, Moriwaki J, Koike J, Takagi A, Miwa T, et al. (2001) Molecular cloning and characterization of FRAT2, encoding a positive regulator of the WNT signaling pathway. *Biochem Biophys Res Commun* 281: 815–820.
86. Killick R, Pollard CC, Asuni AA, Mudher AK, Richardson JC, et al. (2001) Presenilin 1 independently regulates beta-catenin stability and transcriptional activity. *J Biol Chem* 276: 48554–48561.
87. Culbert AA, Brown MJ, Frame S, Hagen T, Cross DA, et al. (2001) GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and beta-catenin stabilisation without elevation of glycogen synthase activity. *FEBS Lett* 507: 288–294.

88. Crowder RJ, Freeman RS (2000) Glycogen synthase kinase-3 beta activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal. *J Biol Chem* 275: 34266–34271.
89. Katoh M (2007) Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. *Stem Cell Rev* 3: 30–38.
90. Liu C, Wang Y, Smallwood PM, Nathans J (2008) An essential role for Frizzled5 in neuronal survival in the parafascicular nucleus of the thalamus. *J Neurosci* 28: 5641–5653.
91. Carmon KS, Loose DS (2008) Wnt7a interaction with Fzd5 and detection of signaling activation using a split eGFP. *Biochem Biophys Res Commun* 368: 285–291.
92. Steventon B, Araya C, Linker C, Kuriyama S, Mayor R (2009) Differential requirements of BMP and Wnt signalling during gastrulation and neurulation define two steps in neural crest induction. *Development* 136: 771–779.
93. Lee MY, Lim HW, Lee SH, Han HJ (2009) Smad, PI3K/Akt, and Wnt-Dependent Signaling Pathways are Involved in BMP-4-Induced ES Cell Self-Renewal. *Stem Cells*.
94. Kelberman D, de Castro SC, Huang S, Crolla JA, Palmer R, et al. (2008) SOX2 plays a critical role in the pituitary, forebrain, and eye during human embryonic development. *J Clin Endocrinol Metab* 93: 1865–1873.
95. Shi Y, Sun G, Zhao C, Stewart R (2008) Neural stem cell self-renewal. *Crit Rev Oncol Hematol* 65: 43–53.
96. Linker C, Stern CD (2004) Neural induction requires BMP inhibition only as a late step, and involves signals other than FGF and Wnt antagonists. *Development* 131: 5671–5681.
97. Tam WL, Lim CY, Han J, Zhang J, Ang YS, et al. (2008) T-cell factor 3 regulates embryonic stem cell pluripotency and self-renewal by the transcriptional control of multiple lineage pathways. *Stem Cells* 26: 2019–2031.
98. Ruzov A, Hackett JA, Prokhorchouk A, Reddington JP, Madej MJ, et al. (2009) The interaction of xKaiso with xTcf3: a revised model for integration of epigenetic and Wnt signalling pathways. *Development* 136: 723–727.
99. Fancy SP, Baranzini SE, Zhao C, Yuk DI, Irvine KA, et al. (2009) Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. *Genes Dev* 23: 1571–1585.
100. Koslowski MJ, Kubler I, Chamaillard M, Schaeffeler E, Reinisch W, et al. (2009) Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. *PLoS ONE* 4: e4496.
101. Schinner S (2009) Wnt-signalling and the metabolic syndrome. *Horm Metab Res* 41: 159–163.
102. Nazwar TA, Glassmann A, Schilling K (2009) Expression and molecular diversity of Tcf7l2 in the developing murine cerebellum and brain. *J Neurosci Res* 87: 1532–1546.
103. Ye F, Chen Y, Hoang T, Montgomery RL, Zhao XH, et al. (2009) HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction. *Nat Neurosci* 12: 829–838.
104. Murray KD, Rubin CM, Jones EG, Chalupa LM (2008) Molecular correlates of laminar differences in the macaque dorsal lateral geniculate nucleus. *J Neurosci* 28: 12010–12022.
105. Murray KD, Choudary PV, Jones EG (2007) Nucleus- and cell-specific gene expression in monkey thalamus. *Proc Natl Acad Sci U S A* 104: 1989–1994.
106. Lukas J, Mazna P, Valenta T, Doubravska L, Pospichalova V, et al. (2009) Dazap2 modulates transcription driven by the Wnt effector TCF-4. *Nucleic Acids Res* 37: 3007–3020.
107. Lepourcelet M, Shivdasani RA (2002) Characterization of a novel mammalian Groucho isoform and its role in transcriptional regulation. *J Biol Chem* 277: 47732–47740.
108. Bachar-Dahan L, Goltzmann J, Yaniv A, Gazit A (2006) Engrailed-1 negatively regulates beta-catenin transcriptional activity by destabilizing beta-catenin via a glycogen synthase kinase-3beta-independent pathway. *Mol Biol Cell* 17: 2572–2580.
109. Daniels DL, Weis WI (2005) Beta-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. *Nat Struct Mol Biol* 12: 364–371.
110. Bauer J, Plaschke K, Martin E, Bardenheuer HJ, Hoyer S (1997) Causes and consequences of neuronal energy deficit in sporadic Alzheimer's disease. *Ann N Y Acad Sci* 826: 379–381.
111. Lu Y, He X, Zhong S (2007) Cross-species microarray analysis with the OSCAR system suggests an INSR→Pax6→NQO1 neuro-protective pathway in aging and Alzheimer's disease. *Nucleic Acids Res* 35: W105–114.
112. Wang H, Wang R, Zhao Z, Ji Z, Xu S, et al. (2009) Coexistences of insulin signaling-related proteins and choline acetyltransferase in neurons. *Brain Res* 1249: 237–243.
113. Frolich L, Blum-Degen D, Riederer P, Hoyer S (1999) A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. *Ann N Y Acad Sci* 893: 290–293.
114. Hoyer S (1994) Age as risk factor for sporadic dementia of the Alzheimer type? *Ann N Y Acad Sci* 719: 248–256.
115. Hoyer S, Lannert H (1999) Inhibition of the neuronal insulin receptor causes Alzheimer-like disturbances in oxidative/energy brain metabolism and in behavior in adult rats. *Ann N Y Acad Sci* 893: 301–303.
116. Hoyer S, Lee SK, Loffler T, Schliebs R (2000) Inhibition of the neuronal insulin receptor. An in vivo model for sporadic Alzheimer disease? *Ann N Y Acad Sci* 920: 256–258.
117. Hoyer S (1996) Oxidative metabolism deficiencies in brains of patients with Alzheimer's disease. *Acta Neurol Scand Suppl* 165: 18–24.
118. Verkhatsky A, Toescu EC (2003) Endoplasmic reticulum Ca(2+) homeostasis and neuronal death. *J Cell Mol Med* 7: 351–361.
119. Norris CM, Kadish I, Blalock EM, Chen KC, Thibault V, et al. (2005) Calcineurin triggers reactive/inflammatory processes in astrocytes and is upregulated in aging and Alzheimer's models. *J Neurosci* 25: 4649–4658.
120. Bojarski L, Herms J, Kuznicki J (2008) Calcium dysregulation in Alzheimer's disease. *Neurochem Int* 52: 621–633.
121. Cowburn RF, Popescu BO, Ankarcrana M, Dehvari N, Cedazo-Minguez A (2007) Presenilin-mediated signal transduction. *Physiol Behav* 92: 93–97.
122. Giacomello M, Barbiero L, Zatti G, Squitti R, Binetti G, et al. (2005) Reduction of Ca2+ stores and capacitative Ca2+ entry is associated with the familial Alzheimer's disease presenilin-2 T122R mutation and anticipates the onset of dementia. *Neurobiol Dis* 18: 638–648.
123. Peers C, Smith IF, Boyle JP, Pearson HA (2004) Remodelling of Ca2+ homeostasis in type I cortical astrocytes by hypoxia: evidence for association with Alzheimer's disease. *Biol Chem* 385: 285–289.
124. LaFerla FM (2002) Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. *Nat Rev Neurosci* 3: 862–872.
125. Eckert A, Forstl H, Zerfass R, Hennerici M, Muller WE (1997) Free intracellular calcium in peripheral cells in Alzheimer's disease. *Neurobiol Aging* 18: 281–284.
126. Schubert P, Ogata T, Miyazaki H, Marchini C, Ferroni S, et al. (1998) Pathological immuno-reactions of glial cells in Alzheimer's disease and possible sites of interference. *J Neural Transm Suppl* 54: 167–174.
127. Eckert A, Forstl H, Zerfass R, Hartmann H, Muller WE (1996) Lymphocytes and neutrophils as peripheral models to study the effect of beta-amyloid on cellular calcium signalling in Alzheimer's disease. *Life Sci* 59: 499–510.
128. Salkovic-Petrisic M, Hoyer S (2007) Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. *J Neural Transm Suppl* 217–233.
129. Qin W, Zhao W, Ho L, Wang J, Walsh K, et al. (2008) Regulation of forkhead transcription factor FoxO3a contributes to calorie restriction-induced prevention of Alzheimer's disease-type amyloid neuropathology and spatial memory deterioration. *Ann N Y Acad Sci* 1147: 335–347.
130. Carro E, Trejo JL, Spuch C, Bohl D, Heard JM, et al. (2006) Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease? *Neurobiol Aging* 27: 1618–1631.
131. Rhein V, Eckert A (2007) Effects of Alzheimer's amyloid-beta and tau protein on mitochondrial function – role of glucose metabolism and insulin signalling. *Arch Physiol Biochem* 113: 131–141.
132. Abbas T, Faivre E, Holscher C (2009) Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. *Behav Brain Res*.
133. Castri P, Iacovelli L, De Blasi A, Giubilei F, Moretti A, et al. (2007) Reduced insulin-induced phosphatidylinositol-3-kinase activation in peripheral blood mononuclear leucocytes from patients with Alzheimer's disease. *Eur J Neurosci* 26: 2469–2472.
134. Li L, Holscher C (2007) Common pathological processes in Alzheimer disease and type 2 diabetes: a review. *Brain Res Rev* 56: 384–402.
135. Salkovic-Petrisic M, Tribl F, Schmidt M, Hoyer S, Riederer P (2006) Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. *J Neurochem* 96: 1005–1015.
136. Biessels GJ, Kappelle LJ (2005) Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? *Biochem Soc Trans* 33: 1041–1044.
137. Nelson TJ, Alkon DL (2005) Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. *Biochem Soc Trans* 33: 1033–1036.
138. Biessels GJ, Bravenboer B, Gispen WH (2004) Glucose, insulin and the brain: modulation of cognition and synaptic plasticity in health and disease: a preface. *Eur J Pharmacol* 490: 1–4.
139. Morgan C, Colombres M, Nunez MT, Inestrosa NC (2004) Structure and function of amyloid in Alzheimer's disease. *Prog Neurobiol* 74: 323–349.
140. Zhao WQ, Townsend M (2009) Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. *Biochim Biophys Acta* 1792: 482–496.
141. De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, et al. (2009) Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Aβ oligomers. *Proc Natl Acad Sci U S A* 106: 1971–1976.
142. Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, et al. (2009) Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. *Proc Natl Acad Sci U S A* 106: 3907–3912.
143. Pugliese L (2008) Aging of the brain, neurotrophin signaling, and Alzheimer's disease: is IGF1-R the common culprit? *Neurobiol Aging* 29: 795–811.
144. Jolivalt CG, Lee CA, Beiswenger KK, Smith JL, Orlov M, et al. (2008) Defective insulin signaling pathway and increased glycogen synthase kinase-3

- activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. *J Neurosci Res* 86: 3265–3274.
145. de Tullio MB, Morelli L, Castano EM (2008) The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme: a biological perspective. *Prion* 2: 51–56.
  146. Dore S, Kar S, Quirion R (1997) Insulin-like growth factor I protects and rescues hippocampal neurons against beta-amyloid- and human amylin-induced toxicity. *Proc Natl Acad Sci U S A* 94: 4772–4777.
  147. Gandy S, Czernik AJ, Greengard P (1988) Phosphorylation of Alzheimer disease amyloid precursor peptide by protein kinase C and Ca<sup>2+</sup>/calmodulin-dependent protein kinase II. *Proc Natl Acad Sci U S A* 85: 6218–6221.
  148. Deutsch SI, Rosse RB, Lakshman RM (2006) Dysregulation of tau phosphorylation is a hypothesized point of convergence in the pathogenesis of Alzheimer's disease, frontotemporal dementia and schizophrenia with therapeutic implications. *Prog Neuropsychopharmacol Biol Psychiatry* 30: 1369–1380.
  149. Wickelgren I (1998) Tracking insulin to the mind. *Science* 280: 517–519.
  150. Jafferali S, Dumont Y, Sotty F, Robitaille Y, Quirion R, et al. (2000) Insulin-like growth factor-I and its receptor in the frontal cortex, hippocampus, and cerebellum of normal human and Alzheimer disease brains. *Synapse* 38: 450–459.
  151. Brune S, Kolsch H, Ptok U, Majores M, Schulz A, et al. (2003) Polymorphism in the peroxisome proliferator-activated receptor alpha gene influences the risk for Alzheimer's disease. *J Neural Transm* 110: 1041–1050.
  152. Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, et al. (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. *J Neural Transm* 105: 423–438.
  153. Grunblatt E, Hoyer S, Riederer P (2004) Gene expression profile in streptozotocin rat model for sporadic Alzheimer's disease. *J Neural Transm* 111: 367–386.
  154. Hoyer S (1998) Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. *J Neural Transm* 105: 415–422.
  155. Hoyer S (2002) The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review. *J Neural Transm* 109: 991–1002.
  156. Hoyer S (2002) The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. *J Neural Transm* 109: 341–360.
  157. Hoyer S, Nitsch R (1989) Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type. *J Neural Transm* 75: 227–232.
  158. Xu WH, Huber R, Riepe MW (2007) Gender- and region-specific expression of insulin receptor protein in mouse brain: effect of mild inhibition of oxidative phosphorylation. *J Neural Transm* 114: 373–377.
  159. Hoyer S, Nitsch R, Oesterreich K (1991) Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases. *J Neural Transm Park Dis Dement Sect 3*: 1–14.
  160. Blum-Degen D, Frolich L, Hoyer S, Riederer P (1995) Altered regulation of brain glucose metabolism as a cause of neurodegenerative disorders? *J Neural Transm Suppl* 46: 139–147.
  161. Hoyer S (1997) Models of Alzheimer's disease: cellular and molecular aspects. *J Neural Transm Suppl* 49: 11–21.
  162. Hoyer S, Muller D, Plaschke K (1994) Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism. *J Neural Transm Suppl* 44: 259–268.
  163. Aguado-Llera D, Arilla-Ferreiro E, Campos-Barros A, Pueblajimenez L, Barrios V (2005) Protective effects of insulin-like growth factor-I on the somatostatinergic system in the temporal cortex of beta-amyloid-treated rats. *J Neurochem* 92: 607–615.
  164. Crews FT, McElhane R, Freund G, Ballinger WE, Jr., Raizada MK (1992) Insulin-like growth factor I receptor binding in brains of Alzheimer's and alcoholic patients. *J Neurochem* 58: 1205–1210.
  165. Hoyer S (1987) Somatostatin and Alzheimer's disease. *J Neurol* 234: 266–267.
  166. De Ferrari GV, Moon RT (2006) The ups and downs of Wnt signaling in prevalent neurological disorders. *Oncogene* 25: 7545–7553.
  167. Balaraman Y, Limaye AR, Levey AI, Srinivasan S (2006) Glycogen synthase kinase 3beta and Alzheimer's disease: pathophysiological and therapeutic significance. *Cell Mol Life Sci* 63: 1226–1235.
  168. Wideltz R (2005) Wnt signaling through canonical and non-canonical pathways: recent progress. *Growth Factors* 23: 111–116.
  169. Cerpa W, Dinamarca MC, Inestrosa NC (2008) Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses. *Curr Alzheimer Res* 5: 233–243.
  170. Mercado-Gomez O, Hernandez-Fonseca K, Villavicencio-Queijeiro A, Massieu L, Chimal-Monroy J, et al. (2008) Inhibition of Wnt and PI3K signaling modulates GSK-3beta activity and induces morphological changes in cortical neurons: role of tau phosphorylation. *Neurochem Res* 33: 1599–1609.
  171. Magdesian MH, Carvalho MM, Mendes FA, Saraiva LM, Juliano MA, et al. (2008) Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling. *J Biol Chem* 283: 9359–9368.
  172. Esposito G, Scuderi C, Lu J, Savani C, De Filippis D, et al. (2008) S100B induces tau protein hyperphosphorylation via Dickkopf-1 up-regulation and disrupts the Wnt pathway in human neural stem cells. *J Cell Mol Med* 12: 914–927.
  173. Ferrero A, Cereseto M, Sifonios L (2006) [The relationship between the Wnt signaling and the psychiatric diseases]. *Vertex* 17: 165–171.
  174. De Ferrari GV, Papassotiropoulos A, Biechele T, Wavrant De-Vrieze F, Avila ME, et al. (2007) Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. *Proc Natl Acad Sci U S A* 104: 9434–9439.
  175. Inestrosa NC, Varela-Nallar L, Grabowski CP, Colombres M (2007) Synaptotoxicity in Alzheimer's disease: the Wnt signaling pathway as a molecular target. *IUBMB Life* 59: 316–321.
  176. Maiese K, Chong ZZ, Shang YC (2007) Mechanistic insights into diabetes mellitus and oxidative stress. *Curr Med Chem* 14: 1729–1738.
  177. Repetto E, Yoon IS, Zheng H, Kang DE (2007) Presenilin 1 regulates epidermal growth factor receptor turnover and signaling in the endosomal-lysosomal pathway. *J Biol Chem* 282: 31504–31516.
  178. Fuentelba RA, Farias G, Scheu J, Bronfman M, Marzolo MP, et al. (2004) Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease. *Brain Res Brain Res Rev* 47: 275–289.
  179. Inestrosa NC, Urria S, Colombres M (2004) Acetylcholinesterase (AChE)-amyloid-beta-peptide complexes in Alzheimer's disease: the Wnt signaling pathway. *Curr Alzheimer Res* 1: 249–254.
  180. De Ferrari GV, Inestrosa NC (2000) Wnt signaling function in Alzheimer's disease. *Brain Res Brain Res Rev* 33: 1–12.
  181. Inestrosa NC, Alvarez A, Godoy J, Reyes A, De Ferrari GV (2000) Acetylcholinesterase-amyloid-beta-peptide interaction and Wnt signaling involvement in Abeta neurotoxicity. *Acta Neurol Scand Suppl* 176: 53–59.
  182. Small DH (2000) Alzheimer Symposium. Gamma-secretase, presenilins and WNT proteins. *IDrugs* 3: 740–741.
  183. De Strooper B, Annaert W (2001) Where Notch and Wnt signaling meet. The presenilin hub. *J Cell Biol* 152: F17–20.
  184. Caricasole A, Copani A, Caruso A, Caraci F, Iacovelli L, et al. (2003) The Wnt pathway, cell-cycle activation and beta-amyloid: novel therapeutic strategies in Alzheimer's disease? *Trends Pharmacol Sci* 24: 233–238.
  185. De Ferrari GV, Chacon MA, Barria MI, Garrido JL, Godoy JA, et al. (2003) Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. *Mol Psychiatry* 8: 195–208.
  186. Grilli M, Ferrari Toninelli G, Uberti D, Spano P, Memo M (2003) Alzheimer's disease linking neurodegeneration with neurodevelopment. *Funct Neurol* 18: 145–148.
  187. Selkoe D, Kopan R (2003) Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. *Annu Rev Neurosci* 26: 565–597.
  188. Alvarez AR, Godoy JA, Mullendorff K, Olivares GH, Bronfman M, et al. (2004) Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. *Exp Cell Res* 297: 186–196.
  189. Busby V, Goossens S, Nowotny P, Hamilton G, Smemo S, et al. (2004) Alpha-T-catenin is expressed in human brain and interacts with the Wnt signaling pathway but is not responsible for linkage to chromosome 10 in Alzheimer's disease. *Neuromolecular Med* 5: 133–146.
  190. Caricasole A, Copani A, Caraci F, Aronica E, Rozemuller AJ, et al. (2004) Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. *J Neurosci* 24: 6021–6027.
  191. Chong ZZ, Maiese K (2004) Targeting WNT, protein kinase B, and mitochondrial membrane integrity to foster cellular survival in the nervous system. *Histol Histopathol* 19: 495–504.
  192. Toledo EM, Colombres M, Inestrosa NC (2008) Wnt signaling in neuroprotection and stem cell differentiation. *Prog Neurobiol* 86: 281–296.
  193. Boonen RA, van Tijn P, Zivkovic D (2009) Wnt signaling in Alzheimer's disease: up or down, that is the question. *Ageing Res Rev* 8: 71–82.
  194. Cairney CJ, Sanguinetti G, Ranghini E, Chantry AD, Nostro MC, et al. (2009) A systems biology approach to Down syndrome: identification of Notch/Wnt dysregulation in a model of stem cells aging. *Biochim Biophys Acta* 1792: 353–363.
  195. Caricasole A, Bakker A, Copani A, Nicoletti F, Gaviraghi G, et al. (2005) Two sides of the same coin: Wnt signaling in neurodegeneration and neurooncology. *Biosci Rep* 25: 309–327.
  196. Lee EO, Shin YJ, Chong YH (2004) Mechanisms involved in prostaglandin E<sub>2</sub>-mediated neuroprotection against TNF-alpha: possible involvement of multiple signal transduction and beta-catenin/T-cell factor. *J Neuroimmunol* 155: 21–31.
  197. Doble BW, Woodgett JR (2003) GSK-3: tricks of the trade for a multi-tasking kinase. *J Cell Sci* 116: 1175–1186.
  198. Anderton BH, Dayanandan R, Killick R, Lovestone S (2000) Does dysregulation of the Notch and wingless/Wnt pathways underlie the pathogenesis of Alzheimer's disease? *Mol Med Today* 6: 54–59.
  199. Weihl CC, Ghadge GD, Kennedy SG, Hay N, Miller RJ, et al. (1999) Mutant presenilin-1 induces apoptosis and downregulates Akt/PKB. *J Neurosci* 19: 5360–5369.
  200. Ray A, Dhar S, Shakya A, Ray P, Okada Y, et al. (2009) SAF-3, a novel splice variant of the SAF-1/MAZ/Pur-1 family, is expressed during inflammation. *FEBS J*.

201. Jordan-Sciotto KL, Dragich JM, Caltagarone J, Hall DJ, Bowser R (2000) Fetal Alz-50 clone 1 (FAC1) protein interacts with the Myc-associated zinc finger protein (ZF87/MAZ) and alters its transcriptional activity. *Biochemistry* 39: 3206–3215.
202. Bowden NA, Weidenhofer J, Scott RJ, Schall U, Todd J, et al. (2006) Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. *Schizophr Res* 82: 175–183.
203. Batailler L, Wade DF, Graus F, Rosenfeld MR, Dalmau J (2003) The MAZ protein is an autoantigen of Hodgkin's disease and paraneoplastic cerebellar dysfunction. *Ann Neurol* 53: 123–127.
204. Sajan FD, Martiniuk F, Marcus DL, Frey WH, 2nd, Hite R, et al. (2007) Apoptotic gene expression in Alzheimer's disease hippocampal tissue. *Am J Alzheimers Dis Other Demen* 22: 319–328.
205. Lim AC, Qj RZ (2003) Cyclin-dependent kinases in neural development and degeneration. *J Alzheimers Dis* 5: 329–335.
206. Jordan-Sciotto KL, Malaiyandi LM, Bowser R (2002) Altered distribution of cell cycle transcriptional regulators during Alzheimer disease. *J Neuropathol Exp Neurol* 61: 358–367.
207. Jordan-Sciotto K, Rhodes J, Bowser R (2001) Altered subcellular distribution of transcriptional regulators in response to Abeta peptide and during Alzheimer's disease. *Mech Ageing Dev* 123: 11–20.
208. Motonaga K, Itoh M, Hirayama A, Hirano S, Becker LE, et al. (2001) Up-regulation of E2F-1 in Down's syndrome brain exhibiting neuropathological features of Alzheimer-type dementia. *Brain Res* 905: 250–253.
209. Putzer BM (2006) Targeting E2F1 Death Signaling: Opposing Role in Cancer Control and Neurodegeneration. *Discov Med* 6: 123–127.
210. Strachan GD, Koike MA, Siman R, Hall DJ, Jordan-Sciotto KL (2005) E2F1 induces cell death, calpain activation, and MDMX degradation in a transcription independent manner implicating a novel role for E2F1 in neuronal loss in SIV encephalitis. *J Cell Biochem* 96: 728–740.
211. Fortin A, MacLaurin JG, Arbour N, Cregan SP, Kushwaha N, et al. (2004) The proapoptotic gene SIVA is a direct transcriptional target for the tumor suppressors p53 and E2F1. *J Biol Chem* 279: 28706–28714.
212. Jordan-Sciotto KL, Wang G, Murphey-Corb M, Wiley CA (2002) Cell cycle proteins exhibit altered expression patterns in lentiviral-associated encephalitis. *J Neurosci* 22: 2185–2195.
213. Jordan-Sciotto KL, Murray Fenner BA, Wiley CA, Achim CL (2001) Response of cell cycle proteins to neurotrophic factor and chemokine stimulation in human neuroglia. *Exp Neurol* 167: 205–214.
214. Jordan-Sciotto KL, Wang G, Murphy-Corb M, Wiley CA (2000) Induction of cell-cycle regulators in simian immunodeficiency virus encephalitis. *Am J Pathol* 157: 497–507.
215. Strachan GD, Kopp AS, Koike MA, Morgan KL, Jordan-Sciotto KL (2005) Chemokine- and neurotrophic factor-induced changes in E2F1 localization and phosphorylation of the retinoblastoma susceptibility gene product (pRb) occur by distinct mechanisms in murine cortical cultures. *Exp Neurol* 193: 455–468.
216. Verdaguer E, Susana Gde A, Clemens A, Pallas M, Camins A (2007) Implication of the transcription factor E2F-1 in the modulation of neuronal apoptosis. *Biomed Pharmacother* 61: 390–399.
217. Ranganathan S, Bowser R (2003) Alterations in G(1) to S phase cell-cycle regulators during amyotrophic lateral sclerosis. *Am J Pathol* 162: 823–835.
218. MacManus JP, Jian M, Preston E, Rasquinha I, Webster J, et al. (2003) Absence of the transcription factor E2F1 attenuates brain injury and improves behavior after focal ischemia in mice. *J Cereb Blood Flow Metab* 23: 1020–1028.
219. Konishi Y, Bonni A (2003) The E2F-Cdc2 cell-cycle pathway specifically mediates activity deprivation-induced apoptosis of postmitotic neurons. *J Neurosci* 23: 1649–1658.
220. Cooper-Kuhn CM, Vroemen M, Brown J, Ye H, Thompson MA, et al. (2002) Impaired adult neurogenesis in mice lacking the transcription factor E2F1. *Mol Cell Neurosci* 21: 312–323.
221. MacGibbon GA, Lawlor PA, Walton M, Sirimanne E, Faul RL, et al. (1997) Expression of Fos, Jun, and Krox family proteins in Alzheimer's disease. *Exp Neurol* 147: 316–332.
222. Revest JM, Di Blasi F, Kitchener P, Rouge-Pont F, Desmedt A, et al. (2005) The MAPK pathway and Egr-1 mediate stress-related behavioral effects of glucocorticoids. *Nat Neurosci* 8: 664–672.
223. Illing RB, Michler SA, Kraus KS, Laszig R (2002) Transcription factor modulation and expression in the rat auditory brainstem following electrical intracochlear stimulation. *Exp Neurol* 175: 226–244.
224. Bozon B, Davis S, Laroche S (2003) A requirement for the immediate early gene zif268 in reconsolidation of recognition memory after retrieval. *Neuron* 40: 695–701.
225. Knapka E, Kaczmarek L (2004) A gene for neuronal plasticity in the mammalian brain: Zif268/Egr-1/NGF1-A/Krox-24/TIS8/ZENK? *Prog Neurobiol* 74: 183–211.
226. Bozon B, Kelly A, Josselyn SA, Silva AJ, Davis S, et al. (2003) MAPK, CREB and zif268 are all required for the consolidation of recognition memory. *Philos Trans R Soc Lond B Biol Sci* 358: 805–814.
227. Alder J, Thakker-Varia S, Bangasser DA, Kuroiwa M, Plummer MR, et al. (2003) Brain-derived neurotrophic factor-induced gene expression reveals novel actions of VGF in hippocampal synaptic plasticity. *J Neurosci* 23: 10800–10808.
228. Illing RB (2001) Activity-dependent plasticity in the adult auditory brainstem. *Audiol Neurootol* 6: 319–345.
229. Poirier R, Cheval H, Mailhes C, Garel S, Charnay P, et al. (2008) Distinct functions of egr gene family members in cognitive processes. *Front Neurosci* 2: 47–55.
230. Poirier R, Cheval H, Mailhes C, Charnay P, Davis S, et al. (2007) Paradoxical role of an egr transcription factor family member, egr2/krox20, in learning and memory. *Front Behav Neurosci* 1: 6.
231. Desjardins S, Mayo W, Vallee M, Hancock D, Le Moal M, et al. (1997) Effect of aging on the basal expression of c-Fos, c-Jun, and Egr-1 proteins in the hippocampus. *Neurobiol Aging* 18: 37–44.
232. Dong S, Replogle KL, Hasadsri L, Imai BS, Yau PM, et al. (2009) Discrete molecular states in the brain accompany changing responses to a vocal signal. *Proc Natl Acad Sci U S A* 106: 11364–11369.
233. Velho TA, Mello CV (2008) Synapsins are late activity-induced genes regulated by birdsong. *J Neurosci* 28: 11871–11882.
234. Velho TA, Lovell P, Mello CV (2007) Enriched expression and developmental regulation of the middle-weight neurofilament (NF-M) gene in song control nuclei of the zebra finch. *J Comp Neurol* 500: 477–497.
235. Zhu MX (2005) Multiple roles of calmodulin and other Ca(2+)-binding proteins in the functional regulation of TRP channels. *Physiol Rev* 85: 105–115.
236. Zhou H, Yu K, McCoy KL, Lee A (2005) Molecular mechanism for divergent regulation of Cav1.2 Ca2+ channels by calmodulin and Ca2+-binding protein-1. *J Biol Chem* 280: 29612–29619.
237. Wingard JN, Chan J, Bosanac I, Haeseleer F, Palczewski K, et al. (2005) Structural analysis of Mg2+ and Ca2+ binding to CaBP1, a neuron-specific regulator of calcium channels. *J Biol Chem* 280: 37461–37470.
238. Li C, Chan J, Haeseleer F, Mikoshiba K, Palczewski K, et al. (2009) Structural insights into Ca2+-dependent regulation of inositol 1,4,5-trisphosphate receptors by CaBP1. *J Biol Chem* 284: 2472–2481.
239. Chen ML, Chen YC, Peng IW, Kang RL, Wu MP, et al. (2008) Ca2+ binding protein-1 inhibits Ca2+ currents and exocytosis in bovine chromaffin cells. *J Biomed Sci* 15: 169–181.
240. Tippens AL, Lee A (2007) Caldendrin, a neuron-specific modulator of Cav1.2 (L-type) Ca2+ channels. *J Biol Chem* 282: 8464–8473.
241. Haynes LP, Fitzgerald DJ, Wareing B, O'Callaghan DW, Morgan A, et al. (2006) Analysis of the interacting partners of the neuronal calcium-binding proteins L-CaBP1, hippocalcin, NCS-1 and neurocalcine delta. *Proteomics* 6: 1822–1832.
242. Lautermilch NJ, Few AP, Scheuer T, Catterall WA (2005) Modulation of CaV2.1 channels by the neuronal calcium-binding protein visinin-like protein-2. *J Neurosci* 25: 7062–7070.
243. Haeseleer F, Imanishi Y, Maeda T, Possin DE, Maeda A, et al. (2004) Essential role of Ca2+-binding protein 4, a Cav1.4 channel regulator, in photoreceptor synaptic function. *Nat Neurosci* 7: 1079–1087.
244. Eran A, Graham KR, Vatalaro K, McCarthy J, Collins C, et al. (2009) Comment on "Autistic-like phenotypes in Cadps2-knockout mice and aberrant CADPS2 splicing in autistic patients". *J Clin Invest* 119: 679–680. author reply 680–671.
245. Sadakata T, Furuichi T (2009) Developmentally Regulated Ca(2+)-Dependent Activator Protein for Secretion 2 (CAPS2) is Involved in BDNF Secretion and is Associated with Autism Susceptibility. *Cerebellum*.
246. Sadakata T, Washida M, Furuichi T (2007) Alternative splicing variations in mouse CAPS2: differential expression and functional properties of splicing variants. *BMC Neurosci* 8: 25.
247. Sadakata T, Washida M, Iwayama Y, Shoji S, Sato Y, et al. (2007) Autistic-like phenotypes in Cadps2-knockout mice and aberrant CADPS2 splicing in autistic patients. *J Clin Invest* 117: 931–943.
248. Sadakata T, Kakegawa W, Mizoguchi A, Washida M, Katoh-Semba R, et al. (2007) Impaired cerebellar development and function in mice lacking CAPS2, a protein involved in neurotrophin release. *J Neurosci* 27: 2472–2482.
249. Sadakata T, Washida M, Morita N, Furuichi T (2007) Tissue distribution of Ca2+-dependent activator protein for secretion family members CAPS1 and CAPS2 in mice. *J Histochem Cytochem* 55: 301–311.
250. Feng G, Krejci E, Molgo J, Cunningham JM, Massoulié J, et al. (1999) Genetic analysis of collagen Q: roles in acetylcholinesterase and butyrylcholinesterase assembly and in synaptic structure and function. *J Cell Biol* 144: 1349–1360.
251. Fritschy JM, Schweizer C, Brunig I, Luscher B (2003) Pre- and post-synaptic mechanisms regulating the clustering of type A gamma-aminobutyric acid receptors (GABAA receptors). *Biochem Soc Trans* 31: 889–892.
252. Banks GB, Chamberlain JS, Froehner SC (2009) Truncated dystrophins can influence neuromuscular synapse structure. *Mol Cell Neurosci* 40: 433–441.
253. Fradkin LG, Baines RA, van der Plas MC, Noordermeer JN (2008) The dystrophin Dp186 isoform regulates neurotransmitter release at a central synapse in Drosophila. *J Neurosci* 28: 5105–5114.
254. Bogdanik L, Framery B, Frolich A, Franco B, Mornet D, et al. (2008) Muscle dystroglycan organizes the postsynapse and regulates presynaptic neurotransmitter release at the Drosophila neuromuscular junction. *PLoS One* 3: e2084.
255. Minatel E, Neto HS, Marques MJ (2003) Acetylcholine receptor distribution and synapse elimination at the developing neuromuscular junction of mdx mice. *Muscle Nerve* 28: 561–569.
256. Marchand S, Stetzkowski-Marden F, Cartaud J (2001) Differential targeting of components of the dystrophin complex to the postsynaptic membrane. *Eur J Neurosci* 13: 221–229.



257. Monroig O, Rotllant J, Sanchez E, Cerda-Reverter JM, Tocher DR (2009) Expression of long-chain polyunsaturated fatty acid (LC-PUFA) biosynthesis genes during zebrafish *Danio rerio* early embryogenesis. *Biochim Biophys Acta*.
258. Fernandez M, Segura MF, Sole C, Colino A, Comella JX, et al. (2007) Lifeguard/neuronal membrane protein 35 regulates Fas ligand-mediated apoptosis in neurons via microdomain recruitment. *J Neurochem* 103: 190–203.
259. Reimers K, Choi CY, Mau-Thek E, Vogt PM (2006) Sequence analysis shows that Lifeguard belongs to a new evolutionarily conserved cytoprotective family. *Int J Mol Med* 18: 729–734.
260. Chen W, Lee J, Cho SY, Fine HA (2004) Proteasome-mediated destruction of the cyclin a/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo. *Cancer Res* 64: 3949–3957.
261. Somia NV, Schmitt MJ, Vetter DE, Van Antwerp D, Heinemann SF, et al. (1999) LFG: an anti-apoptotic gene that provides protection from Fas-mediated cell death. *Proc Natl Acad Sci U S A* 96: 12667–12672.
262. Lopez-Bendito G, Shigemoto R, Kulik A, Paulsen O, Fairen A, et al. (2002) Expression and distribution of metabotropic GABA receptor subtypes GABABR1 and GABABR2 during rat neocortical development. *Eur J Neurosci* 15: 1766–1778.
263. Fatemi SH, Folsom TD, Reutiman TJ, Thurais PD (2009) Expression of GABA(B) receptors is altered in brains of subjects with autism. *Cerebellum* 8: 64–69.
264. Correa SA, Munton R, Nishimune A, Fitzjohn S, Henley JM (2004) Development of GABAB subunits and functional GABAB receptors in rat cultured hippocampal neurons. *Neuropharmacology* 47: 475–484.
265. Straessle A, Loup F, Arabadzisz D, Ohning GV, Fritschy JM (2003) Rapid and long-term alterations of hippocampal GABAB receptors in a mouse model of temporal lobe epilepsy. *Eur J Neurosci* 18: 2213–2226.
266. Mead AN, Morris HV, Dixon CI, Rulten SL, Mayne LV, et al. (2006) AMPA receptor GluR2, but not GluR1, subunit deletion impairs emotional response conditioning in mice. *Behav Neurosci* 120: 241–248.
267. Beveridge NJ, Tooney PA, Carroll AP, Gardiner E, Bowden N, et al. (2008) Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. *Hum Mol Genet* 17: 1156–1168.
268. Le-Niculescu H, Balaraman Y, Patel S, Tan J, Sidhu K, et al. (2007) Towards understanding the schizophrenia code: an expanded convergent functional genomics approach. *Am J Med Genet B Neuropsychiatr Genet* 144B: 129–158.
269. Dhar SS, Liang HL, Wong-Riley MT (2009) Nuclear respiratory factor 1 co-regulates AMPA glutamate receptor subunit 2 and cytochrome c oxidase: tight coupling of glutamatergic transmission and energy metabolism in neurons. *J Neurochem* 108: 1595–1606.
270. Mead AN, Stephens DN (2003) Involvement of AMPA receptor GluR2 subunits in stimulus-reward learning: evidence from glutamate receptor *gria2* knock-out mice. *J Neurosci* 23: 9500–9507.
271. Williams C, Mehrian Shai R, Wu Y, Hsu YH, Sitzer T, et al. (2009) Transcriptome analysis of synaptoneuroosomes identifies neuroplasticity genes overexpressed in incipient Alzheimer's disease. *PLoS One* 4: e4936.
272. Perlis RH, Smoller JW, Ferreira MA, McQuillin A, Bass N, et al. (2009) A genome-wide association study of response to lithium for prevention of recurrence in bipolar disorder. *Am J Psychiatry* 166: 718–725.
273. Medvedev NI, Rodriguez-Arellano JJ, Popov VI, Davies HA, Tigaret CM, et al. (2008) The glutamate receptor 2 subunit controls post-synaptic density complexity and spine shape in the dentate gyrus. *Eur J Neurosci* 27: 315–325.
274. Hou Q, Zhang D, Jarzylo L, Haganir RL, Man HY (2008) Homeostatic regulation of AMPA receptor expression at single hippocampal synapses. *Proc Natl Acad Sci U S A* 105: 775–780.
275. Heine M, Thoumine O, Mondin M, Tessier B, Giannone G, et al. (2008) Activity-independent and subunit-specific recruitment of functional AMPA receptors at neuroligin/neurexin contacts. *Proc Natl Acad Sci U S A* 105: 20947–20952.
276. Bagal AA, Kao JP, Tang CM, Thompson SM (2005) Long-term potentiation of exogenous glutamate responses at single dendritic spines. *Proc Natl Acad Sci U S A* 102: 14434–14439.
277. Passafaro M, Nakagawa T, Sala C, Sheng M (2003) Induction of dendritic spines by an extracellular domain of AMPA receptor subunit GluR2. *Nature* 424: 677–681.
278. Tsim KW, Choi RC, Siow NL, Cheng AW, Ling KK, et al. (2003) ATP induces post-synaptic gene expressions in vertebrate skeletal neuromuscular junctions. *J Neurocytol* 32: 603–617.
279. Zhang GC, Mao LM, Liu XY, Parekhar NK, Arora A, et al. (2007) In vivo regulation of Homer1a expression in the striatum by cocaine. *Mol Pharmacol* 71: 1148–1158.
280. Todd KJ, Auld DS, Robitaille R (2007) Neurotrophins modulate neuron-glia interactions at a vertebrate synapse. *Eur J Neurosci* 25: 1287–1296.
281. Mao L, Yang L, Tang Q, Samdani S, Zhang G, et al. (2005) The scaffold protein Homer1b/c links metabotropic glutamate receptor 5 to extracellular signal-regulated protein kinase cascades in neurons. *J Neurosci* 25: 2741–2752.
282. Ogasawara H, Doi T, Kawato M (2008) Systems biology perspectives on cerebellar long-term depression. *Neurosignals* 16: 300–317.
283. Faraut B, Barbier J, Ravel-Chapuis A, Doyennette MA, Jandrot-Perrus M, et al. (2003) Thrombin downregulates muscle acetylcholine receptors via an IP3 signaling pathway by activating its G-protein-coupled protease-activated receptor-1. *J Cell Physiol* 196: 105–112.
284. Sakae N, Yamasaki N, Kitaichi K, Fukuda T, Yamada M, et al. (2008) Mice lacking the schizophrenia-associated protein FEZ1 manifest hyperactivity and enhanced responsiveness to psychostimulants. *Hum Mol Genet* 17: 3191–3203.
285. Konno D, Ko JA, Usui S, Hori K, Maruoka H, et al. (2002) The postsynaptic density and dendritic raft localization of PSD-Zip70, which contains an N-myristoylation sequence and leucine-zipper motifs. *J Cell Sci* 115: 4695–4706.
286. Bardoni B, Giglio S, Schenck A, Rocchi M, Mandel JL (2000) Assignment of NUFIP1 (nuclear FMRP interacting protein 1) gene to chromosome 13q14 and assignment of a pseudogene to chromosome 6q12. *Cytogenet Cell Genet* 89: 11–13.
287. Bardoni B, Schenck A, Mandel JL (1999) A novel RNA-binding nuclear protein that interacts with the fragile X mental retardation (FMR1) protein. *Hum Mol Genet* 8: 2557–2566.
288. Bardoni B, Willemsen R, Weiler IJ, Schenck A, Severijnen LA, et al. (2003) NUFIP1 (nuclear FMRP interacting protein 1) is a nucleocytoplasmic shuttling protein associated with active synaptoneuroosomes. *Exp Cell Res* 289: 95–107.
289. Macauley SL, Wozniak DF, Kielar C, Tan Y, Cooper JD, et al. (2009) Cerebellar pathology and motor deficits in the palmitoyl protein thioesterase 1-deficient mouse. *Exp Neurol* 217: 124–135.
290. Tardy C, Sabourdy F, Garcia V, Jalanko A, Therville N, et al. (2009) Palmitoyl protein thioesterase 1 modulates tumor necrosis factor alpha-induced apoptosis. *Biochim Biophys Acta* 1793: 1250–1258.
291. Kim SJ, Zhang Z, Sarkar C, Tsai PC, Lee YC, et al. (2008) Palmitoyl protein thioesterase-1 deficiency impairs synaptic vesicle recycling at nerve terminals, contributing to neuropathology in humans and mice. *J Clin Invest* 118: 3075–3086.
292. Zhang Z, Lee YC, Kim SJ, Choi MS, Tsai PC, et al. (2007) Production of lysophosphatidylcholine by cPLA2 in the brain of mice lacking PPT1 is a signal for phagocyte infiltration. *Hum Mol Genet* 16: 837–847.
293. Ramadan H, Al-Din AS, Ismail A, Balen F, Varma A, et al. (2007) Adult neuronal ceroid lipofuscinosis caused by deficiency in palmitoyl protein thioesterase 1. *Neurology* 68: 387–388.
294. Qiao X, Lu JY, Hofmann SL (2007) Gene expression profiling in a mouse model of infantile neuronal ceroid lipofuscinosis reveals upregulation of immediate early genes and mediators of the inflammatory response. *BMC Neurosci* 8: 95.
295. Lyly A, von Schantz C, Salonen T, Kopra O, Saarela J, et al. (2007) Glycosylation, transport, and complex formation of palmitoyl protein thioesterase 1 (PPT1)—distinct characteristics in neurons. *BMC Cell Biol* 8: 22.
296. Kielar C, Maddox L, Bible E, Pontikis CC, Macauley SL, et al. (2007) Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis. *Neurobiol Dis* 25: 150–162.
297. Kalviainen R, Eriksson K, Losekoot M, Sorri I, Harvima I, et al. (2007) Juvenile-onset neuronal ceroid lipofuscinosis with infantile CLN1 mutation and palmitoyl-protein thioesterase deficiency. *Eur J Neurol* 14: 369–372.
298. Ahtiaainen L, Kolikova J, Mutka AL, Luuro K, Gentile M, et al. (2007) Palmitoyl protein thioesterase 1 (Ppt1)-deficient mouse neurons show alterations in cholesterol metabolism and calcium homeostasis prior to synaptic dysfunction. *Neurobiol Dis* 28: 52–64.
299. Zhang Z, Lee YC, Kim SJ, Choi MS, Tsai PC, et al. (2006) Palmitoyl-protein thioesterase-1 deficiency mediates the activation of the unfolded protein response and neuronal apoptosis in INCL. *Hum Mol Genet* 15: 337–346.
300. Bible E, Gupta P, Hofmann SL, Cooper JD (2004) Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosis. *Neurobiol Dis* 16: 346–359.
301. Ahtiaainen L, Van Diggelen OP, Jalanko A, Kopra O (2003) Palmitoyl protein thioesterase 1 is targeted to the axons in neurons. *J Comp Neurol* 455: 368–377.
302. Francis SC, Sunshine C, Kirk KL (2002) Coordinate regulation of catecholamine uptake by rab3 and phosphoinositide 3-kinase. *J Biol Chem* 277: 7816–7823.
303. Schluter OM, Basu J, Sudhof TC, Rosenmund C (2006) Rab3 superprimed synaptic vesicles for release: implications for short-term synaptic plasticity. *J Neurosci* 26: 1239–1246.
304. Sons MS, Plomp JJ (2006) Rab3A deletion selectively reduces spontaneous neurotransmitter release at the mouse neuromuscular synapse. *Brain Res* 1089: 126–134.
305. Nishioka H, Haraoka J (2005) Significance of immunohistochemical expression of Rab3B and SNAP-25 in growth hormone-producing pituitary adenomas. *Acta Neuropathol* 109: 598–602.
306. Schluter OM, Schmitz F, Jahn R, Rosenmund C, Sudhof TC (2004) A complete genetic analysis of neuronal Rab3 function. *J Neurosci* 24: 6629–6637.
307. Matsuno A, Itoh J, Takekoshi S, Itoh Y, Ohsugi Y, et al. (2003) Dynamics of subcellular organelles, growth hormone, Rab3B, SNAP-25, and syntaxin in rat pituitary cells caused by growth hormone releasing hormone and somatostatin. *Microsc Res Tech* 62: 232–239.
308. Sidhu RS, Bhullar RP (2001) Rab3B in human platelet is membrane bound and interacts with Ca(2+)/calmodulin. *Biochem Biophys Res Commun* 289: 1039–1043.

309. Masumoto N, Ikebuchi Y, Tahara M, Yokoi T, Tasaka K, et al. (1998) Expression of Rab3A in the cortical region in mouse metaphase II eggs. *J Exp Zool* 280: 91–96.
310. Madison DL, Kruger WH, Kim T, Pfeiffer SE (1996) Differential expression of rab3 isoforms in oligodendrocytes and astrocytes. *J Neurosci Res* 45: 258–268.
311. Grabs D, Bergmann M, Urban M, Post A, Gratzl M (1996) Rab3 proteins and SNAP-25, essential components of the exocytosis machinery in conventional synapses, are absent from ribbon synapses of the mouse retina. *Eur J Neurosci* 8: 162–168.
312. Stettler O, Nothias F, Tavittian B, Vernier P (1995) Double in situ hybridization reveals overlapping neuronal populations expressing the low molecular weight GTPases Rab3a and Rab3b in Rat brain. *Eur J Neurosci* 7: 702–713.
313. Redecker P, Cetin Y, Grube D (1995) Differential distribution of synaptotagmin I and rab3 in the anterior pituitary of four mammalian species. *Neuroendocrinology* 62: 101–110.
314. Fischer von Mollard G, Stahl B, Khokhlatchev A, Sudhof TC, Jahn R (1994) Rab3C is a synaptic vesicle protein that dissociates from synaptic vesicles after stimulation of exocytosis. *J Biol Chem* 269: 10971–10974.
315. Lledo PM, Vernier P, Vincent JD, Mason WT, Zorec R (1993) Inhibition of Rab3B expression attenuates Ca<sup>2+</sup>-dependent exocytosis in rat anterior pituitary cells. *Nature* 364: 540–544.
316. Lledo PM, Johannes L, Vernier P, Henry JP, Vincent JD, et al. (1993) [Calcium-dependent regulated secretion is controlled by GTPase Rab3 in neuroendocrine cells]. *C R Seances Soc Biol Fil* 187: 726–736.
317. Karniguan A, Zahraoui A, Tavittian A (1993) Identification of small GTP-binding rab proteins in human platelets: thrombin-induced phosphorylation of rab3B, rab6, and rab8 proteins. *Proc Natl Acad Sci U S A* 90: 7647–7651.
318. Weidenhofer J, Scott RJ, Tooney PA (2009) Investigation of the expression of genes affecting cytomatrix active zone function in the amygdala in schizophrenia: effects of antipsychotic drugs. *J Psychiatr Res* 43: 282–290.
319. Fujimoto K, Shibasaki T, Yokoi N, Kashima Y, Matsumoto M, et al. (2002) Piccolo, a Ca<sup>2+</sup> sensor in pancreatic beta-cells. Involvement of cAMP-GEFII-Rim2. Piccolo complex in cAMP-dependent exocytosis. *J Biol Chem* 277: 50497–50502.
320. Kashima Y, Miki T, Shibasaki T, Ozaki N, Miyazaki M, et al. (2001) Critical role of cAMP-GEFII-Rim2 complex in incretin-potentiated insulin secretion. *J Biol Chem* 276: 46046–46053.
321. Ozaki N, Shibasaki T, Kashima Y, Miki T, Takahashi K, et al. (2000) cAMP-GEFII is a direct target of cAMP in regulated exocytosis. *Nat Cell Biol* 2: 805–811.
322. Brandstatter JH, Dick O, Boeckers TM (2004) The postsynaptic scaffold proteins ProSAP1/Shank2 and Homer1 are associated with glutamate receptor complexes at rat retinal synapses. *J Comp Neurol* 475: 551–563.
323. Uemura T, Mori H, Mishina M (2004) Direct interaction of GluRdelta2 with Shank scaffold proteins in cerebellar Purkinje cells. *Mol Cell Neurosci* 26: 330–341.
324. Boeckers TM, Segger-Junius M, Iglauer P, Bockmann J, Gundelfinger ED, et al. (2004) Differential expression and dendritic transcript localization of Shank family members: identification of a dendritic targeting element in the 3' untranslated region of Shank1 mRNA. *Mol Cell Neurosci* 26: 182–190.
325. Qualmann B, Boeckers TM, Jeromin M, Gundelfinger ED, Kessels MM (2004) Linkage of the actin cytoskeleton to the postsynaptic density via direct interactions of Abp1 with the ProSAP/Shank family. *J Neurosci* 24: 2481–2495.
326. de Bartolomeis A, Fiore D (2004) Postsynaptic density scaffolding proteins at excitatory synapse and disorders of synaptic plasticity: implications for human behavior pathologies. *Int Rev Neurobiol* 59: 221–254.
327. Hwang JI, Kim HS, Lee JR, Kim E, Ryu SH, et al. (2005) The interaction of phospholipase C-beta3 with Shank2 regulates mGluR-mediated calcium signal. *J Biol Chem* 280: 12467–12473.
328. Bresler T, Shapira M, Boeckers T, Dresbach T, Futter M, et al. (2004) Postsynaptic density assembly is fundamentally different from presynaptic active zone assembly. *J Neurosci* 24: 1507–1520.
329. Kim JY, Han W, Namkung W, Lee JH, Kim KH, et al. (2004) Inhibitory regulation of cystic fibrosis transmembrane conductance regulator anion-transporting activities by Shank2. *J Biol Chem* 279: 10389–10396.
330. Park E, Na M, Choi J, Kim S, Lee JR, et al. (2003) The Shank family of postsynaptic density proteins interacts with and promotes synaptic accumulation of the beta PIX guanine nucleotide exchange factor for Rac1 and Cdc42. *J Biol Chem* 278: 19220–19229.
331. Kreienkamp HJ, Soltan M, Richter D, Bockers T (2002) Interaction of G-protein-coupled receptors with synaptic scaffolding proteins. *Biochem Soc Trans* 30: 464–468.
332. Boeckers TM, Bockmann J, Kreutz MR, Gundelfinger ED (2002) ProSAP/Shank proteins - a family of higher order organizing molecules of the postsynaptic density with an emerging role in human neurological disease. *J Neurochem* 81: 903–910.
333. Ehlers MD (2002) Molecular morphogens for dendritic spines. *Trends Neurosci* 25: 64–67.
334. Okamoto PM, Gamby C, Wells D, Fallon J, Vallee RB (2001) Dynamitin isoform-specific interaction with the shank/ProSAP scaffolding proteins of the postsynaptic density and actin cytoskeleton. *J Biol Chem* 276: 48458–48465.
335. Kreienkamp HJ, Zitzer H, Richter D (2000) Identification of proteins interacting with the rat somatostatin receptor subtype 2. *J Physiol Paris* 94: 193–198.
336. Tobaben S, Sudhof TC, Stahl B (2000) The G protein-coupled receptor CL1 interacts directly with proteins of the Shank family. *J Biol Chem* 275: 36204–36210.
337. Sheng M, Kim E (2000) The Shank family of scaffold proteins. *J Cell Sci* 113 (Pt 11): 1851–1856.
338. Ehlers MD (1999) Synapse structure: glutamate receptors connected by the shanks. *Curr Biol* 9: R848–850.
339. Boeckers TM, Winter C, Smalla KH, Kreutz MR, Bockmann J, et al. (1999) Proline-rich synapse-associated proteins ProSAP1 and ProSAP2 interact with synaptic proteins of the SAPAP/GKAP family. *Biochem Biophys Res Commun* 264: 247–252.
340. Lim S, Naisbitt S, Yoon J, Hwang JI, Suh PG, et al. (1999) Characterization of the Shank family of synaptic proteins. Multiple genes, alternative splicing, and differential expression in brain and development. *J Biol Chem* 274: 29510–29518.
341. Bajjalieh SM, Peterson K, Linial M, Scheller RH (1993) Brain contains two forms of synaptic vesicle protein 2. *Proc Natl Acad Sci U S A* 90: 2150–2154.
342. Lynch BA, Lambeng N, Nocka K, Kensch-Hammes P, Bajjalieh SM, et al. (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. *Proc Natl Acad Sci U S A* 101: 9861–9866.
343. Bindra PS, Knowles R, Buckley KM (1993) Conservation of the amino acid sequence of SV2, a transmembrane transporter in synaptic vesicles and endocrine cells. *Gene* 137: 299–302.
344. Schivell AE, Batchelor RH, Bajjalieh SM (1996) Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin. *J Biol Chem* 271: 27770–27775.
345. Yao J, Bajjalieh SM (2008) Synaptic vesicle protein 2 binds adenine nucleotides. *J Biol Chem* 283: 20628–20634.
346. Iezzi M, Theander S, Janz R, Loze C, Wollheim CB (2005) SV2A and SV2C are not vesicular Ca<sup>2+</sup> transporters but control glucose-evoked granule recruitment. *J Cell Sci* 118: 5647–5660.
347. Lockhart ST, Mead JN, Pisano JM, Slonimsky JD, Birren SJ (2000) Nerve growth factor collaborates with myocyte-derived factors to promote development of presynaptic sites in cultured sympathetic neurons. *J Neurobiol* 42: 460–476.
348. Hayashi M, Yamamoto A, Yatsushiro S, Yamada H, Futai M, et al. (1998) Synaptic vesicle protein SV2B, but not SV2A, is predominantly expressed and associated with microvesicles in rat pinealocytes. *J Neurochem* 71: 356–365.
349. Scranton TW, Iwata M, Carlson SS (1993) The SV2 protein of synaptic vesicles is a keratan sulfate proteoglycan. *J Neurochem* 61: 29–44.
350. Bajjalieh SM, Frantz GD, Weimann JM, McConnell SK, Scheller RH (1994) Differential expression of synaptic vesicle protein 2 (SV2) isoforms. *J Neurosci* 14: 5223–5235.
351. Custer KL, Austin NS, Sullivan JM, Bajjalieh SM (2006) Synaptic vesicle protein 2 enhances release probability at quiescent synapses. *J Neurosci* 26: 1303–1313.
352. Janz R, Hofmann K, Sudhof TC (1998) SVOP, an evolutionarily conserved synaptic vesicle protein, suggests novel transport functions of synaptic vesicles. *J Neurosci* 18: 9269–9281.
353. Dong M, Liu H, Tepp WH, Johnson EA, Janz R, et al. (2008) Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. *Mol Biol Cell* 19: 5226–5237.
354. Schivell AE, Mochida S, Kensch-Hammes P, Custer KL, Bajjalieh SM (2005) SV2A and SV2C contain a unique synaptotagmin-binding site. *Mol Cell Neurosci* 29: 56–64.
355. Janz R, Goda Y, Geppert M, Missler M, Sudhof TC (1999) SV2A and SV2B function as redundant Ca<sup>2+</sup> regulators in neurotransmitter release. *Neuron* 24: 1003–1016.
356. Lambeng N, Grossmann M, Chatelain P, Fuks B (2006) Solubilization and immunoprecipitation of rat brain synaptic vesicle protein 2A with maintained binding properties. *Neurosci Lett* 398: 107–112.
357. Janz R, Sudhof TC (1999) SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. *Neuroscience* 94: 1279–1290.
358. Clegg N, Ferguson C, True LD, Arnold H, Moorman A, et al. (2003) Molecular characterization of prostatic small-cell neuroendocrine carcinoma. *Prostate* 55: 55–64.
359. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, et al. (2006) SV2 is the protein receptor for botulinum neurotoxin A. *Science* 312: 592–596.
360. Leonoudakis D, Conti LR, Radeke CM, McGuire LM, Vandenberg CA (2004) A multiprotein trafficking complex composed of SAP97, CASK, Veli, and Mint1 is associated with inward rectifier Kir2 potassium channels. *J Biol Chem* 279: 19051–19063.
361. Atasoy D, Schoch S, Ho A, Nadasy KA, Liu X, et al. (2007) Deletion of CASK in mice is lethal and impairs synaptic function. *Proc Natl Acad Sci U S A* 104: 2525–2530.
362. Klemmer P, Smit AB, Li KW (2009) Proteomics analysis of immunoprecipitated synaptic protein complexes. *J Proteomics* 72: 82–90.
363. Hernandez-Ortega K, Ferrera P, Arias C (2007) Sequential expression of cell-cycle regulators and Alzheimer's disease-related proteins in entorhinal cortex after hippocampal excitotoxic damage. *J Neurosci Res* 85: 1744–1751.

364. Utreras E, Maccioni R, Gonzalez-Billault C (2009) Cyclin-dependent kinase 5 activator p35 over-expression and amyloid beta synergism increase apoptosis in cultured neuronal cells. *Neuroscience* 161: 978–987.
365. Ubeda M, Kemp DM, Habener JF (2004) Glucose-induced expression of the cyclin-dependent protein kinase 5 activator p35 involved in Alzheimer's disease regulates insulin gene transcription in pancreatic beta-cells. *Endocrinology* 145: 3023–3031.
366. Mateo I, Vazquez-Higuera JL, Sanchez-Juan P, Rodriguez-Rodriguez E, Infante J, et al. (2008) Epistasis between tau phosphorylation regulating genes (CDK5R1 and GSK-3beta) and Alzheimer's disease risk. *Acta Neurol Scand.*
367. Moncini S, Bevilacqua A, Venturin M, Fallini C, Ratti A, et al. (2007) The 3' untranslated region of human Cyclin-Dependent Kinase 5 Regulatory subunit 1 contains regulatory elements affecting transcript stability. *BMC Mol Biol* 8: 111.
368. Rademakers R, Sleegers K, Theuns J, Van den Broeck M, Bel Kacem S, et al. (2005) Association of cyclin-dependent kinase 5 and neuronal activators p35 and p39 complex in early-onset Alzheimer's disease. *Neurobiol Aging* 26: 1145–1151.
369. Lopes JP, Oliveira CR, Agostinho P (2007) Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: implications for Alzheimer's disease and prion-related encephalopathies. *Cell Mol Neurobiol* 27: 943–957.
370. Monaco EA, 3rd (2004) Recent evidence regarding a role for Cdk5 dysregulation in Alzheimer's disease. *Curr Alzheimer Res* 1: 33–38.
371. Maccioni RB, Otth C, Concha II, Munoz JP (2001) The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology. *Eur J Biochem* 268: 1518–1527.
372. Sato S, Xu J, Okuyama S, Martinez LB, Walsh SM, et al. (2008) Spatial learning impairment, enhanced CDK5/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1. *J Neurosci* 28: 14511–14521.
373. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, et al. (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. *Nature* 402: 615–622.
374. Orellana DI, Quintanilla RA, Maccioni RB (2007) Neuroprotective effect of TNFalpha against the beta-amyloid neurotoxicity mediated by CDK5 kinase. *Biochim Biophys Acta* 1773: 254–263.
375. Ubeda M, Rukstalis JM, Habener JF (2006) Inhibition of cyclin-dependent kinase 5 activity protects pancreatic beta cells from glucotoxicity. *J Biol Chem* 281: 28858–28864.
376. Camins A, Verdaguer E, Folch J, Canudas AM, Pallas M (2006) The role of CDK5/P25 formation/inhibition in neurodegeneration. *Drug News Perspect* 19: 453–460.
377. Quintanilla RA, Orellana DI, Gonzalez-Billault C, Maccioni RB (2004) Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. *Exp Cell Res* 295: 245–257.
378. Lee MS, Tsai LH (2003) Cdk5: one of the links between senile plaques and neurofibrillary tangles? *J Alzheimers Dis* 5: 127–137.
379. Kesavapany S, Li BS, Pant HC (2003) Cyclin-dependent kinase 5 in neurofilament function and regulation. *Neurosignals* 12: 252–264.
380. Mauzeri D, Gardoni F, Marcello E, Di Luca M (2007) Dual role of CaMKII-dependent SAP97 phosphorylation in mediating trafficking and insertion of NMDA receptor subunit NR2A. *J Neurochem* 100: 1032–1046.
381. Surena AL, de Faria GP, Studler JM, Peiretti F, Pidoux M, et al. (2009) DLG1/SAP97 modulates transforming growth factor alpha bioavailability. *Biochim Biophys Acta* 1793: 264–272.
382. Sato J, Shimazu D, Yamamoto N, Nishikawa T (2008) An association analysis of synapse-associated protein 97 (SAP97) gene in schizophrenia. *J Neural Transm* 115: 1355–1365.
383. Cai C, Li H, Kangasniemi A, Pihlajamaa T, Von Ossowski L, et al. (2008) Somatostatin receptor subtype 1 is a PDZ ligand for synapse-associated protein 97 and a potential regulator of growth cone dynamics. *Neuroscience* 157: 833–843.
384. Miguez PV, Cammarota M, Kavanagh J, Atkinson R, Powis DA, et al. (2007) Maturation changes in the subunit composition of AMPA receptors and the functional consequences of their activation in chicken forebrain. *Dev Neurosci* 29: 232–240.
385. Cai C, Li H, Rivera C, Keinänen K (2006) Interaction between SAP97 and PSD-95, two Maguk proteins involved in synaptic trafficking of AMPA receptors. *J Biol Chem* 281: 4267–4273.
386. Nash JE, Johnston TH, Collingridge GL, Garner CC, Brotchie JM (2005) Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia. *FASEB J* 19: 583–585.
387. Wakabayashi K, Narisawa-Saito M, Iwakura Y, Arai T, Ikeda K, et al. (1999) Phenotypic down-regulation of glutamate receptor subunit GluR1 in Alzheimer's disease. *Neurobiol Aging* 20: 287–295.
388. Tavalin SJ (2008) AKAP79 selectively enhances protein kinase C regulation of GluR1 at a Ca2+-calmodulin-dependent protein kinase II/protein kinase C site. *J Biol Chem* 283: 11445–11452.
389. Gerdjikov TV, Rudolph U, Keist R, Mohler H, Feldon J, et al. (2008) Hippocampal alpha 5 subunit-containing GABA A receptors are involved in the development of the latent inhibition effect. *Neurobiol Learn Mem* 89: 87–94.
390. Glykys J, Mann EO, Mody I (2008) Which GABA(A) receptor subunits are necessary for tonic inhibition in the hippocampus? *J Neurosci* 28: 1421–1426.
391. Bonin RP, Martin IJ, MacDonald JF, Orser BA (2007) Alpha5GABAA receptors regulate the intrinsic excitability of mouse hippocampal pyramidal neurons. *J Neurophysiol* 98: 2244–2254.
392. Dawson GR, Maubach KA, Collinson N, Cobain M, Everitt BJ, et al. (2006) An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition. *J Pharmacol Exp Ther* 316: 1335–1345.
393. Caraiscos VB, Newell JG, You-Ten KE, Elliott EM, Rosahl TW, et al. (2004) Selective enhancement of tonic GABAergic inhibition in murine hippocampal neurons by low concentrations of the volatile anesthetic isoflurane. *J Neurosci* 24: 8454–8458.
394. Zarnowska ED, Keist R, Rudolph U, Pearce RA (2009) GABAA receptor alpha5 subunits contribute to GABAA, slow synaptic inhibition in mouse hippocampus. *J Neurophysiol* 101: 1179–1191.
395. Fernandez F, Esposito T, Lea RA, Colson NJ, Ciccodicola A, et al. (2008) Investigation of gamma-aminobutyric acid (GABA) A receptors genes and migraine susceptibility. *BMC Med Genet* 9: 109.
396. Weiss J, O'Sullivan GA, Heinze L, Chen HX, Betz H, et al. (2008) Glycinergic input of small-field amacrine cells in the retinas of wildtype and glycine receptor deficient mice. *Mol Cell Neurosci* 37: 40–55.
397. Ramanathan S, Woodroffe A, Flodman PL, Mays LZ, Hanouni M, et al. (2004) A case of autism with an interstitial deletion on 4q leading to hemizygosity for genes encoding for glutamine and glycine neurotransmitter receptor sub-units (AMPA 2, GLRA3, GLRB) and neuropeptide receptors NPY1R, NPY5R. *BMC Med Genet* 5: 10.
398. Nikolic Z, Laube B, Weber RG, Lichter P, Kioschis P, et al. (1998) The human glycine receptor subunit alpha3. Glra3 gene structure, chromosomal localization, and functional characterization of alternative transcripts. *J Biol Chem* 273: 19708–19714.
399. Hunter RG, Bellani R, Bloss E, Costa A, McCarthy K, et al. (2009) Regulation of kainate receptor subunit mRNA by stress and corticosteroids in the rat hippocampus. *PLoS One* 4: e4328.
400. Parisiadou L, Bethani I, Michaki V, Krousti K, Rapti G, et al. (2008) Homer2 and Homer3 interact with amyloid precursor protein and inhibit Abeta production. *Neurobiol Dis* 30: 353–364.
401. Cao M, Xu J, Shen C, Kam C, Haganir RL, et al. (2007) PICK1-ICA69 heteromeric BAR domain complex regulates synaptic targeting and surface expression of AMPA receptors. *J Neurosci* 27: 12945–12956.
402. Huang Z, Shimazu K, Woo NH, Zang K, Muller U, et al. (2006) Distinct roles of the beta 1-class integrins at the developing and the mature hippocampal excitatory synapse. *J Neurosci* 26: 11208–11219.
403. Thomas U (2002) Modulation of synaptic signalling complexes by Homer proteins. *J Neurochem* 81: 407–413.
404. Scott LJ, Muglia P, Kong XQ, Guan W, Flickinger M, et al. (2009) Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry. *Proc Natl Acad Sci U S A* 106: 7501–7506.
405. Shin OH, Han W, Wang Y, Sudhof TC (2005) Evolutionarily conserved multiple C2 domain proteins with two transmembrane regions (MCTPs) and unusual Ca2+ binding properties. *J Biol Chem* 280: 1641–1651.
406. Enz R, Croci C (2003) Different binding motifs in metabotropic glutamate receptor type 7b for filamin A, protein phosphatase 1C, protein interacting with protein kinase C (PICK) 1 and syntrophin allow the formation of multimeric protein complexes. *Biochem J* 372: 183–191.
407. Boczan J, Leenders AG, Sheng ZH (2004) Phosphorylation of syntrophin by cAMP-dependent protein kinase modulates its interaction with syntaxin-1 and annuls its inhibitory effect on vesicle exocytosis. *J Biol Chem* 279: 18911–18919.
408. Kang JS, Tian JH, Pan PY, Zald P, Li C, et al. (2008) Docking of axonal mitochondria by syntrophin controls their mobility and affects short-term facilitation. *Cell* 132: 137–148.
409. Das S, Gerwin C, Sheng ZH (2003) Syntrophin binds to dynamin-1 and inhibits dynamin-dependent endocytosis. *J Biol Chem* 278: 41221–41226.
410. Das S, Boczan J, Gerwin C, Zald PB, Sheng ZH (2003) Regional and developmental regulation of syntrophin expression in the brain: a candidate molecular element of synaptic functional differentiation. *Brain Res Mol Brain Res* 116: 38–49.
411. Lao G, Scheuss V, Gerwin CM, Su Q, Mochida S, et al. (2000) Syntrophin: a syntaxin-1 clamp that controls SNARE assembly. *Neuron* 25: 191–201.
412. Mahad DJ, Ziabreva I, Campbell G, Lax N, White K, et al. (2009) Mitochondrial changes within axons in multiple sclerosis. *Brain* 132: 1161–1174.
413. Funakoshi E, Hamano A, Fukui M, Nishiyama N, Ogita K, et al. (2006) Molecular cloning of the m-Golsyn gene and its expression in the mouse brain. *Gene Expr* 13: 27–40.
414. Funakoshi E, Nakagawa KY, Hamano A, Hori T, Shimizu A, et al. (2005) Molecular cloning and characterization of gene for Golgi-localized syntrophin-related protein on human chromosome 8q23. *Gene* 344: 259–271.
415. Zhou D, Wang J, Zapala MA, Xue J, Schork NJ, et al. (2008) Gene expression in mouse brain following chronic hypoxia: role of sarcospan in glial cell death. *Physiol Genomics* 32: 370–379.
416. Williams D, Aleman T, Lillo C, Lopes VS, Hughes LC, et al. (2009) Harmonin in the murine retina and the retinal phenotypes of Ush1c-mutant mice and human USH1C. *Invest Ophthalmol Vis Sci*.

417. Lillo C, Kitamoto J, Williams DS (2006) Roles and interactions of usher 1 proteins in the outer retina. *Adv Exp Med Biol* 572: 341–348.
418. Reiners J, Nagel-Wolfrum K, Jurgens K, Marker T, Wolfrum U (2006) Molecular basis of human Usher syndrome: deciphering the meshes of the Usher protein network provides insights into the pathomechanisms of the Usher disease. *Exp Eye Res* 83: 97–119.
419. Keri S, Seres I, Kelemen O, Benedek G (2009) The Relationship Among Neuregulin 1-Stimulated Phosphorylation of AKT, Psychosis Proneness, and Habituation of Arousal in Nonclinical Individuals. *Schizophr Bull*.
420. Le Strat Y, Ramoz N, Gorwood P (2009) The role of genes involved in neuroplasticity and neurogenesis in the observation of a gene-environment interaction (GxE) in schizophrenia. *Curr Mol Med* 9: 506–518.
421. Schijndel JE, Loo KM, Zweeden MV, Djurovic S, Andreassen OA, et al. (2009) Three-cohort targeted gene screening reveals a non-synonymous TRKA polymorphism associated with schizophrenia. *J Psychiatr Res*.
422. So HC, Fong PY, Chen RY, Hui TC, Ng MY, et al. (2009) Identification of neuroglycan C and interacting partners as potential susceptibility genes for schizophrenia in a Southern Chinese population. *Am J Med Genet B Neuropsychiatr Genet*.
423. Wood JD, Bonath F, Kumar S, Ross CA, Cunliffe VT (2009) Disrupted-in-schizophrenia 1 and neuregulin 1 are required for the specification of oligodendrocytes and neurons in the zebrafish brain. *Hum Mol Genet* 18: 391–404.
424. Wong J, Weickert CS (2009) Transcriptional Interaction of an Estrogen Receptor Splice Variant and ErbB4 Suggests Convergence in Gene Susceptibility Pathways in Schizophrenia. *J Biol Chem* 284: 18824–18832.
425. Wang F, Jiang T, Sun Z, Teng SL, Luo X, et al. (2009) Neuregulin 1 genetic variation and anterior cingulum integrity in patients with schizophrenia and healthy controls. *J Psychiatry Neurosci* 34: 181–186.
426. Voineskos D, De Luca V, Macgregor S, Likhodi O, Miller L, et al. (2009) Neuregulin 1 and age of onset in the major psychoses. *J Neural Transm* 116: 479–486.
427. Tabares-Seisdedos R, Rubenstein JL (2009) Chromosome 8p as a potential hub for developmental neuropsychiatric disorders: implications for schizophrenia, autism and cancer. *Mol Psychiatry* 14: 563–589.
428. Reinhard S, Vela E, Bombara N, Devries GH, Raabe TD (2009) Developmental regulation of Neuregulin1 isoforms and erbB receptor expression in intact rat dorsal root ganglia. *Neurochem Res* 34: 17–22.
429. Prata DP, Breen G, Osborne S, Munro J, St Clair D, et al. (2009) An association study of the neuregulin 1 gene, bipolar affective disorder and psychosis. *Psychiatr Genet* 19: 113–116.
430. Pedrosa E, Nolan KA, Stefanescu R, Hershcovitz P, Novak T, et al. (2009) Analysis of a Promoter Polymorphism in the SMDF Neuregulin 1 Isoform in Schizophrenia. *Neuropsychobiology* 59: 205–212.
431. Mata I, Perez-Iglesias R, Roiz-Santianez R, Tordesillas-Gutierrez D, Gonzalez-Mandly A, et al. (2009) A neuregulin 1 variant is associated with increased lateral ventricle volume in patients with first-episode schizophrenia. *Biol Psychiatry* 65: 535–540.
432. Kircher T, Thienel R, Wagner M, Reske M, Habel U, et al. (2009) Neuregulin 1 ICE-single nucleotide polymorphism in first episode schizophrenia correlates with cerebral activation in fronto-temporal areas. *Eur Arch Psychiatry Clin Neurosci* 259: 72–79.
433. Kircher T, Krug A, Markov V, Whitney C, Krach S, et al. (2009) Genetic variation in the schizophrenia-risk gene neuregulin 1 correlates with brain activation and impaired speech production in a verbal fluency task in healthy individuals. *Hum Brain Mapp*.
434. Keri S, Seres I, Kelemen O, Benedek G (2009) Neuregulin 1-stimulated phosphorylation of AKT in psychotic disorders and its relationship with neurocognitive functions. *Neurochem Int*.
435. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, et al. (2006) Control of peripheral nerve myelination by the beta-secretase BACE1. *Science* 314: 664–666.
436. Savonenko AV, Melnikova T, Laird FM, Stewart KA, Price DL, et al. (2008) Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. *Proc Natl Acad Sci U S A* 105: 5585–5590.
437. Hu X, He W, Diaconu C, Tang X, Kidd GJ, et al. (2008) Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. *FASEB J* 22: 2970–2980.
438. Pankonin MS, Sohi J, Kamholz J, Loeb JA (2009) Differential distribution of neuregulin in human brain and spinal fluid. *Brain Res* 1258: 1–11.
439. Li B, Woo RS, Mei L, Malinow R (2007) The neuregulin-1 receptor erbB4 controls glutamatergic synapse maturation and plasticity. *Neuron* 54: 583–597.
440. Go RC, Perry RT, Wiener H, Bassett SS, Blacker D, et al. (2005) Neuregulin-1 polymorphism in late onset Alzheimer's disease families with psychoses. *Am J Med Genet B Neuropsychiatr Genet* 139B: 28–32.
441. Gallagher JP, Orozco-Cabal LF, Liu J, Shinnick-Gallagher P (2008) Synaptic physiology of central CRH system. *Eur J Pharmacol* 583: 215–225.
442. Liu Y, Tao YM, Woo RS, Xiong WC, Mei L (2007) Stimulated ErbB4 internalization is necessary for neuregulin signaling in neurons. *Biochem Biophys Res Commun* 354: 505–510.
443. MacDonald AW, 3rd, Chafee MV (2006) Translational and developmental perspective on N-methyl-D-aspartate synaptic deficits in schizophrenia. *Dev Psychopathol* 18: 853–876.
444. Jaworski A, Burden SJ (2006) Neuromuscular synapse formation in mice lacking motor neuron- and skeletal muscle-derived Neuregulin-1. *J Neurosci* 26: 655–661.
445. Jacobson C, Duggan D, Fischbach G (2004) Neuregulin induces the expression of transcription factors and myosin heavy chains typical of muscle spindles in cultured human muscle. *Proc Natl Acad Sci U S A* 101: 12218–12223.
446. Okada M, Corfas G (2004) Neuregulin1 downregulates postsynaptic GABAA receptors at the hippocampal inhibitory synapse. *Hippocampus* 14: 337–344.
447. Bennett AOM (2008) Dual constraints on synapse formation and regression in schizophrenia: neuregulin, neuroligin, dysbindin, DISC1, MuSK and agrin. *Aust N Z J Psychiatry* 42: 662–677.
448. Papadopoulos V, Lecanu L, Brown RC, Han Z, Yao ZX (2006) Peripheralt-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders. *Neuroscience* 138: 749–756.
449. Hazell AS (2002) Astrocytes and manganese neurotoxicity. *Neurochem Int* 41: 271–277.
450. Roberts JC, Friel SL, Roman S, Perren M, Harper A, et al. (2009) Autoradiographic imaging of PPARgamma agonist effects on PBR/TSPO binding in TASTPM mice. *Exp Neurol* 216: 459–470.
451. Ji B, Maeda J, Sawada M, Ono M, Okauchi T, et al. (2008) Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies. *J Neurosci* 28: 12255–12267.
452. Gulyas B, Makkai B, Kasa P, Gulya K, Bakota L, et al. (2009) A comparative autoradiography study in post mortem whole hemisphere human brain slices taken from Alzheimer patients and age-matched controls using two radiolabelled DAA1106 analogues with high affinity to the peripheral benzodiazepine receptor (PBR) system. *Neurochem Int* 54: 28–36.
453. Wang M, Gao M, Hutchins GD, Zheng QH (2009) Synthesis of [<sup>11</sup>C]FEDAA1106 as a new PET imaging probe of peripheral benzodiazepine receptor expression. *Eur J Med Chem* 44: 2748–2753.
454. Yasuno F, Ota M, Kosaka J, Ito H, Higuchi M, et al. (2008) Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [<sup>11</sup>C]DAA1106. *Biol Psychiatry* 64: 835–841.
455. Laquintana V, Denora N, Lopodota A, Suzuki H, Sawada M, et al. (2007) N-benzyl-2-(6,8-dichloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-N-(6-(7-nitrobenzo[c][1,2,5]oxadiazol-4-ylamino)hexyl)acetamide as a new fluorescent probe for peripheral benzodiazepine receptor and microglial cell visualization. *Bioconjug Chem* 18: 1397–1407.
456. Walker DG, Dalsing-Hernandez JE, Lue LF (2008) Human postmortem brain-derived cerebrovascular smooth muscle cells express all genes of the classical complement pathway: a potential mechanism for vascular damage in cerebral amyloid angiopathy and Alzheimer's disease. *Microvasc Res* 75: 411–419.
457. Veerhuis R, Janssen I, De Groot CJ, Van Muiswinkel FL, Hack CE, et al. (1999) Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor. *Exp Neurol* 160: 289–299.
458. Yasojima K, McGeer EG, McGeer PL (1999) Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease. *Brain Res* 833: 297–301.
459. Bergamaschini L, Canziani S, Bottasso B, Cugno M, Braidotti P, et al. (1999) Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner. *Clin Exp Immunol* 115: 526–533.
460. Yasojima K, Schwab C, McGeer EG, McGeer PL (1999) Up-regulated production and activation of the complement system in Alzheimer's disease brain. *Am J Pathol* 154: 927–936.
461. Terai K, Walker DG, McGeer EG, McGeer PL (1997) Neurons express proteins of the classical complement pathway in Alzheimer disease. *Brain Res* 769: 385–390.
462. Mori M, Sawashita J, Higuchi K (2007) Functional polymorphisms of the Lss and Fdft1 genes in laboratory rats. *Exp Anim* 56: 93–101.
463. Funfshilling U, Saher G, Xiao L, Mobius W, Nave KA (2007) Survival of adult neurons lacking cholesterol synthesis in vivo. *BMC Neurosci* 8: 1.
464. Tang J, Song M, Wang Y, Fan X, Xu H, et al. (2009) Noggin and BMP4 co-modulate adult hippocampal neurogenesis in the APP(swe)/PS1(DeltaE9) transgenic mouse model of Alzheimer's disease. *Biochem Biophys Res Commun* 385: 341–345.
465. Li D, Tang J, Xu H, Fan X, Bai Y, et al. (2008) Decreased hippocampal cell proliferation correlates with increased expression of BMP4 in the APPswe/PS1DeltaE9 mouse model of Alzheimer's disease. *Hippocampus* 18: 692–698.
466. Malm TM, Magga J, Kuh GF, Vatanen T, Koistinaho M, et al. (2008) Minocycline reduces engraftment and activation of bone marrow-derived cells but sustains their phagocytic activity in a mouse model of Alzheimer's disease. *Glia* 56: 1767–1779.
467. Kobayashi K, Hayashi M, Nakano H, Fukutani Y, Sasaki K, et al. (2002) Apoptosis of astrocytes with enhanced lysosomal activity and oligodendrocytes in white matter lesions in Alzheimer's disease. *Neuropathol Appl Neurobiol* 28: 238–251.
468. Fiala M, Liu QN, Sayre J, Pop V, Brahmamdam V, et al. (2002) Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. *Eur J Clin Invest* 32: 360–371.

469. Heneka MT, Wiesinger H, Dumitrescu-Ozimek L, Riederer P, Feinstein DL, et al. (2001) Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. *J Neuropathol Exp Neurol* 60: 906–916.
470. Kobayashi K, Muramori F, Aoki T, Hayashi M, Miyazu K, et al. (1998) KP-1 is a marker for extraneuronal neurofibrillary tangles and senile plaques in Alzheimer diseased brains. *Dement Geriatr Cogn Disord* 9: 13–19.
471. Reynolds WF, Rhee J, Maciejewski D, Paladino T, Sieburg H, et al. (1999) Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. *Exp Neurol* 155: 31–41.
472. Damjanac M, Rioux Bilan A, Barrier L, Pontcharraud R, Anne C, et al. (2007) Fluoro-Jade B staining as useful tool to identify activated microglia and astrocytes in a mouse transgenic model of Alzheimer's disease. *Brain Res* 1128: 40–49.
473. Sim KG, Cheong JK, Hsu SI (2006) The TRIP-Br family of transcriptional regulators is essential for the execution of cyclin E-mediated cell cycle progression. *Cell Cycle* 5: 1111–1115.
474. Cheong JK, Gunaratnam L, Zang ZJ, Yang CM, Sun X, et al. (2009) TRIP-Br2 promotes oncogenesis in nude mice and is frequently overexpressed in multiple human tumors. *J Transl Med* 7: 8.
475. Zang ZJ, Sim KG, Cheong JK, Yang CM, Yap CS, et al. (2007) Exploiting the TRIP-Br family of cell cycle regulatory proteins as chemotherapeutic drug targets in human cancer. *Cancer Biol Ther* 6: 712–718.
476. An L, Sato H, Konishi Y, Walker DG, Beach TG, et al. (2009) Expression and localization of lactotransferrin messenger RNA in the cortex of Alzheimer's disease. *Neurosci Lett* 452: 277–280.
477. Leveugle B, Spik G, Perl DP, Bouras C, Fillit HM, et al. (1994) The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. *Brain Res* 650: 20–31.
478. Kawamata T, Tooyama I, Yamada T, Walker DG, McGeer PL (1993) Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. *Am J Pathol* 142: 1574–1585.
479. Morozova N, Khrapko K, Panec J, Liu W, Harney JW, et al. (2007) Glutathione depletion in hippocampal cells increases levels of H and L ferritin and glutathione S-transferase mRNAs. *Genes Cells* 12: 561–567.
480. Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P (1995) A quantitative analysis of isoform ferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. *J Neurochem* 65: 717–724.
481. Vidal R, Miravalle L, Gao X, Barbeito AG, Baraibar MA, et al. (2008) Expression of a mutant form of the ferritin light chain gene induces neurodegeneration and iron overload in transgenic mice. *J Neurosci* 28: 60–67.
482. Thomas M, Jankovic J (2004) Neurodegenerative disease and iron storage in the brain. *Curr Opin Neurol* 17: 437–442.
483. Wimmer U, Wang Y, Georgiev O, Schaffner W (2005) Two major branches of anti-cadmium defense in the mouse: MTF-1/metallothioneins and glutathione. *Nucleic Acids Res* 33: 5715–5727.
484. Bellingham SA, Coleman LA, Masters CL, Camakaris J, Hill AF (2009) Regulation of prion gene expression by transcription factors SP1 and metal transcription factor-1. *J Biol Chem* 284: 1291–1301.
485. Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, et al. (2002) Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. *J Neurosci Res* 70: 462–473.
486. Holloway AF, Stennard FA, West AK (1997) Human metallothionein gene MT1L mRNA is present in several human tissues but is unlikely to produce a metallothionein protein. *FEBS Lett* 404: 41–44.
487. Hahn Y, Lee B (2006) Human-specific nonsense mutations identified by genome sequence comparisons. *Hum Genet* 119: 169–178.
488. Choi KH, Elashoff M, Higgs BW, Song J, Kim S, et al. (2008) Putative psychosis genes in the prefrontal cortex: combined analysis of gene expression microarrays. *BMC Psychiatry* 8: 87.
489. Concalves I, Quintela T, Baltazar G, Almeida MR, Saraiva MJ, et al. (2008) Transthyretin interacts with metallothionein 2. *Biochemistry* 47: 2244–2251.
490. Aschner M, West AK (2005) The role of MT in neurological disorders. *J Alzheimers Dis* 8: 139–145. discussion 209–115.
491. Richarz AN, Bratter P (2002) Speciation analysis of trace elements in the brains of individuals with Alzheimer's disease with special emphasis on metallothioneins. *Anal Bioanal Chem* 372: 412–417.
492. Irie Y, Keung WM (2001) Metallothionein-III antagonizes the neurotoxic and neurotrophic effects of amyloid beta peptides. *Biochem Biophys Res Commun* 282: 416–420.
493. Kobayashi K, Hayashi M, Nakano H, Shimazaki M, Sugimori K, et al. (2004) Correlation between astrocyte apoptosis and Alzheimer changes in gray matter lesions in Alzheimer's disease. *J Alzheimers Dis* 6: 623–632. discussion 673–681.
494. Mattson MP (2008) Glutamate and neurotrophic factors in neuronal plasticity and disease. *Ann N Y Acad Sci* 1144: 97–112.
495. Stahelin RV, Long F, Diraviyam K, Bruzik KS, Murray D, et al. (2002) Phosphatidylinositol 3-phosphate induces the membrane penetration of the FYVE domains of Vps27p and Hrs. *J Biol Chem* 277: 26379–26388.
496. Falasca M, Maffucci T (2006) Emerging roles of phosphatidylinositol 3-monophosphate as a dynamic lipid second messenger. *Arch Physiol Biochem* 112: 274–284.
497. Sansom SN, Griffiths DS, Faedo A, Kleinjan DJ, Ruan Y, et al. (2009) The level of the transcription factor Pax6 is essential for controlling the balance between neural stem cell self-renewal and neurogenesis. *PLoS Genet* 5: e1000511.
498. von Bohlen Und Halbach O (2007) Immunohistological markers for staging neurogenesis in adult hippocampus. *Cell Tissue Res* 329: 409–420.
499. Kallur T, Gislur R, Lindvall O, Kokaia Z (2008) Pax6 promotes neurogenesis in human neural stem cells. *Mol Cell Neurosci* 38: 616–628.
500. Levers TE, Edgar JM, Price DJ (2001) The fates of cells generated at the end of neurogenesis in developing mouse cortex. *J Neurobiol* 48: 265–277.
501. Hardy RJ (1998) QKI expression is regulated during neuron-glial cell fate decisions. *J Neurosci Res* 54: 46–57.
502. Bibel M, Richter J, Schrenk K, Tucker KL, Staiger V, et al. (2004) Differentiation of mouse embryonic stem cells into a defined neuronal lineage. *Nat Neurosci* 7: 1003–1009.
503. Baer K, Eriksson PS, Faull RL, Rees MI, Curtis MA (2007) Sox-2 is expressed by glial and progenitor cells and Pax-6 is expressed by neuroblasts in the human subventricular zone. *Exp Neurol* 204: 828–831.
504. Nacher J, Varea E, Blasco-Ibanez JM, Castillo-Gomez E, Crespo C, et al. (2005) Expression of the transcription factor Pax 6 in the adult rat dentate gyrus. *J Neurosci Res* 81: 753–761.
505. Malaterre J, Mantamadiotis T, Dworkin S, Lightowler S, Yang Q, et al. (2008) c-Myb is required for neural progenitor cell proliferation and maintenance of the neural stem cell niche in adult brain. *Stem Cells* 26: 173–181.
506. Lauriat TL, Shiue L, Haroutunian V, Verbitsky M, Ares M, Jr., et al. (2008) Developmental expression profile of quaking, a candidate gene for schizophrenia, and its target genes in human prefrontal cortex and hippocampus shows regional specificity. *J Neurosci Res* 86: 785–796.
507. Chen Y, Tian D, Ku L, Osterhout DJ, Feng Y (2007) The selective RNA-binding protein quaking 1 (QKI) is necessary and sufficient for promoting oligodendroglia differentiation. *J Biol Chem* 282: 23553–23560.
508. Zhao L, Ku L, Chen Y, Xia M, LoPresti P, et al. (2006) QKI binds MAP1B mRNA and enhances MAP1B expression during oligodendrocyte development. *Mol Biol Cell* 17: 4179–4186.
509. Aberg K, Saetre P, Jareborg N, Jazin E (2006) Human QKI, a potential regulator of mRNA expression of human oligodendrocyte-related genes involved in schizophrenia. *Proc Natl Acad Sci U S A* 103: 7482–7487.
510. Galarneau A, Richard S (2005) Target RNA motif and target mRNAs of the Quaking STAR protein. *Nat Struct Mol Biol* 12: 691–698.
511. Valjent E, Aubier B, Corbille AG, Brami-Cherrier K, Caboche J, et al. (2006) Plasticity-associated gene Krox24/Zif268 is required for long-lasting behavioral effects of cocaine. *J Neurosci* 26: 4956–4960.
512. Nikitin VP, Kozyrev SA (2007) Effects of antisense oligonucleotides to mRNA for the early gene zif268 on the mechanisms of synapse-specific plasticity. *Neurosci Behav Physiol* 37: 607–612.
513. Poirier GL, Amin E, Aggleton JP (2008) Qualitatively different hippocampal subfield engagement emerges with mastery of a spatial memory task by rats. *J Neurosci* 28: 1034–1045.
514. Renaudineau S, Poucet B, Laroche S, Davis S, Save E (2009) Impaired long-term stability of CA1 place cell representation in mice lacking the transcription factor zif268/egr1. *Proc Natl Acad Sci U S A* 106: 11771–11775.
515. Romcy-Pereira RN, Erraji-Bencheikroun L, Smyrniotopoulos P, Ogawa S, Mello CV, et al. (2009) Sleep-dependent gene expression in the hippocampus and prefrontal cortex following long-term potentiation. *Physiol Behav* 98: 44–52.
516. Bailey DJ, Wade J (2003) Differential expression of the immediate early genes FOS and ZENK following auditory stimulation in the juvenile male and female zebra finch. *Brain Res Mol Brain Res* 116: 147–154.
517. Ede-Fujiwara H, Satoh R, Bolhuis JJ, Kimura T (2003) Neuronal activation in female budgerigars is localized and related to male song complexity. *Eur J Neurosci* 17: 149–154.
518. Shimizu T, Bowers AN, Budzynski CA, Kahn MC, Bingman VP (2004) What does a pigeon (*Columba livia*) brain look like during homing? selective examination of ZENK expression. *Behav Neurosci* 118: 845–851.
519. Terpstra NJ, Bolhuis JJ, den Boer-Visser AM (2004) An analysis of the neural representation of birdsong memory. *J Neurosci* 24: 4971–4977.
520. Bailey DJ, Wade J (2005) FOS and ZENK responses in 45-day-old zebra finches vary with auditory stimulus and brain region, but not sex. *Behav Brain Res* 162: 108–115.
521. Terpstra NJ, Bolhuis JJ, Den Boer-Visser AM, Ten Cate C (2005) Neuronal activation related to auditory perception in the brain of a non-songbird, the ring dove. *J Comp Neurol* 488: 342–351.
522. Bischofe HJ, Lieshoff C, Watanabe S (2006) Spatial memory and hippocampal function in a non-feeding songbird, the zebra finch (*Taeniopygia guttata*). *Rev Neurosci* 17: 43–52.
523. Brito I, Brito LR, Ferrari EA (2006) Classical tone-shock conditioning induces Zenk expression in the pigeon (*Columba livia*) hippocampus. *Behav Neurosci* 120: 353–361.
524. Terpstra NJ, Bolhuis JJ, Riebel K, van der Burg JM, den Boer-Visser AM (2006) Localized brain activation specific to auditory memory in a female songbird. *J Comp Neurol* 494: 784–791.
525. Vignal C, Bouchut C, Mathevon N (2008) Sound-induced brain activity depends on stimulus subjective salience in female zebra finches. *C R Biol* 331: 347–356.

526. Fischer AJ, McGuire JJ, Schaeffel F, Stell WK (1999) Light- and focus-dependent expression of the transcription factor ZENK in the chick retina. *Nat Neurosci* 2: 706–712.
527. Mello CV, Vicario DS, Clayton DF (1992) Song presentation induces gene expression in the songbird forebrain. *Proc Natl Acad Sci U S A* 89: 6818–6822.
528. Mello CV, Clayton DF (1994) Song-induced ZENK gene expression in auditory pathways of songbird brain and its relation to the song control system. *J Neurosci* 14: 6652–6666.
529. Mello C, Nottebohm F, Clayton D (1995) Repeated exposure to one song leads to a rapid and persistent decline in an immediate early gene's response to that song in zebra finch telencephalon. *J Neurosci* 15: 6919–6925.
530. Mello CV, Clayton DF (1995) Differential induction of the ZENK gene in the avian forebrain and song control circuit after metrazole-induced depolarization. *J Neurobiol* 26: 145–161.
531. Mello CV, Ribeiro S (1998) ZENK protein regulation by song in the brain of songbirds. *J Comp Neurol* 393: 426–438.
532. Ribeiro S, Cecchi GA, Magnasco MO, Mello CV (1998) Toward a song code: evidence for a syllabic representation in the canary brain. *Neuron* 21: 359–371.
533. Tischmeyer W, Grimm R (1999) Activation of immediate early genes and memory formation. *Cell Mol Life Sci* 55: 564–574.
534. Nedivi E, Hevroni D, Naot D, Israeli D, Citri Y (1993) Numerous candidate plasticity-related genes revealed by differential cDNA cloning. *Nature* 363: 718–722.
535. Li L, Yun SH, Keblesh J, Trommer BL, Xiong H, et al. (2007) Egr3, a synaptic activity regulated transcription factor that is essential for learning and memory. *Mol Cell Neurosci* 35: 76–88.
536. Soule J, Penke Z, Kanhema T, Alme MN, Laroche S, et al. (2008) Object-place recognition learning triggers rapid induction of plasticity-related immediate early genes and synaptic proteins in the rat dentate gyrus. *Neural Plast* 2008: 269097.
537. Takahata T, Higo N, Kaas JH, Yamamori T (2009) Expression of immediate-early genes reveals functional compartments within ocular dominance columns after brief monocular inactivation. *Proc Natl Acad Sci U S A*.
538. Lam BY, Zhang W, Enticknap N, Haggis E, Cader MZ, et al. (2009) Inverse regulation of plasticity-related immediate early genes by calcineurin in hippocampal neurons. *J Biol Chem* 284: 12562–12571.
539. Pfenning AR, Schwartz R, Barth AL (2007) A comparative genomics approach to identifying the plasticity transcriptome. *BMC Neurosci* 8: 20.
540. Nikitin VP (2007) A new mechanism of synapse-specific neuronal plasticity. *Neurosci Behav Physiol* 37: 559–570.
541. Toscano CD, McGlothlin JL, Guilarte TR (2006) Experience-dependent regulation of zif268 gene expression and spatial learning. *Exp Neurol* 200: 209–215.
542. Jenkins TA, Amin E, Brown MW, Aggleton JP (2006) Changes in immediate early gene expression in the rat brain after unilateral lesions of the hippocampus. *Neuroscience* 137: 747–759.
543. James AB, Conway AM, Morris BJ (2006) Regulation of the neuronal proteasome by Zif268 (Egr1). *J Neurosci* 26: 1624–1634.
544. Ihara H, Mie M, Funabashi H, Takahashi F, Sawasaki T, et al. (2006) In vitro selection of zinc finger DNA-binding proteins through ribosome display. *Biochem Biophys Res Commun* 345: 1149–1154.
545. Hernandez PJ, Schiltz CA, Kelley AE (2006) Dynamic shifts in corticostriatal expression patterns of the immediate early genes Homer 1a and Zif268 during early and late phases of instrumental training. *Learn Mem* 13: 599–608.
546. James AB, Conway AM, Morris BJ (2005) Genomic profiling of the neuronal target genes of the plasticity-related transcription factor – Zif268. *J Neurochem* 95: 796–810.
547. Lee JL, Everitt BJ, Thomas KL (2004) Independent cellular processes for hippocampal memory consolidation and reconsolidation. *Science* 304: 839–843.
548. Korzus E (2003) The relation of transcription to memory formation. *Acta Biochim Pol* 50: 775–782.
549. Davis S, Bozon B, Laroche S (2003) How necessary is the activation of the immediate early gene zif268 in synaptic plasticity and learning? *Behav Brain Res* 142: 17–30.
550. Blanchard J, Decorte L, Noguez X, Micheau J (2009) Characterization of cognition alteration across the course of the disease in APP751SL mice with parallel estimation of cerebral A $\beta$  deposition. *Behav Brain Res* 201: 147–157.
551. Blanchard J, Martel G, Guillou JL, Noguez X, Micheau J (2008) Impairment of spatial memory consolidation in APP(751SL) mice results in cue-guided response. *Neurobiol Aging* 29: 1011–1021.
552. Becker M, Lavie V, Solomon B (2007) Stimulation of endogenous neurogenesis by anti-EFRH immunization in a transgenic mouse model of Alzheimer's disease. *Proc Natl Acad Sci U S A* 104: 1691–1696.
553. Dickey CA, Loring JF, Montgomery J, Gordon MN, Eastman PS, et al. (2003) Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein+presenilin-1 transgenic mice. *J Neurosci* 23: 5219–5226.
554. Dickey CA, Gordon MN, Mason JE, Wilson NJ, Diamond DM, et al. (2004) Amyloid suppresses induction of genes critical for memory consolidation in APP+PS1 transgenic mice. *J Neurochem* 88: 434–442.
555. Kashani AH, Qiu Z, Jurata L, Lee SK, Pfaff S, et al. (2006) Calcium activation of the LMO4 transcription complex and its role in the patterning of thalamocortical connections. *J Neurosci* 26: 8398–8408.
556. Bulchand S, Subramanian L, Tole S (2003) Dynamic spatiotemporal expression of LIM genes and cofactors in the embryonic and postnatal cerebral cortex. *Dev Dyn* 226: 460–469.
557. Azim E, Shneider SJ, Cederquist GY, Sohr U, Macklis JD (2009) Lmo4 and Clim1 progressively delineate cortical projection neuron subtypes during development. *Cereb Cortex* 19 Suppl 1: i62–69.
558. Miyajima N, Maruyama S, Nonomura K, Hatakeyama S (2009) TRIM36 interacts with the kinetochore protein CENP-H and delays cell cycle progression. *Biochem Biophys Res Commun* 381: 383–387.
559. Harrill JA, Li Z, Wright FA, Radio NM, Mundy WR, et al. (2008) Transcriptional response of rat frontal cortex following acute in vivo exposure to the pyrethroid insecticides permethrin and deltamethrin. *BMC Genomics* 9: 546.
560. Takemoto-Kimura S, Terai H, Takamoto M, Ohmae S, Kikumura S, et al. (2003) Molecular cloning and characterization of CLICK-III/CaMKIgamma, a novel membrane-anchored neuronal Ca2+/calmodulin-dependent protein kinase (CaMK). *J Biol Chem* 278: 18597–18605.
561. Takemoto-Kimura S, Ageta-Ishihara N, Nonaka M, Adachi-Morishima A, Mano T, et al. (2007) Regulation of dendritogenesis via a lipid-raft-associated Ca2+/calmodulin-dependent protein kinase CLICK-III/CaMKIgamma. *Neuron* 54: 755–770.
562. Korostynski M, Piechota M, Kaminska D, Solecki W, Przewlocki R (2007) Morphine effects on striatal transcriptome in mice. *Genome Biol* 8: R128.
563. Glorioso C, Sabatini M, Unger T, Hashimoto T, Monteggia LM, et al. (2006) Specificity and timing of neocortical transcriptome changes in response to BDNF gene ablation during embryogenesis or adulthood. *Mol Psychiatry* 11: 633–648.
564. Nishimura H, Sakagami H, Uezu A, Fukunaga K, Watanabe M, et al. (2003) Cloning, characterization and expression of two alternatively splicing isoforms of Ca2+/calmodulin-dependent protein kinase I gamma in the rat brain. *J Neurochem* 85: 1216–1227.
565. Zhao C, Braunevel KH (2008) Expression of the neuronal calcium sensor visinin-like protein-1 in the rat hippocampus. *Neuroscience* 153: 1202–1212.
566. Youn H, Jeoung M, Koo Y, Ji H, Markesbery WR, et al. (2007) Kalirin is under-expressed in Alzheimer's disease hippocampus. *J Alzheimers Dis* 11: 385–397.
567. Huang JC, Babak T, Corson TW, Chua G, Khan S, et al. (2007) Using expression profiling data to identify human microRNA targets. *Nat Methods* 4: 1045–1049.
568. Liu T, Papagiannakopoulos T, Puskar K, Qi S, Santiago F, et al. (2007) Detection of a microRNA signal in an in vivo expression set of mRNAs. *PLoS One* 2: e804.
569. Nikitin A, Egorov S, Daraselia N, Mazo I (2003) Pathway studio—the analysis and navigation of molecular networks. *Bioinformatics* 19: 2155–2157.
570. Bucan M, Abrahams BS, Wang K, Glessner JT, Herman EI, et al. (2009) Genome-wide analyses of exonic copy number variants in a family-based study point to novel autism susceptibility genes. *PLoS Genet* 5: e1000536.
571. Bourgeron T (2009) A synaptic trek to autism. *Curr Opin Neurobiol*.
572. Glessner JT, Wang K, Cai G, Korvatska O, Kim CE, et al. (2009) Autism genome-wide copy number variation reveals ubiquitous and neuronal genes. *Nature* 459: 569–573.
573. Kumar RA, Christian SL (2009) Genetics of autism spectrum disorders. *Curr Neurol Neurosci Rep* 9: 188–197.
574. Bourgeron T (2007) The possible interplay of synaptic and clock genes in autism spectrum disorders. *Cold Spring Harb Symp Quant Biol* 72: 645–654.
575. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, et al. (2008) Structural variation of chromosomes in autism spectrum disorder. *Am J Hum Genet* 82: 477–488.
576. Kim HG, Kishikawa S, Higgins AW, Seong IS, Donovan DJ, et al. (2008) Disruption of neurexin 1 associated with autism spectrum disorder. *Am J Hum Genet* 82: 199–207.
577. Owen MJ, Williams HJ, O'Donovan MC (2009) Schizophrenia genetics: advancing on two fronts. *Curr Opin Genet Dev* 19: 266–270.
578. Need AC, Ge D, Weale ME, Maia J, Feng S, et al. (2009) A genome-wide investigation of SNPs and CNVs in schizophrenia. *PLoS Genet* 5: e1000373.
579. Rujescu D, Ingason A, Cichon S, Pietilainen OP, Barnes MR, et al. (2009) Disruption of the neurexin 1 gene is associated with schizophrenia. *Hum Mol Genet* 18: 988–996.
580. Vrijenhoek T, Buizer-Voskamp JE, van der Stelt I, Strengman E, Sabatti C, et al. (2008) Recurrent CNVs disrupt three candidate genes in schizophrenia patients. *Am J Hum Genet* 83: 504–510.
581. Kirov G, Gumus D, Chen W, Norton N, Georgieva L, et al. (2008) Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. *Hum Mol Genet* 17: 458–465.
582. Nussbaum J, Xu Q, Payne TJ, Ma JZ, Huang W, et al. (2008) Significant association of the neurexin-1 gene (NRXN1) with nicotine dependence in European- and African-American smokers. *Hum Mol Genet* 17: 1569–1577.
583. Bierut IJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, et al. (2007) Novel genes identified in a high-density genome wide association study for nicotine dependence. *Hum Mol Genet* 16: 24–35.
584. Yang HC, Chang CC, Lin CY, Chen CL, Fann CS (2005) A genome-wide scanning and fine mapping study of COGA data. *BMC Genet* 6 Suppl 1: S30.

585. Zahir FR, Baross A, Delaney AD, Eydoux P, Fernandes ND, et al. (2008) A patient with vertebral, cognitive and behavioural abnormalities and a de novo deletion of NRXN1alpha. *J Med Genet* 45: 239–243.
586. Cabodi S, Morello V, Masi A, Cicchi R, Broggio C, et al. (2009) Convergence of integrins and EGF receptor signaling via PI3K/Akt/FoxO pathway in early gene Egr-1 expression. *J Cell Physiol* 218: 294–303.
587. Nowak K, Killmer K, Gessner C, Lutz W (2007) E2F-1 regulates expression of FOXO1 and FOXO3a. *Biochim Biophys Acta* 1769: 244–252.
588. Yuan Z, Lehtinen MK, Merlo P, Villen J, Gygi S, et al. (2009) Regulation of neuronal cell death by MST1-FOXO1 signaling. *J Biol Chem* 284: 11285–11292.
589. Yuan Z, Becker EB, Merlo P, Yamada T, DiBacco S, et al. (2008) Activation of FOXO1 by Cdk1 in cycling cells and postmitotic neurons. *Science* 319: 1665–1668.
590. Kim AH, Bonni A (2008) Cdk1-FOXO1: a mitotic signal takes center stage in post-mitotic neurons. *Cell Cycle* 7: 3819–3822.
591. van der Heide LP, Ramakers GM, Smidt MP (2006) Insulin signaling in the central nervous system: learning to survive. *Prog Neurobiol* 79: 205–221.
592. Horwood JM, Dufour F, Laroche S, Davis S (2006) Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat. *Eur J Neurosci* 23: 3375–3384.
593. Polter A, Yang S, Zmijewska AA, van Groen T, Paik JH, et al. (2009) Forkhead box, class O transcription factors in brain: regulation and behavioral manifestation. *Biol Psychiatry* 65: 150–159.
594. Wu H, Lu D, Jiang H, Xiong Y, Qu C, et al. (2008) Increase in phosphorylation of Akt and its downstream signaling targets and suppression of apoptosis by simvastatin after traumatic brain injury. *J Neurosurg* 109: 691–698.
595. Sasaki T, Han F, Shioda N, Moriguchi S, Kasahara J, et al. (2006) Lithium-induced activation of Akt and CaM kinase II contributes to its neuroprotective action in a rat microsphere embolism model. *Brain Res* 1108: 98–106.
596. Hoekman MF, Jacobs FM, Smidt MP, Burbach JP (2006) Spatial and temporal expression of FoxO transcription factors in the developing and adult murine brain. *Gene Expr Patterns* 6: 134–140.
597. Samarin J, Cicha I, Goppelt-Strube M (2009) Cell type-specific regulation of CCN2 protein expression by PI3K-AKT-FoxO signaling. *J Cell Commun Signal* 3: 79–84.
598. Fukuda M, Jones JE, Olson D, Hill J, Lee CE, et al. (2008) Monitoring FoxO1 localization in chemically identified neurons. *J Neurosci* 28: 13640–13648.
599. Tajés M, Yeste-Velasco M, Zhu X, Chou SP, Smith MA, et al. (2009) Activation of Akt by lithium: pro-survival pathways in aging. *Mech Ageing Dev* 130: 253–261.
600. Chiang CW, Yan L, Yang E (2008) Phosphatases and regulation of cell death. *Methods Enzymol* 446: 237–257.
601. Lukiw WJ, Pogue AI (2007) Induction of specific micro RNA (miRNA) species by ROS-generating metal sulfates in primary human brain cells. *J Inorg Biochem* 101: 1265–1269.
602. Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, et al. (2008) Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. *Brain Pathol* 18: 484–496.
603. Marzolo MP, Bu G (2009) Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease. *Semin Cell Dev Biol* 20: 191–200.
604. Jaeger S, Pietrzik CU (2008) Functional role of lipoprotein receptors in Alzheimer's disease. *Curr Alzheimer Res* 5: 15–25.
605. Cam JA, Bu G (2006) Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family. *Mol Neurodegener* 1: 8.
606. Bu G, Cam J, Zerbinatti C (2006) LRP in amyloid-beta production and metabolism. *Ann N Y Acad Sci* 1086: 35–53.
607. Carter CJ (2007) Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. *Neurochem Int* 50: 12–38.
608. Cam JA, Zerbinatti CV, Knisely JM, Hecimovic S, Li Y, et al. (2004) The low density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production. *J Biol Chem* 279: 29639–29646.
609. Duilio A, Faraonio R, Minopoli G, Zambrano N, Russo T (1998) Fe65L2: a new member of the Fe65 protein family interacting with the intracellular domain of the Alzheimer's beta-amyloid precursor protein. *Biochem J* 330(Pt 1): 513–519.
610. Tanahashi H, Tabira T (1999) Genome structure and chromosomal mapping of the gene for Fe65L2 interacting with Alzheimer's beta-amyloid precursor protein. *Biochem Biophys Res Commun* 258: 385–389.
611. Tanahashi H, Tabira T (1999) Molecular cloning of human Fe65L2 and its interaction with the Alzheimer's beta-amyloid precursor protein. *Neurosci Lett* 261: 143–146.
612. Tanahashi H, Asada T, Tabira T (2002) c954C→T polymorphism in the Fe65L2 gene is associated with early-onset Alzheimer's disease. *Ann Neurol* 52: 691–693.
613. Tamayev R, Zhou D, D'Adamio L (2009) The interactome of the amyloid beta precursor protein family members is shaped by phosphorylation of their intracellular domains. *Mol Neurodegener* 4: 28.
614. Zhou D, Zambrano N, Russo T, D'Adamio L (2009) Phosphorylation of a tyrosine in the amyloid-beta protein precursor intracellular domain inhibits Fe65 binding and signaling. *J Alzheimers Dis* 16: 301–307.
615. McLoughlin DM, Miller CC (2008) The FE65 proteins and Alzheimer's disease. *J Neurosci Res* 86: 744–754.
616. Chang Y, Tesco G, Jeong WJ, Lindsley L, Eckman EA, et al. (2003) Generation of the beta-amyloid peptide and the amyloid precursor protein C-terminal fragment gamma are potentiated by FE65L1. *J Biol Chem* 278: 51100–51107.
617. Poduslo SE, Huang R, Spiro A, 3rd (2010) A genome screen of successful aging without cognitive decline identifies LRP1B by haplotype analysis. *Am J Med Genet B Neuropsychiatr Genet* 153B.
618. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group\* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* 34: 939.
619. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. *Journal of Psychiatric Research* 12: 189–198.
620. Rosen W, Mohs R, Davis K (1984) A new rating scale for Alzheimer's disease. *Am J Psychiatry* 141: 1356–1364.
621. Schmitt FA, Wetherby MMC, Wekstein DR, Dearth CMS, Markesbery WR (2001) Brain Donation in Normal Aging: Procedures, Motivations, and Donor Characteristics From the Biologically Resilient Adults in Neurological Studies (BRAiNS) Project. *Gerontologist* 41: 716–722.
622. Geddes JW, Tekirian TL, Soutanian NS, Ashford JW, Davis DG, et al. (1997) Comparison of neuropathologic criteria for the diagnosis of Alzheimer's disease. *Neurobiol Aging* 18: S99–105.
623. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol* 82: 239–259.
624. Bancher C, Braak H, Fischer P, Jellinger KA (1993) Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. *Neurosci Lett* 162: 179–182.
625. Braak H, Braak E (1995) Staging of Alzheimer's disease-related neurofibrillary changes. *Neurobiol Aging* 16: 271–278. discussion 278–284.
626. Fayyad UM, Irani KB, eds. (1993) Multi-Interval Discretization of Continuous-Valued Attributes for Classification Learning Morgan Kaufmann. pp 1022–1029.
627. Berretta R, Mendes A, Moscato P (2007) Selection of Discriminative Genes in Microarray Experiments Using Mathematical Programming. *Journal of Research and Practice in Information Technology* 39: 287–299.
628. Cotta C, Sloper C, Moscato P (2004) Evolutionary Search of Thresholds for Robust Feature Set Selection: Application to the Analysis of Microarray Data. In: Raidl GR, Cagnoni S, Branke J, Corne DW, Drechsler R, et al. eds. Applications of Evolutionary Computing Springer Berlin/Heidelberg. pp 21–30.
629. Gómez Ravetti M, Berretta R, Moscato P (2009) Novel Biomarkers for Prostate Cancer Revealed by (α,β)-k-Feature Sets. *Foundations of Computational Intelligence Volume 5*. pp 149–175.
630. Hourani M, Berretta R, Mendes A, Moscato P (2008) Genetic signatures for a rodent model of Parkinson's disease using combinatorial optimization methods. *Methods Mol Biol* 453: 379–392.
631. Mendes A, Scott RJ, Moscato P (2008) Microarrays—identifying molecular portraits for prostate tumors with different Gleason patterns. *Methods Mol Med* 141: 131–151.
632. Rosso OA, Mendes A, Berretta R, Rostas JA, Hunter M, et al. (2009) Distinguishing childhood absence epilepsy patients from controls by the analysis of their background brain electrical activity (II): a combinatorial optimization approach for electrode selection. *J Neurosci Methods* 181: 257–267.
633. Cotta C, Langston MA, Moscato P (2007) Combinatorial and Algorithmic Issues for Microarray Analysis. In: Gonzalez TF, ed. Handbook of Approximation Algorithms and Metaheuristics Chapman & Hall/CRC. pp 74.71–74.14.
634. Chang JT, Nevins JR (2006) GATHER: a systems approach to interpreting genomic signatures. *Bioinformatics* 22: 2926–2933.
635. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, et al. (2004) Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. *Proc Natl Acad Sci U S A* 101: 2173–2178.
636. Zhao CJ, Noack C, Brackmann M, Gloveli T, Maelicke A, et al. (2009) Neuronal Ca<sup>2+</sup> sensor VILIP-1 leads to the upregulation of functional alpha4beta2 nicotinic acetylcholine receptors in hippocampal neurons. *Mol Cell Neurosci* 40: 280–292.
637. Bernstein HG, Braunewell KH (2009) Some notes on visinin-like protein 1 and Alzheimer disease. *Clin Chem* 55: 1041–1043.
638. Lee JM, Blennow K, Andreasen N, Laterza O, Modur V, et al. (2008) The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. *Clin Chem* 54: 1617–1623.
639. Zhao C, Anand R, Braunewell KH (2009) Nicotine-induced Ca<sup>2+</sup>-myristoyl switch of neuronal Ca<sup>2+</sup> sensor VILIP-1 in hippocampal neurons: a possible crosstalk mechanism for nicotinic receptors. *Cell Mol Neurobiol* 29: 273–286.



640. Gierke P, Zhao C, Bernstein HG, Noack C, Anand R, et al. (2008) Implication of neuronal Ca<sup>2+</sup> -sensor protein VILIP-1 in the glutamate hypothesis of schizophrenia. *Neurobiol Dis* 32: 162–175.
641. Schnurra I, Bernstein HG, Riederer P, Braunevel KH (2001) The neuronal calcium sensor protein VILIP-1 is associated with amyloid plaques and extracellular tangles in Alzheimer's disease and promotes cell death and tau phosphorylation in vitro: a link between calcium sensors and Alzheimer's disease? *Neurobiol Dis* 8: 900–909.
642. Braunevel K, Riederer P, Spilker C, Gundelfinger ED, Bogerts B, et al. (2001) Abnormal localization of two neuronal calcium sensor proteins, visinin-like proteins (vilips)-1 and -3, in neocortical brain areas of Alzheimer disease patients. *Dement Geriatr Cogn Disord* 12: 110–116.
643. Killick R, Scales G, Leroy K, Causevic M, Hooper C, et al. (2009) Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. *Biochem Biophys Res Commun* 386: 257–262.
644. Bulbarelli A, Lonati E, Cazzaniga E, Gregori M, Masserini M (2009) Pin1 affects Tau phosphorylation in response to Abeta oligomers. *Mol Cell Neurosci* 42: 75–80.
645. Zhao WQ, Feng C, Alkon DL (2003) Impairment of phosphatase 2A contributes to the prolonged MAP kinase phosphorylation in Alzheimer's disease fibroblasts. *Neurobiol Dis* 14: 458–469.
646. Valai SB, Stock JB (2002) Protein phosphatase 2A methylation: a link between elevated plasma homocysteine and Alzheimer's Disease. *FEBS Lett* 518: 1–4.
647. Wei Q, Holzer M, Brueckner MK, Liu Y, Arendt T (2002) Dephosphorylation of tau protein by calcineurin triturated into neural living cells. *Cell Mol Neurobiol* 22: 13–24.
648. Tian Q, Wang J (2002) Role of serine/threonine protein phosphatase in Alzheimer's disease. *Neurosignals* 11: 262–269.
649. Gong CX, Wang JZ, Iqbal K, Grundke-Iqbal I (2003) Inhibition of protein phosphatase 2A induces phosphorylation and accumulation of neurofilaments in metabolically active rat brain slices. *Neurosci Lett* 340: 107–110.
650. Munch G, Kuhla B, Luth HJ, Arendt T, Robinson SR (2003) Anti-AGEing defences against Alzheimer's disease. *Biochem Soc Trans* 31: 1397–1399.
651. Sontag E, Luangpirom A, Hladik C, Mudrak I, Ogris E, et al. (2004) Altered expression levels of the protein phosphatase 2A A $\beta$ Alphac enzyme are associated with Alzheimer disease pathology. *J Neuropathol Exp Neurol* 63: 287–301.
652. Rametti A, Esclaire F, Yardin C, Terro F (2004) Linking alterations in tau phosphorylation and cleavage during neuronal apoptosis. *J Biol Chem* 279: 54518–54528.
653. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I (2009) Mechanisms of tau-induced neurodegeneration. *Acta Neuropathol* 118: 53–69.
654. Deters N, Ittner LM, Gotz J (2009) Substrate-specific reduction of PP2A activity exaggerates tau pathology. *Biochem Biophys Res Commun* 379: 400–405.
655. Liang Z, Liu F, Iqbal K, Grundke-Iqbal I, Wegiel J, et al. (2008) Decrease of protein phosphatase 2A and its association with accumulation and hyperphosphorylation of tau in Down syndrome. *J Alzheimers Dis* 13: 295–302.
656. Chen S, Li B, Grundke-Iqbal I, Iqbal K (2008) I1PP2A affects tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A. *J Biol Chem* 283: 10513–10521.
657. Liu R, Zhou XW, Tanila H, Bjorkdahl C, Wang JZ, et al. (2008) Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology. *J Cell Mol Med* 12: 241–257.
658. Meske V, Albert F, Ohm TG (2008) Coupling of mammalian target of rapamycin with phosphoinositide 3-kinase signaling pathway regulates protein phosphatase 2A- and glycogen synthase kinase-3 -dependent phosphorylation of Tau. *J Biol Chem* 283: 100–109.
659. Walton JR (2007) An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration. *J Inorg Biochem* 101: 1275–1284.
660. Nowotny P, Bertelsen S, Hinrichs AL, Kauwe JS, Mayo K, et al. (2007) Association studies between common variants in prolyl isomerase Pin1 and the risk for late-onset Alzheimer's disease. *Neurosci Lett* 419: 15–17.
661. Chohan MO, Khatoon S, Iqbal IG, Iqbal K (2006) Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine. *FEBS Lett* 580: 3973–3979.
662. Plattner F, Angelo M, Giese KP (2006) The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. *J Biol Chem* 281: 25457–25465.
663. Kerr F, Rickle A, Nayeem N, Brandner S, Cowburn RF, et al. (2006) PTEN, a negative regulator of PI3 kinase signalling, alters tau phosphorylation in cells by mechanisms independent of GSK-3. *FEBS Lett* 580: 3121–3128.
664. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. *Eur J Neurosci* 22: 1942–1950.
665. Madeira A, Pommet JM, Prochiantz A, Allinquant B (2005) SET protein (TAF1beta, I2PP2A) is involved in neuronal apoptosis induced by an amyloid precursor protein cytoplasmic subdomain. *FASEB J* 19: 1905–1907.
666. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, et al. (2005) Regulation of NMDA receptor trafficking by amyloid-beta. *Nat Neurosci* 8: 1051–1058.
667. Rahman A, Grundke-Iqbal I, Iqbal K (2006) PP2B isolated from human brain preferentially dephosphorylates Ser-262 and Ser-396 of the Alzheimer disease abnormally hyperphosphorylated tau. *J Neural Transm* 113: 219–230.
668. Rahman A, Grundke-Iqbal I, Iqbal K (2005) Phosphothreonine-212 of Alzheimer abnormally hyperphosphorylated tau is a preferred substrate of protein phosphatase-1. *Neurochem Res* 30: 277–287.
669. Cheng LY, Wang JZ, Gong CX, Pei JJ, Zaidi T, et al. (2000) Multiple forms of phosphatase from human brain: isolation and partial characterization of affi-gel blue binding phosphatases. *Neurochem Res* 25: 107–120.
670. Garver TD, Lehman RA, Billingsley ML (1996) Microtubule assembly competence analysis of freshly-biopsied human tau, dephosphorylated tau, and Alzheimer tau. *J Neurosci Res* 44: 12–20.
671. Matsuo ES, Shin RW, Billingsley ML, Van deVoorde A, O'Connor M, et al. (1994) Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. *Neuron* 13: 989–1002.
672. Bajo M, Yoo BC, Cairns N, Gratzner M, Lubec G (2001) Neurofilament proteins NF-L, NF-M and NF-H in brain of patients with Down syndrome and Alzheimer's disease. *Amino Acids* 21: 293–301.
673. Blass JP, Markesbery WR, Ko LW, DeGiorgio L, Sheu KF, et al. (1994) Presence of neuronal proteins in serially cultured cells from autopsy human brain. *J Neurol Sci* 121: 132–138.
674. Cairns NJ, Uryu K, Bigio EH, Mackenzie IR, Gearing M, et al. (2004) alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. *Acta Neuropathol* 108: 213–223.
675. DeGiorgio LA, Sheu KF, Blass JP (1994) Culture from human leptomeninges of cells containing neurofilament protein and neuron-specific enolase. *J Neurol Sci* 124: 141–148.
676. Deng Y, Li B, Liu F, Iqbal K, Grundke-Iqbal I, et al. (2008) Regulation between O-GlcNAcylation and phosphorylation of neurofilament-M and their dysregulation in Alzheimer disease. *FASEB J* 22: 138–145.
677. Faigon M, Hadas E, Alroy G, Chapman J, Auerbach JM, et al. (1991) Monoclonal antibodies to the heavy neurofilament subunit (NF-H) of Torpedo cholinergic neurons. *J Neurosci Res* 29: 490–498.
678. Hollosi M, Holly S, Majer Z, Laczko I, Fasman GD (1995) Complexes of aluminium with peptide ligands: a Fourier transform IR spectroscopic study. *Biopolymers* 36: 381–389.
679. Hollosi M, Shen ZM, Perczel A, Fasman GD (1994) Stable intrachain and interchain complexes of neurofilament peptides: a putative link between A13+ and Alzheimer disease. *Proc Natl Acad Sci U S A* 91: 4902–4906.
680. Hollosi M, Urge L, Perczel A, Kajtar J, Teplan I, et al. (1992) Metal ion-induced conformational changes of phosphorylated fragments of human neurofilament (NF-M) protein. *J Mol Biol* 223: 673–682.
681. Holly S, Laczko I, Fasman GD, Hollosi M (1993) FT-IR spectroscopy indicates that Ca(2+)-binding to phosphorylated C-terminal fragments of the mid-sized neurofilament protein subunit results in beta-sheet formation and beta-aggregation. *Biochem Biophys Res Commun* 197: 755–762.
682. Hu YY, He SS, Wang XC, Duan QH, Khatoon S, et al. (2002) Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. *Neurosci Lett* 320: 156–160.
683. Julien JP, Mushynski WE (1998) Neurofilaments in health and disease. *Prog Nucleic Acid Res Mol Biol* 61: 1–23.
684. Kittur S, Hoh J, Endo H, Tourtellotte W, Weeks BS, et al. (1994) Cytoskeletal neurofilament gene expression in brain tissue from Alzheimer's disease patients. I. Decrease in NF-L and NF-M message. *J Geriatr Psychiatry Neurol* 7: 153–158.
685. Ksiazek-Reding H, Yen SH (1987) Two monoclonal antibodies recognize Alzheimer's neurofibrillary tangles, neurofilament, and microtubule-associated proteins. *J Neurochem* 48: 455–462.
686. Lee VM, Otvos L, Jr., Carden MJ, Hollosi M, Dietzschold B, et al. (1988) Identification of the major multiphosphorylation site in mammalian neurofilaments. *Proc Natl Acad Sci U S A* 85: 1998–2002.
687. Li SP, Deng YQ, Wang XC, Wang YP, Wang JZ (2004) Melatonin protects SH-SY5Y neuroblastoma cells from calyculin A-induced neurofilament impairment and neurotoxicity. *J Pineal Res* 36: 186–191.
688. Miller CC, Brion JP, Calvert R, Chin TK, Eagles PA, et al. (1986) Alzheimer's paired helical filaments share epitopes with neurofilament side arms. *Embo J* 5: 269–276.
689. Pollak D, Cairns N, Lubec G (2003) Cytoskeleton derangement in brain of patients with Down syndrome, Alzheimer's disease and Pick's disease. *J Neural Transm Suppl*: 149–158.
690. Roder HM, Ingram VM (1991) Two novel kinases phosphorylate tau and the KSP site of heavy neurofilament subunits in high stoichiometric ratios. *J Neurosci* 11: 3325–3343.
691. Save MP, Shetty VP, Shetty KT, Antia NH (2004) Alterations in neurofilament protein(s) in human leprosy nerves: morphology, immunohistochemistry and Western immunoblot correlative study. *Neuropathol Appl Neurobiol* 30: 635–650.
692. Schmidt ML, Lee VM, Trojanowski JQ (1989) Analysis of epitopes shared by Hirano bodies and neurofilament proteins in normal and Alzheimer's disease hippocampus. *Lab Invest* 60: 513–522.
693. Schmidt ML, Lee VM, Trojanowski JQ (1991) Comparative epitope analysis of neuronal cytoskeletal proteins in Alzheimer's disease senile plaque neurites and neuropil threads. *Lab Invest* 64: 352–357.
694. Shen ZM, Perczel A, Hollosi M, Nagypal I, Fasman GD (1994) Study of A13+ binding and conformational properties of the alanine-substituted C-terminal





- domain of the NF-M protein and its relevance to Alzheimer's disease. *Biochemistry* 33: 9627–9636.
695. Trojanowski JQ, Schmidt ML, Otvos L, Jr., Gur RC, Gur RE, et al. (1989) Selective expression of epitopes in multiphosphorylation repeats of the high and middle molecular weight neurofilament proteins in Alzheimer neurofibrillary tangles. *Ann Med* 21: 113–116.
696. Troy CM, Greene LA, Shelanski ML (1992) Neurite outgrowth in peripherin-depleted PC12 cells. *J Cell Biol* 117: 1085–1092.
697. Wang J, Tung YC, Wang Y, Li XT, Iqbal K, et al. (2001) Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells. *FEBS Lett* 507: 81–87.
698. Wang Y, Wang Q, Wang J (2002) [Detection of level and mutation of neurofilament mRNA in Alzheimer's disease]. *Zhonghua Yi Xue Za Zhi* 82: 519–522.
699. Wang YP, Wei ZL, Wang XC, Wang Q, Wang JZ (2001) [Comparative study of the expression and phosphorylation of neurofilament proteins of brain gray matter in Alzheimer's disease]. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao* 23: 445–449.
700. Wurtman RJ, Ulus IH, Cansev M, Watkins CJ, Wang L, et al. (2006) Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally. *Brain Res* 1088: 83–92.
701. Yang X, Yang Y, Luo Y, Li G, Wang J, et al. (2009) Hyperphosphorylation and Accumulation of Neurofilament Proteins in Transgenic Mice with Alzheimer Presenilin 1 Mutation. *Cell Mol Neurobiol*.
702. Yao PJ, Coleman PD (1998) Reduced O-glycosylated clathrin assembly protein AP180: implication for synaptic vesicle recycling dysfunction in Alzheimer's disease. *Neurosci Lett* 252: 33–36.
703. Laterza OF, Modur VR, Crimmins DL, Olander JV, Landt Y, et al. (2006) Identification of novel brain biomarkers. *Clin Chem* 52: 1713–1721.
704. Zhao C, Anand R, Braunevel KH (2008) Nicotine-induced Ca(2+)-myristoyl Switch of Neuronal Ca(2+) Sensor VILIP-1 in Hippocampal Neurons: A Possible Crosstalk Mechanism for Nicotinic Receptors. *Cell Mol Neurobiol*.
705. Zhao C, Noack C, Brackmann M, Gloveli T, Maelicke A, et al. (2008) Neuronal Ca(2+) sensor VILIP-1 leads to the upregulation of functional alpha4beta2 nicotinic acetylcholine receptors in hippocampal neurons. *Mol Cell Neurosci*.
706. Briand C, Kozlov SV, Sonderegger P, Grutter MG (2001) Crystal structure of neuroserpin: a neuronal serpin involved in a conformational disease. *FEBS Lett* 505: 18–22.
707. Bruno MA, Cuello AC (2006) Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. *Proc Natl Acad Sci U S A* 103: 6735–6740.
708. Carrell RW (2005) Cell toxicity and conformational disease. *Trends Cell Biol* 15: 574–580.
709. Crowther DC (2002) Familial conformational diseases and dementias. *Hum Mutat* 20: 1–14.
710. Dufour A, Corsini E, Gelati M, Massa G, Tarcic N, et al. (2000) Mutations in the neuroserpin gene are rare in familial dementia. French Alzheimer's Disease and Fronto-Temporal Dementia Genetics Study Groups. *Ann Neurol* 47: 688.
711. Kinghorn KJ, Crowther DC, Sharp LK, Nerelius C, Davis RL, et al. (2006) Neuroserpin binds Abeta and is a neuroprotective component of amyloid plaques in Alzheimer disease. *J Biol Chem* 281: 29268–29277.
712. Nielsen HM, Minthon L, Londos E, Blennow K, Miranda E, et al. (2007) Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. *Neurology* 69: 1569–1579.
713. Tabira T (2003) [Familial non-Alzheimer dementia]. *Rinsho Shinkeigaku* 43: 775–778.
714. Yamasaki M, Li W, Johnson DJ, Huntington JA (2008) Crystal structure of a stable dimer reveals the molecular basis of serpin polymerization. *Nature* 455: 1255–1258.
715. Opii WO, Joshi G, Head E, Milgram NW, Muggenburg BA, et al. (2008) Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer's disease. *Neurobiol Aging* 29: 51–70.
716. Poon HF, Farr SA, Thongboonkerd V, Lynn BC, Banks WA, et al. (2005) Proteomic analysis of specific brain proteins in aged SAMP8 mice treated with alpha-lipoic acid: implications for aging and age-related neurodegenerative disorders. *Neurochem Int* 46: 159–168.
717. Somerville MJ, Percy ME, Bergeron C, Yoong LK, Grima EA, et al. (1991) Localization and quantitation of 68 kDa neurofilament and superoxide dismutase-1 mRNA in Alzheimer brains. *Brain Res Mol Brain Res* 9: 1–8.
718. Wishart TM, Paterson JM, Short DM, Meredith S, Robertson KA, et al. (2007) Differential proteomics analysis of synaptic proteins identifies potential cellular targets and protein mediators of synaptic neuroprotection conferred by the slow Wallerian degeneration (Wlds) gene. *Mol Cell Proteomics* 6: 1318–1330.
719. Shen Y, Halperin JA, Lee CM (1995) Complement-mediated neurotoxicity is regulated by homologous restriction. *Brain Res* 671: 282–292.
720. Wallace MA (1994) Effects of Alzheimer's disease-related beta amyloid protein fragments on enzymes metabolizing phosphoinositides in brain. *Biochim Biophys Acta* 1227: 183–187.
721. Shimohama S, Matsushima H (1995) Signal transduction mechanisms in Alzheimer disease. *Alzheimer Dis Assoc Disord* 9 Suppl 2: 15–22.
722. Sambamurti K, Sevelev D, Koothan T, Refolo LM, Pinnix I, et al. (1999) Glycosylphosphatidylinositol-anchored proteins play an important role in the biogenesis of the Alzheimer's amyloid beta-protein. *J Biol Chem* 274: 26810–26814.
723. Strosznajder JB, Zambrzycka A, Kacprzak MD, Strosznajder RP (1999) Amyloid beta peptide 25–35 modulates hydrolysis of phosphoinositides by membrane phospholipase(s) C of adult brain cortex. *J Mol Neurosci* 12: 101–109.
724. Zambrzycka A, Cakala M, Kaminska M (2003) Transition metal ions significantly decrease phospholipase C activity degrading phosphatidylinositol-4,5-bisphosphate in the brain cortex. *Pol J Pharmacol* 55: 915–917.
725. Merlos-Suarez A, Ruiz-Paz S, Baseлга J, Arribas J (2001) Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzyme. *J Biol Chem* 276: 48510–48517.
726. Gilmore GC, Wenk HE, Naylor LA, Koss E (1994) Motion perception and Alzheimer's disease. *J Gerontol* 49: P52–57.
727. Hayes TL, Lewis DA (1992) Nonphosphorylated neurofilament protein and calbindin immunoreactivity in layer III pyramidal neurons of human neocortex. *Cereb Cortex* 2: 56–67.
728. Chin J, Palop JJ, Puolivali J, Massaro C, Bien-Ly N, et al. (2005) Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. *J Neurosci* 25: 9694–9703.
729. Falangola MF, Dyakin VV, Lee SP, Bogart A, Babb JS, et al. (2007) Quantitative MRI reveals aging-associated T2 changes in mouse models of Alzheimer's disease. *NMR Biomed* 20: 343–351.
730. Helpert JA, Lee SP, Falangola MF, Dyakin VV, Bogart A, et al. (2004) MRI assessment of neuropathology in a transgenic mouse model of Alzheimer's disease. *Magn Reson Med* 51: 794–798.
731. Lahiri DK, Chen D, Ge YW, Farlow M, Kotwal G, et al. (2003) Does nitric oxide synthase contribute to the pathogenesis of Alzheimer's disease?: effects of beta-amyloid deposition on NOS in transgenic mouse brain with AD pathology. *Ann N Y Acad Sci* 1010: 639–642.
732. Levine S, Saltzman A, Levy E, Ginsberg SD (2009) Systemic pathology in aged mouse models of Down's syndrome and Alzheimer's disease. *Exp Mol Pathol* 86: 18–22.
733. Neiva TJ, Fries DM, Monteiro HP, D'Amico EA, Chamone DA (1997) Aluminum induces lipid peroxidation and aggregation of human blood platelets. *Braz J Med Biol Res* 30: 599–604.
734. Parent A, Linden DJ, Sisodia SS, Borchelt DR (1999) Synaptic transmission and hippocampal long-term potentiation in transgenic mice expressing FAD-linked presenilin 1. *Neurobiol Dis* 6: 56–62.
735. Perez SE, Lumayag S, Kovacs B, Mufson EJ, Xu S (2009) Beta-amyloid deposition and functional impairment in the retina of the APPsw/PS1DeltaE9 transgenic mouse model of Alzheimer's disease. *Invest Ophthalmol Vis Sci* 50: 793–800.
736. Sadowski M, Pankiewicz J, Scholtzova H, Ji Y, Quartermain D, et al. (2004) Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice. *J Neuropathol Exp Neurol* 63: 418–428.
737. Sahara N, Vega IE, Ishizawa T, Lewis J, McGowan E, et al. (2004) Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins. *J Neurochem* 90: 829–838.
738. Wang CY, Shen YC, Lo FY, Su CH, Lee SH, et al. (2007) Normal tension glaucoma is not associated with the interleukin -1alpha (-889) genetic polymorphism. *J Glaucoma* 16: 230–233.
739. Wang CY, Shen YC, Su CH, Lo FY, Lee SH, et al. (2007) Investigation of the association between interleukin-1beta polymorphism and normal tension glaucoma. *Mol Vis* 13: 719–723.
740. Wang X, Su B, Siedlak SL, Moreira PI, Fujioka H, et al. (2008) Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. *Proc Natl Acad Sci U S A* 105: 19318–19323.
741. Yu WH, Matsuoka Y, Sziraki I, Hashim A, Lafrancois J, et al. (2008) Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein. *Neurochem Res* 33: 902–911.
742. Zhuo JM, Prakasam A, Murray ME, Zhang HY, Baxter MG, et al. (2008) An increase in Abeta42 in the prefrontal cortex is associated with a reversal-learning impairment in Alzheimer's disease model Tg2576 APPsw mice. *Curr Alzheimer Res* 5: 385–391.
743. Freude S, Plum L, Schnitker J, Leeser U, Udelhoven M, et al. (2005) Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. *Diabetes* 54: 3343–3348.
744. Lowe XR, Lu X, Marchetti F, Wyrobek AJ (2007) The expression of Troponin T1 gene is induced by ketamine in adult mouse brain. *Brain Res* 1174: 7–17.
745. Morris BJ (2005) A forkhead in the road to longevity: the molecular basis of lifespan becomes clearer. *J Hypertens* 23: 1285–1309.
746. Nakagawa K, Kitazume S, Oka R, Maruyama K, Saido TC, et al. (2006) Sialylation enhances the secretion of neurotoxic amyloid-beta peptides. *J Neurochem* 96: 924–933.
747. Lian Q, Ladner CJ, Magnuson D, Lee JM (2001) Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer's disease cerebral cortex. *Exp Neurol* 167: 158–165.
748. Shibata N, Kobayashi M (2008) [The role for oxidative stress in neurodegenerative diseases]. *Brain Nerve* 60: 157–170.

749. Wang H, Dong K, Li G, Peng X, Zhu H (2009) [Effect of yizhi jiannaog granules on the expression of Pin1 and HMGB1 mRNA in the hippocampus of SAMP8 mice.]. *Zhong Nan Da Xue Xue Bao Yi Xue Ban* 34: 63–66.
750. Yang G, Wang L, Zhu M, Xu D (2008) Identification of non-Alzheimer's disease tauopathies-related proteins by proteomic analysis. *Neurol Res* 30: 613–622.
751. Desjardins P, Ledoux S (1998) Expression of ced-3 and ced-9 homologs in Alzheimer's disease cerebral cortex. *Neurosci Lett* 244: 69–72.
752. Akiyama H, Nishimura T, Kondo H, Ikeda K, Hayashi Y, et al. (1994) Expression of the receptor for macrophage colony stimulating factor by brain microglia and its upregulation in brains of patients with Alzheimer's disease and amyotrophic lateral sclerosis. *Brain Res* 639: 171–174.
753. Boissonneault V, Filali M, Lessard M, Relton J, Wong G, et al. (2009) Powerful beneficial effects of macrophage colony-stimulating factor on {beta}-amyloid deposition and cognitive impairment in Alzheimer's disease. *Brain*.
754. Du Yan S, Zhu H, Fu J, Yan SF, Roher A, et al. (1997) Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. *Proc Natl Acad Sci U S A* 94: 5296–5301.
755. Ebadi M, Bashir RM, Heidrick ML, Hamada FM, Refacy HE, et al. (1997) Neurotrophins and their receptors in nerve injury and repair. *Neurochem Int* 30: 347–374.
756. Flanagan AM, Lader CS (1998) Update on the biologic effects of macrophage colony-stimulating factor. *Curr Opin Hematol* 5: 181–185.
757. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, et al. (2005) Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. *Proc Natl Acad Sci U S A* 102: 2273–2276.
758. Hamilton JA, Whitty G, White AR, Jobling MF, Thompson A, et al. (2002) Alzheimer's disease amyloid beta and prion protein amyloidogenic peptides promote macrophage survival, DNA synthesis and enhanced proliferative response to CSF-1 (M-CSF). *Brain Res* 940: 49–54.
759. Hasegawa Y, Sawada M, Ozaki N, Inagaki T, Suzumura A (2000) Increased soluble tumor necrosis factor receptor levels in the serum of elderly people. *Gerontology* 46: 185–188.
760. Ito S, Sawada M, Haneda M, Fujii S, Oh-Hashi K, et al. (2005) Amyloid-beta peptides induce cell proliferation and macrophage colony-stimulating factor expression via the PI3-kinase/Akt pathway in cultured Ra2 microglial cells. *FEBS Lett* 579: 1995–2000.
761. Kaku M, Tsutsui K, Motokawa M, Kawata T, Fujita T, et al. (2003) Amyloid beta protein deposition and neuron loss in osteopetrotic (op/op) mice. *Brain Res Brain Res Protoc* 12: 104–108.
762. Kawata T, Tsutsui K, Kohno S, Kaku M, Fujita T, et al. (2005) Amyloid beta protein deposition in osteopetrotic (op/op) mice is reduced by injections of macrophage colony stimulating factor. *J Int Med Res* 33: 654–660.
763. Kondo Y, Lemere CA, Seabrook TJ (2007) Osteopetrotic (op/op) mice have reduced microglia, no Abeta deposition, and no changes in dopaminergic neurons. *J Neuroinflammation* 4: 31.
764. Kong QL, Zhang JM, Zhang ZX, Ge PJ, Xu YJ, et al. (2002) [Serum levels of macrophage colony stimulating factor in the patients with Alzheimer's disease]. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao* 24: 298–301.
765. Kumar AP, Piedrafita EJ, Reynolds WF (2004) Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism. *J Biol Chem* 279: 8300–8315.
766. Lee SC, Liu W, Brosnan CF, Dickson DW (1994) GM-CSF promotes proliferation of human fetal and adult microglia in primary cultures. *Glia* 12: 309–318.
767. Li M, Pisalyaput K, Galvan M, Tenner AJ (2004) Macrophage colony stimulatory factor and interferon-gamma trigger distinct mechanisms for augmentation of beta-amyloid-induced microglia-mediated neurotoxicity. *J Neurochem* 91: 623–633.
768. Lue LF, Rydel R, Brigham EF, Yang LB, Hampel H, et al. (2001) Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. *Glia* 35: 72–79.
769. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, et al. (2001) Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. *Exp Neurol* 171: 29–45.
770. Lue LF, Walker DG, Rogers J (2001) Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. *Neurobiol Aging* 22: 945–956.
771. Majumdar A, Cruz D, Asamoah N, Buxbaum A, Sohar I, et al. (2007) Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. *Mol Biol Cell* 18: 1490–1496.
772. Mitrasinovic OM, Grattan A, Robinson CC, Lapustea NB, Poon C, et al. (2005) Microglia overexpressing the macrophage colony-stimulating factor receptor are neuroprotective in a microglial-hippocampal organotypic coculture system. *J Neurosci* 25: 4442–4451.
773. Mitrasinovic OM, Murphy GM, Jr. (2003) Microglial overexpression of the M-CSF receptor augments phagocytosis of opsonized Abeta. *Neurobiol Aging* 24: 807–815.
774. Mitrasinovic OM, Perez GV, Zhao F, Lee YL, Poon C, et al. (2001) Overexpression of macrophage colony-stimulating factor receptor on microglial cells induces an inflammatory response. *J Biol Chem* 276: 30142–30149.
775. Mitrasinovic OM, Robinson CC, Tenen DG, Lee YL, Poon C, et al. (2004) Biolistic expression of the macrophage colony stimulating factor receptor in organotypic cultures induces an inflammatory response. *J Neurosci Res* 77: 420–429.
776. Mitrasinovic OM, Vincent VA, Simsek D, Murphy GM, Jr (2003) Macrophage colony stimulating factor promotes phagocytosis by murine microglia. *Neurosci Lett* 344: 185–188.
777. Murphy GM, Jr., Zhao F, Yang L, Cordell B (2000) Expression of macrophage colony-stimulating factor receptor is increased in the AbetaPP(V717F) transgenic mouse model of Alzheimer's disease. *Am J Pathol* 157: 895–904.
778. Vincent VA, Robinson CC, Simsek D, Murphy GM (2002) Macrophage colony stimulating factor prevents NMDA-induced neuronal death in hippocampal organotypic cultures. *J Neurochem* 82: 1388–1397.
779. Vincent VA, Selwood SP, Murphy GM, Jr (2002) Proinflammatory effects of M-CSF and A beta in hippocampal organotypic cultures. *Neurobiol Aging* 23: 349–362.
780. Wollmer MA, Nitsch RM, Hock C, Papassotiropoulos A (2006) Genetic association study on colony-stimulating factor 1 in Alzheimer's disease. *Neurodegener Dis* 3: 334–337.
781. Yan SD, Stern D, Kane MD, Kuo YM, Lampert HC, et al. (1998) RAGE-Abeta interactions in the pathophysiology of Alzheimer's disease. *Restor Neurol Neurosci* 12: 167–173.
782. Zhang JM, Kong QL, Wang H, Qin C, He W (2004) [Expression of macrophage colony stimulating factor in brains of PDAPPV717I transgenic mice]. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao* 26: 62–65.
783. Marsagishvili LG, Shpagina MD, Emel'ianenko VI, Podlubnaia ZA (2005) [Sarcomeric proteins of the titin family form amyloids]. *Biofizika* 50: 803–809.